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Discover of bioactive lipids and lipid pathways in cell death and disease 
Abstract 
 
Apoptosis is an intricately regulated cellular process required for the health and 
homeostasis of living systems [1].  The mitochondrial apoptotic pathway depends on the BCL-2 
family of pro- and anti-apoptotic members whose interactions regulate cell fate [1].  BAX and 
BAK are key pro-apoptotic proteins required for mitochondrial permeabilization during 
apoptosis [1].  While the mitochondrial death program relies heavily on its protein components, 
evidences support equally crucial roles for lipids and lipid metabolism in promoting or hindering 
apoptosis at the mitochondria [2-4].  To gain insight into the interplay between lipids and BCL-2 
proteins we used a liquid chromatography (LC)–mass spectrometry (MS)-based comparative 
lipidomics approach to uncover lipid changes in the absence of BAX and/or BAK.  Our analysis 
revealed novel functions for BAX and BAK in inflammation and ceramide metabolism.   
In response to inflammatory stimuli, prostaglandins are synthesized from arachidonic 
acid by cyclooxygenase (COX), the target of non-steroidal anti-inflammatory drugs [5, 6]; 
different prostaglandins exhibit a wide range of functions including vasodilation, fever 
generation and bone reabsorption [6].  Absence of BAX and/or BAK led to prostaglandin down-
regulation, arachidonic acid accumulation, and reduced expression of the inducible 
cyclooxygenase isoform COX-2.  Bax
–/–
 fibroblasts displayed blunted COX-2 response to the 
inflammatory agent bacterial lipopolysaccharide through altered kinetics of NFκB and MAPK 
 iv 
 
signaling.  To our knowledge this is the first report of a role for BAX and BAK in COX-2 
regulation.   
Absence of BAX and BAK also led to selective upregulation of unsaturated ceramides 
with additional degree of unsaturation in the sphingoid backbone; unsaturated ceramides were 
significantly more potent in reducing cellular viability than saturated species.  Up until now, 
almost all studies on the pro-apoptotic functions of ceramides have focused on saturated species 
[7-10]; our discovery of a different ceramide pool regulated by BAX and BAK implies the 
synergistic effects between BAX and ceramides in apoptosis could be more complex than 
previously known.   
A targeted LC–MS workflow was also developed for characterization of a novel lipid 
class involved in type 2 diabetes.  Targeted LC–MS revealed altered oxysterol metabolism 
following perturbation of the Sonic hedgehog pathway.  Taken together, our findings 
demonstrate interesting connections among lipids, cell death and disease.   
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Chapter 1 
 
Emerging roles of lipids in apoptosis and metabolism 
 
 
 
 
 
 
 
Adapted from: 
T. Zhang, A. Saghatelian, Emerging roles of lipids in BCL-2 family-regulated apoptosis. 
Biochim. Biophys. Acta. 1831 (2013) 1542-1554. 
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1.1. Apoptosis and lipid metabolism  
Apoptosis is an intricately regulated process required for the health and homeostasis of 
living systems [1].  Apoptosis in mammalian cells proceeds through extrinsic and intrinsic 
pathways [2].  The extrinsic pathway involves binding of extracellular signaling factors to death 
receptors at the plasma membrane [2].  The intrinsic pathway is activated by intracellular stress 
and proceeds through the mitochondria [2].  The mitochondrial apoptotic pathway is regulated by 
the BCL-2 family whose members are classified based on structure and function (Figure 1.1);  
 
 
Figure 1.1. Selected members of the BCL-2 family.  BCL-2 proteins are classified 
based on structure (multidomain or BH3 domain-only) and function (pro- or anti-
apoptotic). 
 
anti-apoptotic proteins such as BCL-2 and BCL-XL share three to four conserved BCL-2 
homology domains (BH1-4) while pro-apoptotic proteins such as BAX and BAK share three 
such domains [1].  A third group of pro-apoptotic BH3 domain-only proteins acts as stress 
sensors that communicate the apoptotic signal to multidomain proteins; BH3 domain-only 
messengers are organized into activators or derepressors based on their ability to either activate 
multidomain pro-apoptotic or deactivate multidomain anti-apoptotic BCL-2 members [1, 3].   
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In the mitochondrial apoptotic pathway, a diverse set of signals recruits distinct BH3 
domain-only proteins to trigger activation of the executioner proteins BAX and BAK [1, 3].  
BAX and BAK oligomerization in the outer mitochondrial membrane (OMM) leads to 
mitochondrial outer membrane permeabilization (MOMP) and release of cytochrome c (cyt c) 
along with other apoptogenic factors, a crucial step in apoptosis [1, 4, 5].  While the 
mitochondrial apoptotic program heavily relies on its protein components, mounting evidence 
pinpoints the membrane as an equally important factor in the successful propagation of the death 
response [6-8].   
The lipid environment of the mitochondrial membrane is critical for BCL-2 protein 
translocation prior to MOMP, and perturbation in mitochondrial lipid composition can lead to 
phenotypes associated with dysregulated cell death [9-11].  The mitochondrial lipid cardiolipin 
(CL) plays an important role in the maintenance of mitochondrial bioenergetics [12], and 
sphingolipid metabolism has been shown to cooperate with BAX and BAK pore formation in the 
mitochondrial membrane [13].  These findings suggest that far beyond their role as inert 
structural elements, lipids and their metabolism can exert key points of control over the BCL-2 
family-regulated apoptotic program.  A review of recent literature on the link between BCL-2 
proteins and metabolism, in particular the role of the sphingolipid metabolic hub ceramide in 
BCL-2 family-regulated apoptosis, will be presented in the following sections.   
 
1.1.1. Ceramide in BCL-2 family-regulated apoptosis 
1.1.1.1. Biosynthesis and the sphingolipid rheostat  
The major pathways of ceramide generation are de novo biosynthesis, sphingomyelin 
(SM) hydrolysis and sphingosine salvage [14-17] (Figure 1.2).  De novo biosynthesis begins with  
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Figure 1.2. Ceramide is the hub of sphingolipid metabolism. 
 
coupling of fatty acyl-CoA to serine via the pyridoxal 5-phosphate-dependent serine 
palmitoyltransferase (SPT) to generate 3-ketosphinganine, CoA and CO2; palmitoyl (C16:0)-
CoA is the predominant SPT substrate in mammalian cells and yeast [15, 18].  3-
Ketosphinganine is reduced to dihydrosphinganine by the NADPH-dependent 3-ketosphinganine 
reductase and subsequently acylated at the amine by the CoA-dependent dihydroceramide 
synthase (CerS) [14, 15, 18].  Dihydroceramide is reduced by dihydroceramide desaturase to 
yield mature ceramide, which contains a trans double bond at C4-C5 of the sphingosine chain 
[14, 15, 18, 19] (Figure 1.2).  Six mammalian CerSs (CerS1-6) have been identified, each 
exhibiting specifity for distinct fatty acyl chains [14, 18].   
SM hydrolysis by sphingomyelinases (SMases) also yields ceramide (Figure 1.2); a 
variety of neutral (n) and acid (a) SMases, each with its own pH optimum, operates in distinct 
cellular compartments [10, 20, 21].  Neutral, acid and alkaline ceramidases with different cellular 
localizations degrade ceramide to sphingosine [10], which can be reacylated to new ceramide via 
the salvage pathway [14], phosphorylated by sphingosine kinase (SPK) to sphingosine-1-
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phosphate (S1P) [22] or irreversibly degraded by sphingosine lyase to ethanolamine phosphate 
and hexadecenal [23] (Figure 1.2).  Ceramidases also possess reverse activity and can reform 
ceramide via a CoA-independent mechanism [24-26] (Figure 1.2).   
 Ceramide is the hub of sphingolipid metabolism.  The diversity of cellular fatty acids 
translates into ceramide species with acyl chains of varying lengths and degrees of unsaturation, 
which are further reflected in the diversity of ceramide metabolites.  More than 200 ceramides 
with distinct structural modifications are known and subject to metabolism by more than 28 
enzymes [27, 28].  As a result of this diversity, different ceramide metabolites or even ceramides 
with different acyl chain lengths can exert opposing influences over key cellular processes such 
as apoptosis [27-30].  The sphingolipid rheostat model states that the balance among different 
sphingolipids, in particular the predominantly pro-apoptotic ceramide and the pro-survival S1P, 
regulates the balance between cell death and proliferation [11, 31]; modulation of enzymes that 
mediate metabolism between these two lipids could have significant impact on cell fate and has 
been demonstrated by the use of SPK and SMase inhibitors as anticancer and anti-inflammatory 
agents [10, 32].   
The distinct compartmentalization of metabolic pathways surrounding ceramide also 
needs to be considered.  CerS is localized to the ER and mitochondria-associated membranes 
(MAM) [14, 16, 33] while several studies have revealed microsomal, mitochondrial, nuclear and 
plasma membrane localizations for ceramidases and SMases [10, 16, 18, 19].  Consequently, 
interaction with components of the mitochondrial apoptotic machinery requires sphingolipid 
mobilization.  The relative sphingolipid concentrations in the cell must also be tightly regulated 
to maintain the sphingolipid rheostat and homeostasis.  Endogenous sphingolipid levels follow 
the scale S1P << ceramide << SM [34, 35]; however, presence of ceramide-enriched 
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macrodomains in the mitochondrial membrane during apoptosis implies local sphingolipid 
concentrations may be significantly higher than whole cell measurements [33, 36].  While the 
question of how sphingolipid metabolism accommodates these key factors in the context of 
BCL-2 family-regulated apoptosis remains to be fully addressed, we would like to review recent 
findings on two metabolic enzymes surrounding ceramide: SMase and CerS.  Non-apoptotic 
roles of BCL-2 proteins in metabolism will also be addressed in subsequent sections.   
 
1.1.1.2. Ceramide metabolism and apoptosis - sphingomyelinase  
The concept of the “sphingomyelin cycle” as a regulator of important cellular processes 
arose several decades ago, when SM turnover was implicated in key pathways such as 
differentiation and protein kinase C regulation [37, 38].  aSMase deficiency due to mutations in 
the SM phosphodiesterase-1 gene leads to Niemann-Pick diseases with serious metabolic 
consequences ranging from hepatosplenomegaly to fatal neurological degeneration [39].  
Distinct SMase populations regulate cell death at the plasma membrane and mitochondria [8, 40, 
41].  BCL-2 family-dependent apoptosis via endogenous SMase-mediated ceramide elevation 
has been observed in different cell types in response to a diverse set of signals, with some of the 
more recent examples including etoposide in G6 glioma cells [42], galectin-1 in T cells [43], 
kainic acid in Sprague-Dawley [44] rats and gemcitabine in mouse astrocytoma and primary 
human glioma cells [45].  The antibiotic minocycline protected rat cortical neurons against 
bacterial sphingomyelinase (bSMase) by up-regulating BCL-2 expression [46].  It is worth 
noting that in some of these cases de novo synthesis and sphingosine salvage could not be 
completely ruled out as alternative pathways to ceramide production.  Ceramide elevation and 
BAX translocation were also observed upon hypoxia/reoxygenation (H/R) of NT-2 human 
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neuronal precursor cells, with both aSMase and CerS5 contributing toward H/R-induced 
ceramide generation [47].  Treatment of leukemia cells with the anticancer agent N-(4-
hydroxyphenyl)retinamide led to a biphasic increase in ceramide level where the first peak 
corresponded to SM hydrolysis and the second peak was attributable to CerS [48].   
Modulation of SMase activity has been employed frequently in the study of ceramide 
function in BCL-2 family-regulated apoptosis.  Birbes et al. observed that mitochondrial 
targeting of bSMase in MCF-7 breast cancer cells triggered ceramide elevation, BAX 
translocation and cyt c-mediated apoptosis that mimicked the phenotypes of TNFα treatment [40, 
49].  BCL-2 overexpression conferred resistance to bSMase targeting [40].  bSMase addition 
increased BAX-membrane association in isolated mitochondria, and bSMase targeted to the 
cytosol, plasma membrane, ER, Golgi or nucleus raised ceramide level without triggering 
apoptosis [40].  These findings, taken together with the previous observation of both CerS and 
SMase-mediated ceramide generation in response to TNFα [50], suggest that a mitochondria-
specific ceramide pool is necessary for mediating the TNFα apoptotic response in MCF-7 cells 
[40, 49].  aSMase was also indispensable for UV-induced BAX conformational change at the 
mitochondria of several cell types [51] (Figure 1.3).  No UV-induced BAX conformational 
change and cyt c release were observed in siRNA knockdown of aSMase in HeLa cells relative 
to wild type (WT), or in lymphoblasts and fibroblasts from Niemann-Pick Disease (NPD) Type 
A patients, which are devoid of aSMase activity [51].  Exogenous C16 ceramide induced BAX 
conformational change in isolated mitochondria, and either exogenous C16 ceramide or aSMase 
overexpression could restore apoptotic phenotypes in NPD cells [51].    
A murine knockout model has been developed for aSMase [52].  aSMase
-/-
 mice appeared 
phenotypically normal at birth but gradually developed ataxia, reduced growth and  
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Figure 1.3. Ionizing radiation (IR)-induced ceramide generation and BCL-2 
family-regulated apoptosis.  IR (Cs-137)-triggered apoptosis of HeLa cells in the 
context of ceramides and BCL-2 proteins occurs through the following sequence: 
1) IR-induced CerS 2, 5 and 6 activation, 2) ceramide generation, 3) ceramide 
macrodomain formation in mitochondrial membrane and preferential BAX 
insertion at ceramide-rich sites, 4) BAX oligomerization followed by 5) MOMP 
and cyt c release.  CerS2 is required for IR-induced C24 ceramide biosynthesis 
while CerS5 and 6 are both required for IR-induced C16 ceramide biosynthesis.  
Overexpression studies reveal pro-survival function for CerS2 and pro-apoptotic 
function for CerS5.  aSMase is also indispensable for UV-induced BAX 
conformational change at the mitochondria in HeLa, human fibroblasts and 
lymphoblasts.  BAK, but not BAX, is required for CerS-mediated synthesis of 
long-chain ceramides (C16, 18 and 20) in UV-C-treated hematopoietic and baby 
mouse embryonic kidney cells.  PM: plasma membrane. 
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neurodegeneration, leading to premature death [52].  aSMase
-/-
 mice exhibited decreased 
radiation-induced pulmonary apoptosis and TNFα-induced liver damage with respect to WT [53, 
54].  BAX translocation was unimpaired in TNFα-treated aSMase-/- mouse hepatocytes, 
suggesting that aSMase could mediate the TNFα response downstream of BCL-2 proteins.  
Interestingly, inhibition of glucosylceramide synthetase protected WT hepatocytes from 
TNFα-induced apoptosis despite raising ceramide levels [54].  The glycosphingolipid 
ganglioside GD3 localized to mitochondria during apoptosis in WT but not aSMase
-/- 
hepatocytes, 
implying participation of additional ceramide metabolites in the aSMase-mediated TNFα 
response [54].  Thymol treatment of bone marrow-derived dendritic cells from WT but not 
aSMase
-/-
 mice led to SMase-mediated ceramide elevation, BCL-2 and BCL-xL down-regulation, 
caspase activation and morphological changes associated with apoptosis [55].  
 
1.1.1.3. Ceramide metabolism and apoptosis - ceramide synthase 
 Of the six mammalian CerSs, murine knockout models exist for CerS1, 2 and 3 [56-58].  
Cers1
-/-
 mice are characterized by neurodegeneration, cerebellar shrinkage and foliation defects 
[56]; Cers2
-/-
 mice are characterized by neurodegeneration, cerebellar shrinkage, altered liver 
metabolism and hepatocarcinoma [57, 58]; and lethal skin barrier disruption occurs in Cer3
-/-
 
mice [59].  siRNA knockdown of individual CerS in MCF-7 cells led to selective up-regulation 
of the remaining CerSs and no change in total sphingolipids, implying a high degree of inter-
regulation [14, 60].  BCL-2 family-regulated apoptosis via endogenous CerS-mediated ceramide 
elevation has been observed in multiple cell types in response to a wide range of stimuli, 
including gemcitabine in lung adenocarcinoma cells [61], saturated fatty acids in rat testicular 
Leydig cells [62], the anti-tumorigenic herb P. urinaria in leukemia cells [63], the AMPK 
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inhibitor Compound C in breast cancer cells [64] and UV-C irradiation of hematopoietic and 
baby mouse kidney cells [65].  A requirement for CerS in BCL-2 protein-dependent caspase 
activation was also observed in irradiated C. elegans germ cells [66].  It is worth noting that in 
some of these cases use of the CerS inhibitor fumonisin B1 (FB1) does not allow decoupling of 
de novo synthesis from the salvage pathway [67].   
Another model system used in the study of CerS and ceramide interaction with the BCL-
2 family-regulated apoptotic program is ionizing radiation (IR)-treated HeLa cells (Figure 1.3).  
Lee et al. observed mitochondria-specific elevation in CerS (but not SMase) activity and 
ceramide level in IR (Cs-137)-treated HeLa cells [33].  Ceramide elevation preceded BAX 
activation, and inhibition of either CerS or SPT led to significantly reduced BAX insertion, 
oligomerization and cyt c release, implying UV-induced de novo ceramide synthesis is required 
for BAX-dependent apoptosis in HeLa cells [33].  Confocal microscopy of mitochondria in 
irradiated HeLa cells revealed an endogenous increase in ceramide macrodomains and BAX-
macrodomain co-localization [33], in agreement with previous finding of BAX association with 
ceramide and cholesterol-rich detergent-resistant mitochondrial membranes [36].  The authors 
calculated up to 80 % of de novo CerS-generated ceramide contributed toward macrodomain 
formation [33].  Macrodomain isolation and characterization confirmed the presence of BAX 
exclusively as a higher molecular weight oligomer, further supporting ceramide-rich 
mitochondrial domains as sites for preferential BAX activation [33].    
Irradiation of HeLa cells also increased de novo ceramide generation via selective 
activation of CerS2, 5 and 6 [29] (Figure 1.3).  CerS2 (C24 ceramide) overexpression protected 
HeLa cells from IR-induced apoptosis while CerS5 (C16 ceramide) overexpression enhanced 
cell death, with similar findings in MCF-7 and HCT-116 cells [29, 68, 69].  Both CerS5 and 6 
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were required for IR-induced C16 ceramide biosynthesis [29].  Co-immunoprecipitation revealed 
direct interactions among CerS2, 5 and 6, suggesting that the balance among different CerS 
activities could modulate cell fate toward apoptosis or survival [29].  Simultaneous knockdown 
of CerS5 and 6 in MCF-7 cells also inhibited UV-C-induced post-mitochondrial plasma 
membrane permeabilization; inhibitor studies revealed the source of the CerS5/6-generated 
ceramides as sphingosine salvage rather than de novo synthesis, implicating the existence of 
distinct ceramide pools in regulating different stages of the apoptotic program [14, 69].  
Interestingly, CerS6-generated C16 ceramide protected human head and neck squamous cell 
carcinomas from ER stress-induced apoptosis via modulation of the ATF6/CHOP pathway, 
suggesting that a single ceramide may exert different functions in the context of different cell 
types and pathways [30].    
 
1.1.2. BCL-2 proteins and metabolism 
1.1.2.1. BCL-2 proteins and ceramide metabolism 
Changes in the expression of BCL-2 proteins can alter apoptotic sensitivity via 
modulation of sphingolipid metabolism.  BCL-2 overexpression in rat C6 glioma cells inhibited 
etoposide-induced nSMase activity, ceramide production, cyt c release and caspase activation 
[70].  Ceramide reduction was also observed in BCL-2-overexpressing C6 cells in response to 
TNFα or cisplatin, and in etoposide-treated C6 cells overexpressing BCL-xL; BAX 
overexpression promoted etoposide-induced apoptosis without altering ceramide production, 
suggesting that ceramide generation was not BAX-dependent in this context [70].  BCL-2 
overexpression reduced Mg
2+
-dependent nSMase activity in hypoxic PC12 cells [71].  Diamide 
treatment of MCF-7 cells led to SM hydrolysis via depletion of the nSMase inhibitor glutathione, 
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a phenotype that was blunted by BCL-xL overexpression; BCL-xL inhibited SM hydrolysis but 
not glutathione depletion, indicating BCL-xL exerted its effect upstream of ceramide metabolism 
but downstream of glutathione [72].  BCL-2 overexpression in human melanoma cells increased 
SPK1 expression while siRNA knockdown of BCL-2 induced the opposite effect [73], in 
agreement with previous finding of the role of BCL-2 in rescuing SPK1 activity from the DNA 
damaging agent ACD [74].  Interestingly, BCL-xL overexpression protected WEH1 cells from 
anti-immunoglobulin-induced apoptosis without altering ceramide level [75].  Similarly, in 
leukemia cells treated with the anticancer agent N-(4-hydroxyphenyl)retinamide, BCL-2 
overexpression inhibited the phenotypes of mitochondrial apoptosis but not early reactive oxide 
species production, which was preceded by ceramide accumulation [48].  These findings suggest 
that overexpression of anti-apoptotic proteins could rescue cells from apoptosis by acting either 
up or downstream of ceramide metabolism.     
BAX and BAK activity can also influence sphingolipid metabolism.  Loss of BAX in 
HT116 and DU 145 cells conferred resistance to ceramide-induced cell death [76].  BAX and 
BAK deficiency individually mimicked aSMase deficiency by protecting mice from lethal 
gastrointestinal syndrome and crypt lethality following radiation exposure [77].  siRNA 
knockdown of BAK in MCF-7 cells inhibited UV-C-induced C18 and C20, but not C16 
ceramide generation, suggesting that specific BCL-2 proteins could regulate distinct ceramide 
pools during apoptosis [69].  Using hematopoietic and baby kidney cells from WT and BAX, 
BAK double knockout (DKO) mice, Siskind et al. demonstrated that DKO cells were highly 
resistant to UV-C and did not up-regulate ceramide relative to WT [65].  Ceramide generation 
occurred independently of MOMP and required BAK but not BAX [65] (Figure 1.3).  CerS 
activity was significantly decreased in BAK KO cells although the enzyme and mRNA levels 
 13 
 
were unaltered, suggesting that BAK could be regulating CerS post-translationally [65].  
Importantly, addition of BAK-containing microsomes to BAK KO microsomes restored CerS 
activity, implying non-redundant functions for BAX and BAK in apoptosis and metabolism [65].   
 
1.1.2.2. BCL-2 proteins in glycolysis and fatty acid metabolism  
 In addition to sphingolipid metabolism, evidences support BCL-2 family involvement in 
glycolysis and fatty acid metabolism.  The serine/threonine kinase Akt, which blocks apoptotic 
events preceding cyt c release in a similar fashion as some anti-apoptotic BCL-2 proteins, 
requires the first committed, hexokinase-catalyzed step of glycolysis for its anti-apoptotic 
function [78].  The inhibitory effect of Akt upon growth factor withdrawal occurred downstream 
of BID cleavage to active tBID, and overexpression of myristoylated Akt in growth factor-
deprived rat fibroblasts blocked tBID-induced BAK oligomerization, a crucial step of the 
mitochondrial apoptotic program [79].  Importantly, proteomics revealed that the BH3-domain 
only pro-apoptotic protein BAD resided in a functional holoenzyme complex with protein kinase 
A, the A kinase anchoring protein WAVE-1, protein phosphatase 1 catalytic units and 
glucokinase [80].  Bad–/– mice failed to assemble this complex and displayed reduced glucose 
tolerance relative to WT [80].  Glucose induced BAD phosphorylation in hepatocytes, and 
reduced glucokinase activity was found in hepatocytes from mice expressing a non-
phosphorylatable BAD, supporting regulation of glukokinase activity by BAD phosphorylation 
status [80, 81].  Glucokinase regulates glycogen synthesis and glucose production in hepatocytes, 
and glucose-dependent insulin secretion in pancreatic β cells [81, 82]; Bad–/– islets displayed 
impaired insulin secretion that could be rescued by treatment with BAD hydrocarbon-stapled 
BH3 helices [81, 83].  Impaired insulin secretion and calcium response, and reduced glucose 
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oxidation were also present in islets from founder 2 mice overexpressing the anti-apoptotic 
protein BCL-xL [84].  These findings implicate BAD, and potentially additional apoptotic 
proteins, in the coordination of major cellular pathways previously thought to be separate; BAD 
phosphorylation in response to cellular nutrient status could be a mechanism for tuning the 
protein’s regulation of glycolysis or apoptosis.    
BAD participation in glycolysis raises the question of whether other BCL-2 members 
could influence different branches of metabolism.  While glucose deprivation induced apoptosis 
in fibroblasts [79], palmitic acid treatment of a murine T cell hybridoma cell line led to dose-
dependent reduction of mitochondrial potential, reactive oxygen species release and nuclear 
apoptosis [85]; these effects were rescued by BCL-2 overexpression, suggesting potential 
crosstalk between fatty acid metabolism and BCL-2 family-regulated apoptosis [85].  Palmitic or 
stearic, but not lauric, myristic or palmitoleic acid, induced cell death with apoptotic morphology 
in murine hematopoietic precursor cells; cell death also correlated with carnitine 
palmitoyltransferase 1 (CPT1) upregulation [86].  Direct BCL-2-CPT1 binding has been 
demonstrated via glutathione S transferase binding assay and co-immunoprecipitation [87].  tBID 
treatment of permeabilized hepatocytes in the presence of caspase inhibitors and exogenous cyt c 
reduced fatty acid oxidation, resulting in palmitoyl-CoA accumulation and depletion of acetyl-
carnitine and acylcarnitines [88]; similar to fatty acid treatment, effects of tBID were blunted by 
BCL-2 overexpression [88].     
 It is also worth noting that recent findings identified additional non-apoptotic functions 
for BAX and BAK in mitochondrial morphogenesis [89], and BID in innate immunity [90].  The 
interesting connections between BCL-2 proteins and metabolism prompted us to perform 
comparative global lipidomic analysis of WT and BAX, BAK-double knockout mouse 
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embryonic fibroblasts.  BAX and BAK were selected given their crucial roles in mitochondrial 
permeabilization during apoptosis [1, 91] and mitochondrial morphogenesis under physiological 
conditions [89], both implying potential interactions between these two proteins and lipids at the 
mitochondria.  As will be discussed in detail in Chapters 2 and 3, our analysis revealed novel 
functions for BAX and BAK in regulation of mitochondrial ceramide distribution and eicosanoid 
metabolism as further support for the interdependence of metabolism and BCL-2 family-
regulated apoptosis.    
 
1.2. Fatty acid and metabolic syndrome 
Metabolic syndrome is a multi-component disorder characterized by insulin resistance, 
atherogenic dyslipidemia, obesity and hypertension; co-occurrence of these symptoms leads to 
increased risk for cardiovascular disease and type 2 diabetes (T2D) [92, 93].  Correlation 
between obesity and T2D implies a negative metabolic role for fatty acids, and the adverse effect 
of plasma non-esterified fatty acids (NEFAs), or free fatty acids (FFAs), on metabolic 
homeostasis was thought to be due to the lipid’s promotion of insulin resistance [94, 95].  FFA 
circulation is a mechanism for shuttling FFAs to their site of utilization [94].  Circulating FFAs 
arise primarily from adipose tissue triglyceride (TG) hydrolysis during fasting [94, 96], and 
partially from spillover when dietary TGs are hydrolyzed by lipoprotein lipase (LPL) to FFAs 
that are taken up by adipocytes for storage [94, 97, 98].  Insulin inhibits lipolysis in adipose 
tissue [99], and FFAs increase insulin resistance via substrate saturation and modification of 
downstream signaling events [100].  Inhibition of the anti-lypolytic function of insulin by 
excessive circulating FFAs increases lipolysis, thereby releasing even more FFAs that adversely 
affect insulin signaling [94, 100].  Lipid infusion significantly reduced insulin stimulation of 
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PI3K, Akt1 and protein kinase Cλ/ζ in rat muscle [100, 101], and saturated FA inhibited insulin 
stimulation of Akt in murine myoblasts [100, 102].    
While evidence supports a deleterious role for FAs in promoting insulin resistance, recent 
findings suggest that interaction between FA metabolism and insulin signaling depends on FA 
structure (Figure 1.4), and is more complex than previously believed [94].  Palmitic (16:0) or 
stearic (18:0) acid, but not palmitoleic (16:1) or oleic (18:1) acid, inhibited insulin signaling 
through Akt in murine myoblasts [102].  TG-palmitate infusion into mice inhibited insulin 
signaling while TG-palmitoleate infusion stimulated downstream insulin actions, strongly 
supporting 16:1 FA function as an insulin-sensitizing lipokine [103].  More recently, the G-
protein coupled receptor GPR120 was identified as a sensor and receptor for ω3-FAs (20:5 and 
22:6 FAs) [104]; receptor stimulation with ω3-FAs significantly reduced cellular inflammatory 
response in murine macrophages; dietary ω3-FAs enhanced insulin sensitivity in WT, but not 
GPR120
–/–
 mice [105]. 
In addition, the nuclear hormone receptor peroxisome proliferator-activated receptor α 
stimulates FA oxidation to acetyl-CoA in liver during fasting [106]; fasting PPARα–/– mice 
exhibit elevated circulating FFAs and hypoglycemia [107, 108].  Linoleic (18:2) acid is an 
endogenous ligand of PPARα [106, 109], supporting a connection between glucose and FA 
metabolism, and a role for FFAs in inducing their own oxidation by acting as PPAR ligands 
[106].  18:2 FA is also a ligand for the insulin sensitizer PPARγ [110]; 18:2 FA activation of 
PPARγ is reduced by inhibiting Δ6 FA desaturase activity, indicating FA unsaturation is 
necessary for receptor interaction [110].  Dietary 18:2 FA delayed onset of T2D in Zucker rats in 
contrast to the insulin resistance role of 16:0 FA [102, 111] as additional evidence for the distinct 
metabolic functions of different FFAs.    
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Figure 1.4. Structures of selected FFAs [15, 112].  A) Structure of docosahexaenoic 
acid.  Docosahexaenoic acid is the trivial name of this FA.  The C:D, cis/trans-∆x 
nomenclature containing information on degrees of unsaturation and double bond 
locations is in parenthesis [15, 113].  In the C:D notation (i.e. 22:6), C denotes total 
number carbons and D total number of double bonds.  In the cis/trans-∆x notation 
each double bond is labeled cis or trans, and numbered based on its starting location 
(x) from the carbonyl carbon, which is numbered 1 [15, 113].  For all FAs the ω 
position refers to the terminal carbon farthest away from the carbonyl carbon [15].  
Docosahexaenoic acid is a ω3-FA given the presence of a double bond starting at the 
third (ω3) carbon relative to the ω carbon [113].  B) Structures of commonly studied 
FFAs.  Additional double bond isomers may be possible.    
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It is also important to note that in the context of T2D, mice overexpressing GLUT4, the 
major glucose transporter of insulin-sensitive tissues, in adipose tissue (AG4OX) exhibited 
enhanced insulin sensitivity but also increased lipogenesis and higher total body lipid content 
due to increased adipocyte number rather than size [114, 115].  Increased lipogenesis and insulin 
sensitivity in AG4OX mice suggest that the beneficial effect of GLUT4 upregulation could be 
carried out through modulation of lipid profile.  In agreement with this hypothesis, LC–MS-
based lipidomics of WT and AG4OX adipose tissues revealed AG4OX-induced upregulation of 
fatty acyl hydroxy fatty acid (FAHFA), a novel lipid class with beneficial effects in glucose 
tolerance and inflammation.  These findings demonstrate that lipid structure could significantly 
affect the former’s influence over insulin sensitivity, and lipid type should be carefully 
considered in addition to lipid quantity in the contexts of insulin signaling and T2D.  Detailed 
optimization of a targeted LC–MS workflow for comprehensive analysis of FAHFA isomers and 
family members will be discussed in Chapter 4.  
 
1.3. Conclusion  
Far from inert structural elements of the membrane bilayer, lipids and their metabolism 
exert key points of control over crucial cellular processes such as apoptosis and insulin signaling 
[6, 94, 100]; dysregulated lipid metabolism can lead to metabolic syndrome and diseases of 
excessive cell death or survival [1, 94, 100, 116-118].  The diverse localization of sphingolipid 
metabolic enzymes and the equally diverse targeting of their lipid products bear significant 
impact over apoptosis and other cellular processes.  Similarly, metabolism and mobilization of 
different fatty acid populations are necessary for receptor signaling and homeostasis.  Difference 
in apoptotic potential among ceramides of varying acyl chain lengths [27, 29, 30] and the 
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selective role of unsaturated FAs in receptor binding [105, 109, 110] raises the important 
question of how different members of the same lipid class could be regulated by and interact 
with protein components in vivo, both spatially and temporally, to achieve the desired 
downstream effects.  It is also important to note that while cellular metabolism can modulate 
apoptosis at the mitochondria, protein components of the apoptotic machinery are also regulators 
of cellular metabolism [88].  As is seen in the case of BAD, BAD phosphorylation is a 
mechanism for shifting the protein’s activity toward either glycolysis or apoptosis, thereby 
linking two major cellular pathways previously believed to be separate [80, 81].       
The notion that metabolism, and not just metabolites themselves, can interact with the 
protein machinery of key cellular processes also calls for a global, unbiased approach in 
quantifying complex metabolite changes in the context of protein deficiency or overexpression, 
which could be aided by recent advances in the field of metabolomics [119-121].  Oxidative 
lipidomics has become an useful tool in the study of lipid transformations during apoptosis [122-
125] and traumatic brain injury [126], and targeted LC–MS has enabled sensitive quantification 
of large numbers of polar [127] or nonpolar metabolites [128, 129] from one biological sample.  
The increased sensitivity and resolution of LC–MS-based techniques also allow identification of 
lipids with subtle differences in chain length, stereochemistry and degrees of unsaturation [130-
132].  As we will demonstrate through our studies of BAX, BAK-knockout MEFs and AG4OX 
mice in the following chapters, the combination of genetic knockout models, biochemical and 
metabolomic techniques could yield valuable information on the crosstalk among lipid 
metabolism, cell death and disease. 
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2.1. Introduction 
 The mitochondrial apoptotic pathway follows a highly regulated sequence of events and 
is dependent on BCL-2 proteins [1].  Named after its founding member, the anti-apoptotic B-cell 
lymphoma-2 [2-4], the BCL-2 family includes pro and anti-apoptotic members whose 
interactions regulate the balance between cell death and survival [1].  BCL-2 members are 
classified based on structure and function into multidomain anti-apoptotic, multidomain pro-
apoptotic and BH3 domain-only pro-apoptotic proteins [1].  A wide range of death signals 
recruits distinct BH3-domain only proteins to activate the executioner proteins BAX and BAK 
[1].  Oligomerization of BAX and BAK in the mitochondrial outer membrane leads to 
mitochondrial outer membrane permeabilization (MOMP), releasing cytochrome c (cyt c) and 
other apoptogenic factors to promote caspase activation and proteolysis [1, 5, 6].  Dysregulated 
expression of BCL-2 proteins is associated with cancer [7], autoimmune and neurodegenerative 
diseases [8, 9].   
Murine knockout models of BCL-2 members have proven useful in understanding the 
cellular functions of these proteins [9, 10].  Lymphocytes and fibroblasts from Bax
–/–
, Bak
–/–
 
(DKO) mice are resistant to apoptosis induced by a range of death signals, supporting an 
indispensable role for these proteins in mitochondrial apoptosis [9, 11, 12].  Cells from Bak
–/–
 
mice could activate both extrinsic and intrinsic apoptotic pathways [11], and either BAX or BAK 
was sufficient for anoikis or serum deprivation-induced cell death [12], implying some degree of 
functional redundancy between these two proteins.  At the molecular level, activation of BH3-
domain only proteins in response to death stimuli is believed to activate BAX and BAK either 
directly or via deactivation of anti-apoptotic proteins sequestering BAX and BAK [13].  Upon 
activation, conformational changes in cytosolic BAX trigger its mitochondrial targeting and 
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subsequent oligomerization; BAK is localized to the mitochondrial outer membrane under 
physiological conditions and oligomerizes upon activation by BH3 domain-only proteins [13, 14].    
While much of apoptosis research has focused on protein components, evidences support 
equally important functions for lipids in promoting or inhibiting apoptosis at the mitochondria 
[15-19].  Successful execution of the mitochondrial apoptotic program requires mobilization of 
key protein factors such as BCL-2 members and cyt c, which requires structural reorganization 
within the lipid bilayer [16, 19].  The mitochondrial lipid cardiolipin (CL) tethers cyt c to the 
inner mitochondrial membrane such that CL peroxidation during apoptosis is a crucial step 
toward cyt c release [20, 21], and more recently, in vitro reconstitution studies revealed 
cooperation of distinct portions of the sphingolipid metabolic pathway with BAX and BAK in 
promoting membrane permeabilization [22].  It is also interesting to note that aside from their 
role in apoptosis, recent finding supports an additional function for BAX and BAK in 
mitochondrial morphogenesis [23].  BAX and BAK co-localized with mitofusin 2 and the 
mitochondrial fission mediator dynamin-related protein 1 at sites of mitochondrial division 
during apoptosis; DKO MEFs displayed shorter, more fragmented mitochondria and lower 
fusion rates relative to WT [23].  This connection between mitochondrial dynamics and lipid 
composition [24-28] suggests that BCL-2 proteins such as BAX and BAK may also modulate 
lipid metabolism at the mitochondria.   
Lipids can also influence BAX function through direct lipid-protein binding [22]. 
Hexadecenal, the breakdown product of sphingosine via sphingosine lyase, has been shown to 
interact with BAX in a chloroform-spotted array and promote BAX oligomerization in large 
unilamellar vesicles [22].  Altered mitochondrial morphology in DKO MEFs, role of lipids in 
apoptosis and maintenance of membrane structure [16], and cooperation between lipids and 
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BCL-2 proteins support a potential function for BAX and BAK in modulating mitochondrial 
lipid levels via regulation of lipid metabolism, with impacts on both mitochondrial morphology 
and apoptosis.  To test this hypothesis, we performed unbiased, comparative global lipidomic 
analysis of WT and DKO MEFs using a quantitative liquid chromatography (LC)–mass 
spectrometry (MS) platform.  Our analysis revealed specific differences in mitochondrial lipid 
composition between DKO and WT MEFs, supporting a role for BAX and BAK in 
mitochondrial lipid metabolism.  
 
2.2. Results 
2.2.1. Comparative metabolite profiling reveals elevated level of unsaturated C16 ceramide 
in DKO mitochondria  
Lipids were extracted [29] from WT and DKO MEF mitochondria isolated using a 
standard protocol [30] and subjected to LC–MS (Figure 2.1A).  Data were analyzed via two 
separate approaches: a targeted approach that quantifies known lipids and an untargeted 
approach that identifies changes in unknown metabolites.  For the targeted approach, extracted 
ion chromatographs (EICs) corresponding to the exact mass-to-charge ratios (m/z) of common 
lipids were manually integrated to yield ion counts corresponding to relative lipid abundances. 
For the untargeted approach, WT and DKO sample files were sorted into two groups and 
analyzed by XCMS [31], which detects metabolites common to all data files through retention 
time alignment and statistically compares abundances of detected metabolites between assigned 
groups [31], enabling identification of both novel and known metabolites not included in the 
targeted analysis.   
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Figure 2.1. Comparative metabolite profiling of WT and DKO MEF mitochondria.  
A) Schematic of unbiased, comparative global lipidomic analysis of WT and 
DKO MEF mitochondrial lipid pools, allowing identification of metabolite 
changes between WT and DKO samples.  B) Volcano plot of XCMS-detected 
parent ions between 5-50 min; each ion is plotted by its DKO/WT fold change 
and associated p-value.  The DKO-elevated m/z 534 metabolite (predicted 
unsaturated C16 ceramide) and its chlorine adduct are in green.  C) Structure of 
d18:1/16:0 ceramide.  D) The DKO-elevated ceramide elutes ~1 min before 
d18:1/16:0 ceramide.  Two-tailed Student’s t-test, n=3. 
 37 
 
The targeted list included free fatty acids, phospholipids, sphingolipids, acylglycerols, 
acylcarnitines, ether lipids, cholesterol and cholesterol esters.  Targeted metabolite levels were 
largely unaltered between WT and DKO MEFs (Table 2.1), revealing that majority of lipid 
metabolic pathways were unaltered in the absence of BAX and BAK.  Untargeted XCMS 
analysis in negative ionization mode uncovered a metabolite with detected m/z 534.4886 that 
was consistently elevated in DKO mitochondria relative to WT (Figure 2.1B).  Discovery of a 
changing metabolite in a background of mostly unaltered metabolites demonstrates specificity in 
the metabolic pathway affected by loss of BAX and BAK. 
Database search (LIPID MAPS [32] and METLIN [33]) with the exact neutral mass of 
the DKO-elevated metabolite afforded the molecular formula C34H65NO3, which is characteristic 
of the sphingolipid ceramide.  One of the major mammalian ceramide species, d18:1/16:0 
ceramide (Figure 2.1C) [34, 35], has the molecular formula C34H67NO3 that differs from the 
DKO-elevated ceramide by two hydrogen atoms.  This difference corresponds to an additional 
unsaturation site in the DKO-elevated ceramide either in the sphingoid backbone (d18:2/16:0 
ceramide) or acyl chain (d18:1/16:1 ceramide) in addition to the C4-C5 trans double bond 
common to the sphingoid backbone of all mature ceramides (Figure 2.1C) [36-38].  A decrease 
of ~1 min in retention time was also observed for the DKO-elevated ceramide relative to 
d18:1/16:0 ceramide (Figure 2.1D) in agreement with the typical phenomenon of decreasing 
retention time with increasing unsaturation in reversed-phase lipid chromatography [39], 
providing further evidence that the DKO-elevated metabolite belongs to the ceramide family.  To 
conclusively identify the structure of the DKO-elevated ceramide we performed tandem MS and 
chemical synthesis.   
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Table 2.1. Comparative metabolite profiling of WT and DKO MEF mitochondria 
revealed no significant change in the levels of most common lipids. PA: 
phosphatidic acid; PE: phosphatidylethanolamine; PC: phosphatidylcholine; PS: 
phosphatidylserine; MAG: monacylglycerol; DAG: diacylglycerol and TAG: 
triacylglycerol.     
 
2.2.2. DKO-elevated metabolite is d18:2/16:0 ceramide  
Tandem MS was performed on d18:1/16:0 and DKO-elevated ceramides to determine the 
location of the unsaturation site.  Fragmentation of d18:1/16:0 ceramide in positive ionization 
mode yielded known product ions at m/z 282, 264 and 252 (Figure 2.2A, B) [40-42], all of which  
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Figure 2.2. Tandem MS of differently saturated ceramides.  A) Predicted major 
product ions for d18:1/16:0 and d18:2/16:0 ceramides in positive mode, 
corresponding to loss of two water molecules and acyl chain [40, 43].  B) Positive 
mode tandem MS of synthetic and endogenous d18:1/16:0 ceramide (m/z 538), 
and the DKO-elevated ceramide (m/z 536).            
 
derive from the sphingoid backbone [40].  Tandem MS of the DKO-elevated ceramide yielded a 
similar group of product ions at m/z 280, 262 and 250, with each ion 2 Da (i.e. an additional 
unsaturation site) lower than its corresponding ion in the d18:1/16:0 spectrum (Figure 2.2B); this 
shift in all sphingoid-derived fragments suggests that the additional unsaturation site is located 
predominantly in the backbone such that the major isomer of the DKO-elevated ceramide is 
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d18:2/16:0 rather than d18:1/16:1.  The d18:2/16:0 structural assignment was further validated 
by tandem MS in negative ionization mode, where the acyl chain-derived product ion (m/z 280) 
corresponds to a saturated (C16:0) acyl chain (Figure 2.3).   
 
 
Figure 2.3. Tandem MS of synthetic d18:1/16:0 ceramide and DKO-elevated ceramide in 
negative and positive modes.  Structures are based on published ceramide fragmentation 
predictions [40, 42-47]. 
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2.2.3. De novo biosynthesis of d18:2/16:0 ceramide from palmitoleic acid  
De novo ceramide biosynthesis occurs via coupling of palmitoyl (C16:0)-CoA to serine 
by serine palmitoyltransferase (SPT), reduction of 3-keto-sphinganine to sphinganine, acylation 
at the amine and desaturation of the resulting dihydroceramide at C4-C5 of the sphingoid 
backbone to yield mature d18:1 ceramide (Figure 2.4A) [35, 36].  This sequence implies two 
possible pathways for d18:2/16:0 ceramide biosynthesis: coupling of hexadecenoyl (16:1)-CoA 
to serine in place of palmitoyl-CoA, or presence of desaturases capable of forming additional 
double bonds across the sphingoid backbone.  Given no additional mammalian desaturases are 
known to directly desaturate dihydroceramides [48], we tested the hypothesis that palmitoleic 
(16:1, cis-∆9) acid, the dominant 16:1 fatty acid isomer in murine tissues [49], can be 
incorporated into d18:2/16:0 ceramide through the de novo pathway.  
Tolerance of the de novo ceramide biosynthetic pathway for palmitoleic acid was 
examined via stable isotope-labeled palmitoleic acid (
2
H14-16:1 FA, Figure 2.4B) feeding to 
MEFs.  
2
H14-C16:1 FA was added to DKO MEFs in cell culture and the cells were harvested at 2 
h and 21 h post-addition.  A peak corresponding to 
2
H12-d18:2/16:0 ceramide was observed at 
both 2 h and 21 h in fatty acid-treated MEFs but not DMSO controls (Figure 2.4B), indicating 
that palmitoleic acid can be incorporated into the de novo biosynthetic pathway in place of 
palmitic acid to generate d18:2 ceramide.   
  
2.2.4. Structure validation of d18:2/16:0 ceramide with synthesized standards  
d18:2/16:0 and d18:1/16:1 ceramides (Figure 2.5A) were chemically synthesized for 
further validation of the d18:2/16:0 ceramide structural assignment.  The cis double bond in the 
d18:2/16:0 standard was installed at C11-C12 given this position would derive from the  
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Figure 2.4. De novo biosynthesis of unsaturated ceramide from unsaturated fatty 
acid.  A) Ceramide biosynthesis.  B) Production of 
2
H12-d18:2/16:0 ceramide (m/z 
548.6  274.3) in DKO MEFs treated with 2H14-palmitoleic acid.   
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Figure 2.5. Structure validation of d18:2/16:0 ceramide with synthesized 
standards.  A) Structures of synthesized d18:2/16:0 and d18:1/16:1 ceramides 
with unsaturation sites as shown.  B) Positive mode tandem MS of synthetic 
d18:1/16:1 and d18:2/16:0 ceramides, and the DKO-elevated ceramide.  C) Co-
injection experiment for d18:2/16:0 ceramide.  
 
incorporation of palmitoleic acid during de novo biosynthesis.  Product ions (m/z 280, 262 and 
250) from the fragmentation of synthetic ∆4, 11-d18:2/16:0 ceramide matched those of the 
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endogenous DKO-elevated ceramide as strong support of the latter’s structure (Figure 2.5B).  
Importantly, fragmentation of the d18:1/16:1 isomer afforded the product ions m/z 282, 264 and 
252 that did not match those from the DKO-elevated ceramide.    
A co-injection experiment was also performed to verify that chromatographic retention of 
the DKO-elevated ceramide was consistent with that of the synthetic ∆4, 11-d18:2/16:0 ceramide.  
Endogenous lipid extract was mixed and co-injected with the ∆4, 11-d18:2/16:0 standard.  
Multiple reaction monitoring (MRM) targeting d18:2/16:0 ceramide (m/z 534.5  280.3) 
yielded a single peak with similar retention time and approximately twice the ion count of either 
the endogenous lipid extract or standard injected alone (Figure 2.5C), further supporting the ∆4-
trans, 11-cis-d18:2/16:0 isomer as the most likely contributor toward the unsaturated C16 
ceramide pool.  Taken together, our data indicate that the major unsaturated C16 ceramide 
isomer in MEFs is d18:2/16:0 rather than d18:1/16:1 (or the dihydroceramide d18:0/16:2), with 
palmitoleic acid incorporation being a feasible pathway toward generation of the DKO-elevated 
ceramide.  It is possible for the additional unsaturation site to be on a different backbone position 
that is beyond the resolution of our current chromatographic method; however, the prevalence of 
palmitoleic acid over additional 16:1 isomers [49] suggests that the majority of d18:2/16:0 
ceramides is likely to be ∆4, 11-d18:2/16:0.   
 
2.2.5. Unsaturated ceramides are selectively upregulated in DKO MEF mitochondria  
Elevated d18:2/16:0 ceramide level in DKO MEF mitochondria relative to WT raises the 
question of whether a similar trend is present in additional ceramide species.  To account for less 
abundant ceramide species not identified during untargeted XCMS analysis, absolute levels of 
saturated and unsaturated C16-C24 ceramides were determined by isotope-dilution MS (IDMS).  
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A 
2
H31-d18:1/16:0 ceramide standard was added to biological samples during lipid extraction, 
allowing ratiometric quantification of endogenous ceramides.  For each acyl chain both the 
saturated and unsaturated species were considered.  We define saturated ceramide as any 
ceramide with a single double bond (i.e. d18:1/16:0) and unsaturated ceramide as species with 
two double bonds (i.e. d18:2/16:0 or d18:1/16:1, collectively designated d18:1/16:0 - 2H).  
Of all detectable ceramides (Figure 2.6), species with C16 acyl chains occurred at highest 
levels (~300-1400 pmol/mg protein), followed by ceramides with C24 acyl chains (~120-600 
pmol/mg protein) (Figure 2.7A).  A decrease in abundance was observed for C18 and C20 
ceramides (~4-17 pmol/mg protein), corresponding to a ~100-fold decrease relative to C16 
ceramides (Figure 2.7A).  Levels of most saturated ceramides (i.e. d18:1/16:0) were unchanged 
between DKO and WT mitochondria.  By contrast, a significant increase (~2-4.5-fold) in most 
unsaturated ceramides was observed in the absence of BAX and BAK (Figure 2.7A). 
Summing individual ceramide changes revealed a ~2-fold elevation in unsaturated-to-
saturated (unsat/sat) total ceramide ratio in DKO MEF mitochondria relative to WT (Figure 
2.7B), which was also observed for individual acyl chains (Figure 2.7C).  No changes were 
observed in free palmitic and palmitoleic acid or in sphingadienine, sphingosine, sphinganine 
and sphingomyelins (Table 2.1, Figure 2.8A, B), suggesting that changes in ceramides were not 
the direct result of alteration in fatty acid composition or in ceramide derivatives along the 
sphingolipid metabolic pathway.  No changes in ceramides were observed in the mitochondria of 
BAX and BAK single knockout (SKO) MEFs (Figure 2.9A-C), implying compensation between 
BAX and BAK in the regulation of ceramide distribution.  A similar dependence on both BAX 
and BAK occurs in the case of mitochondrial morphogenesis, where DKO, but not SKO MEFs 
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displayed a short, fragmented mitochondrial morphology with reduced number of elongated 
tubules relative to WT [23]. 
 
 
Figure 2.6. Detectable ceramides in MEFs. 
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Figure 2.7. Absolute quantification of ceramides reveals elevated unsaturated-to-
saturated ceramide ratio in DKO MEFs relative to WT.  A) Absolute 
quantification of C14-C24 ceramides by IDMS, using 
2
H31-d18:1/16:0 ceramide 
as standard.  B) Unsaturated-to-saturated total mitochondrial ceramide ratio for 
WT and DKO MEFs.  C) Unsaturated-to-saturated mitochondrial ceramide ratio 
by ceramide acyl chain length.  *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001.  Two-
tailed Student’s t test, SEM, n=3. 
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Figure 2.8. Relative levels of additional sphingolipids in WT and DKO MEF 
mitochondria.  A) Sphingadienine, sphingosine and sphinganine levels in WT and 
DKO MEF mitochondria.  B) Sphingomyelin levels in WT and DKO MEF 
mitochondria.  No statistically significant changes were observed.  Two-tailed 
Student’s t test, SEM, n=3.         
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Figure 2.9. Ceramide levels in WT and SKO MEF mitochondria.  A) C16-C24 
ceramide levels in WT and BAX KO MEF mitochondria.  B) C16-C24 ceramide 
levels in WT and BAK KO MEF mitochondria.  C) Unsaturated-to-saturated total 
ceramide ratios in WT and SKO MEF mitochondria.  Two-tailed Student’s t test, 
SEM, n=3.         
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2.2.6. Increase in unsaturated ceramides is driven by upregulation of d18:2 ceramides in 
MEFs and iBMKs 
The DKO-elevated unsaturated-to-saturated ceramide ratio in the case of the C16 acyl 
chain (Figure 2.7C) could be largely attributed to elevation in the d18:2/16:0 ceramide isomer 
based on tandem MS (Figure 2.2B).  To test if absence of BAX and BAK selectively upregulated 
the d18:2 isomer for all DKO-elevated unsaturated ceramides, location of the additional 
unsaturation site (i.e. backbone or acyl chain) was determined for C16-C24 ceramides via MRM 
in negative mode, where the product ion corresponds to the acyl chain (Figures 2.3, 2.10A).  By 
measuring levels of unique product ions generated from precursor ions the relative abundances 
of different unsaturated ceramide isomers (i.e. d18:2/16:0 and d18:1/16:1) could be determined. 
Distinguishing two isobaric ceramide isomers requires two unique MRM transitions. 
d18:2/16:0 and d18:1/16:1 ceramides, for example, share the parent ion m/z 534, but generate 
distinct product ions upon fragmentation in negative mode.  Fragmentation of d18:2/16:0 
ceramide produces the major product ion m/z 280 corresponding to a saturated (16:0) acyl chain 
(Figures 2.3, 2.10A), thus allowing unambiguous identification and quantification of this isomer 
by monitoring its characteristic precursor-to-product ion transition m/z 534  280.  
Fragmentation of d18:1/16:1 ceramide affords the product ion m/z 278 corresponding to an 
unsaturated (16:1) acyl chain, and the transition m/z 534  278.  Taken together, MRM allows 
simultaneous quantification of all saturated and unsaturated C16-C24 ceramides with different 
degrees and locations of unsaturation, given the unique transition associated with each isomer 
(Table 2.2).  The increased sensitivity of MRM also enables detection of ceramide isomers on 
the whole cell (~10
7
 cells) level in addition to mitochondria (isolated from ~2.5 × 10
8
 cells). 
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Table 2.2. List of MRM transitions and instrument parameters for quantification of C16-
C24 ceramide isomers.     
 
Following MRM quantification of individual ceramide isomers, the unsaturated-to-
saturated ratio between DKO and WT MEFs was calculated with the unsaturated fraction being 
either ceramides containing an unsaturated (d18:2) backbone (sphunsat/sat) or those with a 
sphingosine (d18:1) backbone and unsaturated acyl chain (acylunsat/sat).  The unsaturated-to-
saturated ratio was calculated for both total ceramides (Figure 2.10B) and isomers of individual 
acyl chains on the mitochondrial (Figure 2.10C) and whole cell (Figure 2.10D) levels.  Absence 
of BAX and BAK preferentially increased the sphunsat/sat ratio for acyl chains C16-C24, but did 
not consistently alter acylunsat/sat ratios (Figure 2.10C, D); this change was less pronounced on the 
whole cell level relative to mitochondria, implying that this effect may be more localized to an 
organelle. 
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Figure 2.10. Selective regulation of MEF unsaturated ceramide pools by BAX and BAK. A) 
Predicted major fragments for d18:1/16:1 and d18:2/16:0 ceramides in negative mode, 
corresponding to loss of the sphingoid backbone [44, 47].  B) Unsaturated-to-saturated total 
mitochondrial and whole cell ceramide ratios for WT and DKO MEFs. The unsaturated ceramide 
fraction was calculated as either the sum of all d18:2 ceramides (Sphunsat/sat) or as the sum of all 
unsaturated d18:1 ceramides with the additional unsaturation site in the acyl chain (Acylunsat/sat).  
C) MEF mitochondrial Sphunsat/sat and Acylunsat/sat ratios for individual acyl chains.  D) MEF 
whole cell Sphunsat/sat and Acylunsat/sat ratios for individual acyl chains.  *, p ≤ 0.05, **, p ≤ 0.01, 
***, p ≤ 0.001.  Two-tailed Student’s t test, SEM, n=3-5.         
 
To assess the generality of our observation, MRM quantification of ceramide isomers 
was repeated in mitochondrial (Figure 2.11A) and whole cell (Figure 2.11B) fractions of WT and 
DKO immortalized baby mouse kidney epithelial cells (iBMKs).  iBMKs were chosen given 
availability of the BAX, BAK double knockout model and usage of this cell line in previous 
study of ceramides in apoptosis [50].  Importantly, absence of BAX and BAK preferentially 
increased the sphunsat/sat ratio for most C16-C24 acyl chains in iBMKs, in agreement with 
observation in MEFs (Figure 2.11A, B).  A corresponding decrease in acylunsat/sat ratio was also 
detected for several acyl chains in DKO iBMK mitochondria (Figure 2.11A), a potential 
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consequence of diversion of the unsaturated fatty acid pool toward d18:2 ceramide biosynthesis.  
Taken together, our findings suggest that BAX and BAK selectively modulate the metabolism of 
distinct unsaturated ceramide pools in different cell types. 
 
 
Figure 2.11. Selective regulation of iBMK unsaturated ceramide pools by BAX 
and BAK.  A) iBMK mitochondrial Sphunsat/sat and Acylunsat/sat ratios for individual 
acyl chains.  B) iBMK whole cell Sphunsat/sat and Acylunsat/sat ratios for individual 
acyl chains.  *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001.  Two-tailed Student’s t test, 
SEM, n=3-5.         
 
2.2.7. Serum starvation raises unsaturated-to-saturate ceramide ratio in MEFs 
 Selective upregulation of d18:2 ceramides in unperturbed DKO cells raises the question 
of whether this altered lipid state could be affected by cellular stress or apoptosis.  Ceramide 
elevation is a widely observed phenomenon across multiple cell types in response to serum 
starvation [51], UV irradiation [50, 52] or chemical treatments [53-55].  To address the question 
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of whether stress-induced ceramide upregulation correlates with ceramide unsaturation, WT and 
DKO MEFs were deprived of FBS for 13 h, and resulting changes in ceramide isomer levels 
relative to control quantified by MRM.  In agreement with literature [37, 51], serum starvation 
raised total ceramide levels in WT and DKO MEFs (Figure 2.12A) with contribution from both 
saturated and unsaturated species (data not shown).  Importantly, serum starvation also increased 
  
 
Figure 2.12. Serum starvation raises unsaturated-to-saturated ceramide ratio in 
MEFs.  A) Total ceramide level in non-serum starved and serum starved MEFs.  
B) Total unsaturated-to-saturated ceramide ratio in non-serum starved and serum 
starved MEFs.  Total unsaturated ceramide is the sum of Sphunsat and Acylunsat 
species.  C) Total Sphunsat/sat ratios in non-serum starved and serum starved MEFs, 
structure of sphingoid backbone-unsaturated (red) ceramide is on top of graph.  D) 
Total Acylunsat/sat ratios in non-serum starved and serum starved MEFs, structure 
of acyl chain-unsaturated (blue) ceramide is on top of graph.  *, p ≤ 0.05, **, p ≤ 
0.01, ***, p ≤ 0.001, two-tailed Student’s t test, SEM, n=5.  
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the total unsaturated-to-saturated ceramide ratio (Figure 2.12B) by raising the levels of both 
backbone-unsaturated (Figure 2.12C) and acyl chain-unsaturated ceramides (Figure 2.12D) to a 
greater extent than saturated species.  Our findings lead to the hypothesis that differently 
saturated ceramides are differentially regulated due to their distinct biological actions. 
 
2.2.8. d18:2/16:0 ceramide treatment of MEFs and iBMKs leads to greater viability loss 
than d18:1/16:0 ceramide 
The selective upregulation of endogenous d18:2 ceramides in the absence of BAX and 
BAK and during serum starvation, in combination with previous studies demonstrating increased 
resistance of DKO cells toward apoptosis, [9, 11, 12] suggest that differently saturated ceramides 
may exert distinct influences over cellular viability.  To test this hypothesis, WT and DKO MEFs 
and iBMKs were treated with d18:2/16:0 or d18:1/16:0 ceramide at varying doses for 24 h, and 
viability assessed by ATP measurement.  d18:2/16:0 ceramide treatment led to significantly 
higher dose-dependent viability loss than d18:1/16:0 ceramide treatment in both MEFs and 
iBMKs (Figure 2.13).  Taken together, our findings suggest that BAX and BAK could regulate 
cell fate by tuning the ratio of ceramide pools with different effects on cellular viability. 
 
2.3. Discussion 
A global lipidomics approach was used to identify metabolite changes in the absence of 
the key pro-apoptotic proteins BAX and BAK.  Given the additional role of BAX and BAK in 
mitochondrial morphogenesis and the fact that oligomerized BAX and BAK act at the 
mitochondria to facilitate MOMP during apoptosis [6, 23], we hypothesized that these proteins 
could be modulating lipid levels at the mitochondrial membrane, resulting in altered lipid  
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Figure 2.13. Viability of MEFs and iBMKs treated with d18:2/16:0 or d18:1/16:0 ceramide.  
*, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001, two-tailed Student’s t test, SEM, n=5. 
 
composition and subsequently, the changes in membrane structure necessary for successful 
propagation of the apoptotic signal.  In support of our hypothesis, LC–MS analysis of whole cell 
and mitochondrial lipids from WT and DKO MEFs revealed selective upregulation of d18:2 
ceramides in the absence of BAX and BAK.   
The roles of ceramides in apoptosis have been examined in multiple experimental settings 
[17, 19].  Modeling and experimental studies in liposomes and isolated mitochondria support 
assembly of saturated C2 and C16 ceramides into channels to facilitate protein release [56-58].  
Ceramides act synergistically with BAX to cause membrane permeabilization [59], while anti-
apoptotic BCL-2 proteins promote channel disassembly [60].  Interestingly, dihydroceramides 
have been shown to hinder channel formation [61], suggesting that distinct ceramide metabolites 
could exert opposing influences over apoptosis.  Endogenous ceramide level increases in 
response to a wide range of apoptotic signals in multiple cell types [19], and ceramide 
macrodomains in the mitochondrial outer membrane have been shown to act as preferential sites 
of BAX translocation and oligomerization during irradiation-induced apoptosis [62].     
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While the link between ceramide and apoptosis has been confirmed in different biological 
systems, it is important to note that most studies have focused on saturated ceramides [50, 56-58, 
61, 62], thus the effect of ceramide unsaturation on the lipid’s ability to influence apoptosis 
remains unclear.  Interestingly, comprehensive measurement of ceramide isomers in human 
fibroblasts revealed that > 90% of d18:2 ceramides were present in the detergent-soluble fraction 
while the major ceramide species (d18:1/16:0) localized partially (~42 %) to the detergent-
resistant fraction [34], in agreement with ceramide participation in membrane rafts and 
macrodomains that facilitate apoptosis [62-64].  This is not surprising when considered in the 
context of lipid structure, as the cis double bond introduces bending in the d18:2 backbone that 
could hinder tight packing of d18:2 ceramides into detergent-insoluble structures.   
Our LC–MS analysis revealed selective upregulation of unsaturated ceramides in the 
absence of BAX and BAK, which could be attributed to elevation in the d18:2 ceramide isomer. 
To our knowledge this is the first report of BAX and BAK regulation of endogenous 
sphingolipid metabolism, and more specifically, selective regulation of ceramides based on their 
backbone structure.  It is difficult to obtain these results using traditional ceramides analysis 
tools that do not allow simultaneous quantification of differently saturated isomers.  
Consequently, the selective regulation of d18:2 ceramides may be a more general phenomenon, 
and the current strategy could aid in the discovery of similar lipid alterations in different 
biological settings.  This is of particular interest toward the study of apoptosis, where ceramides 
have been known to regulate this process.  Modeling and empirical evidences support ceramide 
assembly into lipid domains or channels that facilitate BAX activation and protein diffusion 
during apoptosis [56, 57, 62], and ceramide release has been observed in multiple cell types in 
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response to a range of apoptotic stimuli [19, 50-55]; it may be of interest to revisit these studies 
to determine the effect of ceramide unsaturation on these processes.   
Interaction between sphingolipids and BCL-2 proteins has also been examined [22].  
Sphingosine-1-phosphate and the sphingosine breakdown product hexadecenal cooperated with 
BAK and BAX respectively to promote membrane permeabilization in in vitro reconstitution 
studies [22].  Importantly, hexadecenal, but not the saturated hexadecanal, was shown to 
physically associate with BAX in a chloroform-spotted array [22].  The cooperation of different 
sphingolipids with BAX and BAK in promoting membrane permeabilization implies that it may 
also be possible for distinct ceramide species to cooperate with BAX and BAK in regulating the 
cell state.   
Serum starvation raised unsaturated-to-saturated ceramide ratio in MEFs, and d18:2/16:0 
ceramide addition to MEFs and iBMKs resulted in significantly higher viability loss than 
d18:1/16:0 ceramide species.  While the d18:1 backbone of saturated ceramides may facilitate 
more efficient assembly into pro-apoptotic lipid domains, preferential localization of d18:2 
ceramides in the detergent-soluble fraction [34] also suggests that unsaturated ceramides may be 
less sequestered in membranes and therefore more freely shuttled across the cytosol as mediators 
of cellular homeostasis.  Mechanisms of ceramide-induced cell death are complex and include 
caspase-dependent and independent pathways [65-67].  Ceramides have been implicated in 
THFα-induced apoptosis [68], and serum starvation or exogenous C2 ceramide addition led to 
JNK/SAPK activation and apoptosis of WT Jurkat cells, but not Fas-resistant mutant clones, 
suggesting that ceramides may also function in the Fas pathway [69].  Ceramides trigger 
autophagy in rich media [37, 70, 71] and starve cells to death via nutrient transporters down-
regulation [37].  The sequential nature of apoptosis and autophagy, in combination with 
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preferential localizations of ceramide species based on structure [34], suggest that successful 
propagation of these events may require temporal regulation by different ceramide populations.  
In the context of our findings, DKO-dependent upregulation of ceramides that more potently 
reduces cellular viability may be a compensatory mechanism toward hindering excessive cellular 
survival in the absence of BAX and BAK, and suggests that these proteins could regulate cell 
fate by tuning the relative abundances of distinct ceramide populations with different impacts on 
cellular homeostasis (Figure 2.14). 
 
 
Figure 2.14. A model illustrating selective up-regulation of d18:2 ceramides in the 
absence of BAX and BAK, which may alter downstream cellular phenotypes.  
PDB ID for BAK (right): 2JCN; PDB ID for BAX (left): 1F16. 
 
Our findings also raise key questions including the cellular mechanism that links BCL-2 
proteins to ceramide metabolism.  Ceramide elevation in response to apoptotic stimuli has been 
attributed to sphingomyelin hydrolysis, de novo biosynthesis and/or sphingosine salvage 
depending on apoptotic signal and cell type [19].  BAK, but not BAX was recently shown to be 
required for UV-C-induced long chain ceramide generation via CerS in multiple cell types [50]; 
interestingly, no change in CerS mRNA or protein was observed in the absence of BAK, 
suggesting that BAK may be regulating CerS post-translationally [50].  Given the complexity in 
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the biochemical regulation of ceramide levels that encompasses multiple production pathways, a 
comprehensive approach will be needed to fully explain the connection between ceramides and 
BCL-2 proteins. 
 
2.4. Conclusion  
While the mitochondrial apoptotic pathway relies heavily on its protein machinery, 
evidences support an equally important role for lipids and lipid metabolism in promoting or 
inhibiting apoptosis at the mitochondria [16, 19].  To understand the interplay between lipids and 
the key pro-apoptotic proteins BAX and BAK, we used a comparative lipidomics approach to 
identify metabolite changes in WT and DKO MEFs.  Our analysis revealed selective 
upregulation of the unsaturated ceramide pool in DKO MEFs, which could be further extended 
into iBMKs.  Interestingly, the additional unsaturation site is present more frequently in the 
sphingoid backbone than the acyl chain, and absence of BAX and BAK selectively upregulates 
d18:2 ceramides.  Addition of heavy-labeled palmitoleic acid to MEFs led to production of the 
corresponding heavy-labeled d18:2/16:0 ceramide, supporting de novo biosynthesis from 
unsaturated fatty acid as a potential pathway toward unsaturated ceramide generation.  We also 
demonstrate that serum starvation raises the total unsaturated-to-saturated ceramide ratio in 
MEFs, and d18:2/16:0 ceramide treatment leads to greater loss of MEFs and iBMKs viability 
than d18:1/16:0 ceramide.  Our findings identify an additional function for BAX and BAK in 
modulating endogenous ceramide distribution, and suggest that BCL-2 proteins could influence 
cellular biology through regulation of lipid metabolism.    
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2.5. Methods  
2.5.1. Materials  
 Grubbs second generation catalyst, N-succinimidyl palmitate, palmitoleic acid and 
triethylamine, vinyl magnesium bromide, and anhydrous tetrahydrofuran were purchased from 
Sigma-Aldrich.  (S)-Garner aldehyde was from TCI America.  Oct-7-enal was from Novel 
Chemical Solutions.  Heptyltriphenylphosphonium bromide, sodium bis(trimethylsilyl)amide 
and oxalyl chloride were from Alfa Aesar.  (2S, 3R, E)-2-aminooctadec-4-ene-1, 3-diol (d18:1 
sphingosine) was from Avanti Polar Lipids.  Pyridine was from Mallinckrodt Chemicals and all 
additional solvents were from EMD Chemicals.         
For mass spectrometry, ammonium formate (516961) and ammonium hydroxide (338818) 
were purchased from Sigma-Aldrich.  Formic acid (06440) was from Fluka.  Water (365-4), 
methanol (230-4), isopropanol (323-4), acetonitrile (017-4) and chloroform (049-1L) were from 
Honeywell Burdick & Jackson.  All analytical columns were from Phenomenex.  The precolumn 
(C-130B) and C18 silica (C-603) were from Upchurch Scientific.  C4 silica (214TPB1520) was 
from Western Analytical Products.   
 
2.5.2. Tissue culture and harvest  
MEFs were maintained at 37 ºC with 5 % CO2 in Dulbecco's Modified Eagle Medium 
(4.5 g/ml glucose, without sodium pyruvate) supplemented with FBS (10 %), penicillin, 
streptomycin, non-essential amino acids and L-glutamine (final concentration is 6 mM).  To 
ensure consistent cell growth between WT and DKO MEFs, all cells were passaged at least three 
times and re-plated based on cell count at each passage.  Cells were harvested at confluency by 
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scraping and mitochondria were isolated immediately upon harvest.  A cell count of ~2.5 × 10
8
 is 
necessary to ensure successful mitochondria preparation.   
 
2.5.3. Mitochondria isolation and lipid extraction  
Mitochondria were isolated from MEFs following known protocol [30], using a sucrose 
isolation buffer (250 mM sucrose, 10 mM Tris-HCl, 0.1 mM EGTA ∙ 4 Na, pH 7.4).  Lipid 
extraction was performed with modifications on the Bligh and Dyer procedure [29].  
Mitochondrial or whole cell pellets were Dounce homogenized in a 2:1:1 mixture of 
chloroform:methanol:citric acid buffer (100 mM trisodium citrate, 1 M NaCl, pH 3.6).  The 
samples were centrifuged at 2200 g, 4 °C for 6 min in a glass vial, allowing separation between 
organic (bottom) and aqueous (top) layers.  The organic layer was carefully removed with a glass 
Pasteur pipet, transferred to a new glass vial and concentrated under a gentle stream of nitrogen.  
Lipids were reconstituted in chloroform, and 1/4-1/8 of sample used for LC–MS analysis.     
 
2.5.4. LC–MS general profiling of WT, DKO and SKO MEFs 
General profiling was performed on an Agilent 6220 LC-ESI-TOF instrument and data 
were acquired in both positive and negative ionization modes.  For negative mode a Gemini 
(Phenomenex) C18 column (5 µm, 4.6 mm × 50 mm) was used with a precolumn (C18, 3.5 µm, 
2 mm × 20 mm).  Solvent A was 95: 5 water: methanol with 0.1 % ammonium hydroxide, and 
solvent B was 60:35:5 isopropanol:methanol:water with 0.1 % ammonium hydroxide.  For 
positive mode a Luna (Phenomenex) C5 column (5 µm, 4.6 mm × 50 mm) was used with a 
precolumn (C4, 3.5 µm, 2 mm × 20 mm).  Solvent A was 95: 5 water: methanol with 0.1 % 
formic acid and 5 mM ammonium formate, and solvent B was 60:35:5 
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isopropanol:methanol:water with 0.1 % formic acid and 5 mM ammonium formate.  Identical 
gradient was used for both modes.  The gradient was held at 0 % B between 0 and 5 min, 
changed to 20 % B at 5.1 min, increased linearly from 20 % B to 100 % B between 5.1 min and 
45 min, held at 100 % B between 45.1 min and 53 min, and returned to 0 % B at 53.1 min and 
held at 0 % B between 53.1 min and 60 min to allow column re-equilibration.  The flow rate was 
maintained at 0.1 mL/min between 0 and 5 min to counter pressure increase due to chloroform 
injection.  The flow rate was 0.4 mL/min between 5.1 min and 45 min, and 0.5 mL/min between 
45.1 min and 60 min.  The injection volume was 30 µL.  The capillary, fragmentor and skimmer 
voltages were 3.5 kV, 100 V and 60 V, respectively.  The drying gas temperature was 350 °C, 
the drying gas flow rate was 10 L min
-1
 and the nebulizer pressure was 45 psi.  Data were 
collected in both profile and centroid modes using a mass range of 100-1500 Da.                                                                
Data were analyzed via targeted and untargeted approaches.  For the targeted approach, 
manual integration of EICs corresponding to exact m/z of known metabolites was performed in 
Agilent Quantitative Analysis.  Statistical significance was determined by two-tailed Student’s t-
test.  For the untargeted approach, raw data were converted from .d into .mzXML format via 
trapper [72]; WT and knockout samples were sorted into two groups and analyzed by XCMS 
[31].  Following filtering of XCMS output files by statistical significance, fold change and 
reproducibility across independent data sets, the remaining metabolite changes were further 
verified by manual integration in Qualitative Analysis and two-tailed Student’s t-test.  Confirmed 
unknown metabolites could then be identified through database search and tandem MS.  
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2.5.5. Synthesis of d18:2/16:0 ceramide 
 
 
Figure 2.15. synthesis of d18:2/16:0 ceramide. 
 
2.5.5.1. Synthesis of (S)-tert-butyl 4-((R, E)-1-hydroxy-9-oxonon-2-en-1-yl)-2, 2-
dimethyloxazolidine-3-carboxylate 
Stereoselective addition of vinyl magnesium bromide to (S)-Garner aldehyde was carried 
out in THF and the crude product purified by silica gel chromatography based on known 
procedures [73, 74] to yield (S)-tert-butyl 4-((R)-1-hydroxyallyl)-2,2-dimethyloxazolidine-3-
carboxylate for synthesis of d18:2/16:0 ceramide.  
 To a solution of (S)-tert-butyl 4-((R)-1-hydroxyallyl)-2, 2-dimethyloxazolidine-3-
carboxylate (280 mg, 1.1 mmol, 1 eq.) in dry DCM (10 mL) were added oct-7-enal (549 mg, 660 
μL, 4.4 mmol, 4 eq.) and Grubbs second generation catalyst (23 mg, 0.027 mmol, 0.025 eq.).  
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The solution was refluxed overnight (approximately 16 h) and completion of reaction confirmed 
by TLC (40: 60 ethyl acetate: hexanes, PMA stain, Rf = 0.35-0.4).  The reaction was 
concentrated and purified by silica gel chromatography (35: 65 ethyl acetate: hexanes).  
Fractions containing product were concentrated to afford (S)-tert-butyl 4-((R, E)-1-hydroxy-9-
oxonon-2-en-1-yl)-2, 2-dimethyloxazolidine-3-carboxylate (190 mg, 41 % yield) as a colorless 
oil.  
1
H-NMR (500 MHz, CDCl3): 1.19-1.54 (m, 21H), 1.94 (dt, 2H), 2.31 (t, 2H), 3.73-4.07 (m, 
5H including OH), 5.35 (dd, J = 15.3, 6.3, 1H), 5.9 (m, 1H), 9.64 (s, 1H).  ESI-MS: exact mass 
calculated for C19H33NO5Na
+
 (sodium adduct): 378.2251, mass detected: 378.2224, ppm 
difference 7.14. 
 
2.5.5.2. Synthesis of (S)-tert-butyl 4-((R, 2E, 9Z)-1-hydroxyhexadeca-2, 9-dien-1-yl)-2, 2-
dimethyloxazolidine-3-carboxylate  
To a suspension of heptyltriphenylphosphonium bromide (330 mg, 0.75 mmol, 3 eq.) in 
dry THF (10 mL) at 0 °C was added sodium bis(trimethylsilyl)amide (725 μL of 1 M solution in 
dry THF, 2.9 mmol, 2.9 eq.).  The solution immediately turned orange and was allowed to stir at 
0 °C for 30 min.  The solution was then cooled to -78 °C and a THF solution (2 mL) of (S)-tert-
butyl 4-((R, E)-1-hydroxy-9-oxonon-2-en-1-yl)-2,2-dimethyloxazolidine-3-carboxylate (90 mg, 
0.25 mmol, 1 eq.) was added.  The reaction was allowed to proceed overnight where it warmed 
from -78 °C to room temperature (rt) and the color dissipated until white.  Saturated aqueous 
sodium bicarbonate was added, and the aqueous phase was extracted three times with diethyl 
ether (10 mL).  The combined organic phases were washed with brine, dried over anhydrous 
sodium sulfate, concentrated and purified by silica gel chromatography (15: 85 ethyl acetate: 
hexanes, Rf = 0.3) to yield (S)-tert-butyl 4-((R, 2E, 9Z)-1-hydroxyhexadeca-2, 9-dien-1-yl)-2, 2-
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dimethyloxazolidine-3-carboxylate (36 mg, 32 % yield) as a colorless oil.  
1
H-NMR (400 MHz, 
CDCl3): 0.88 (t, 3H), 1.25-1.62 (m, 29H), 2.02 (m, 6H), 3.83 (m, 1H), 4.02 (m, 1H), 4.14 (m, 2H), 
5.34 (m, 2H), 5.44 (dd, J = 15.3, 5.2, 1H), 5.73 (m, 1H).  ESI-MS: mass calculated for 
C26H47NO4Na
+
 (sodium adduct): 460.3397, mass detected: 460.3388, ppm difference 1.96. 
 
2.5.5.3. Synthesis of N-((2S, 3R, 4E, 11Z)-1, 3-dihydroxyoctadeca-4, 11-dien-2-
yl)palmitamide  
A solution of (S)-tert-butyl 4-((R, 2E, 9Z)-1-hydroxyhexadeca-2, 9-dien-1-yl)-2, 2-
dimethyloxazolidine-3-carboxylate (33 mg, 0.076 mmol, 1 eq.) in 1 M HCl (0.75 mL) and 
dioxane (0.75 mL) was heated at 100 °C for 1 h.  The mixture was cooled to rt and neutralized 
with 1 M NaOH (1 mL).  This mixture was then extracted twice with ethyl acetate (3 mL) and 
the organic layer was sent through a plug of sodium sulfate and concentrated to yield crude 
sphingosine.  The yellowish solid was then dissolved in THF (0.5 mL) and N-succinimidyl 
palmitate (40 mg, 0.11 mmol, 1.5 eq.) was added followed by triethylamine (22 μL).  After 
stirring overnight, 1 M HCl (1 mL) was added and the mixture extracted twice with ethyl acetate 
(2 mL).  The combined organic phases were dried over anhydrous sodium sulfate, concentrated 
and purified by silica gel chromatography (66: 34 ethyl acetate: hexanes, Rf = 0.5) to yield N-
((2S, 3R, 4E, 11Z)-1, 3-dihydroxyoctadeca-4, 11-dien-2-yl)palmitamide (17 mg, 41 % yield) as a 
white solid.  
1
H-NMR (500 MHz, CDCl3): 0.88 (m, 6H), 1.25-1.35 (m, 46H), 1.63 (m, 2H), 2.00-
2.08 (m, 6H), 2.25 (t, J = 7.5, 2H), 2.88 (s, 1H), 3.70 (m, 1H), 3.88-3.96 (m, 2H), 4.3 (m, 1H), 
5.34 (m, 1H), 5.53 (dd, J = 15.5, 6.5, 1H), 5.78 (m, 1H), 6.29 (d, J = 7.5, 1H).  ESI-MS: mass 
calculated for C34H66NO3
+
 (hydrogen adduct): 536.5037, mass detected: 536.5029, ppm 
difference 1.49. 
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2.5.6. Synthesis of d18:1/16:1 ceramide [(Z)-N-((2S, 3R, E)-1, 3-dihydroxyoctadec-4-en-2-
yl)hexadec-9-enamide]  
 
Figure 2.16. Synthesis of d18:1/16:1 ceramide. 
 
To a stirring solution of (Z)-hexadec-9-enoic acid (9.7 mg, 0.038 mmol, 1eq.) at RT was 
added oxalyl dichloride (1 mL, excess).  Formation of bubbles was observed over the next 30 
min, and the reaction was stirred overnight at rt before being concentrated to afford the crude 
(Z)-hexadec-9-enoyl chloride.  The crude acyl chloride was dried under vacuum for 3 h, 
dissolved in a mixture of pyridine (15.1 μL, 0.195 mmol, 5 eq. assuming 100 % yield for 
previous reaction) and chloroform (0.5 mL), and added dropwise to a stirring solution of (2S, 3R, 
E)-2-aminooctadec-4-ene-1, 3-diol (14.7 mg, 0.049 mmol, 1.3 eq. assuming 100 % yield for 
previous reaction) in chloroform (4 mL).  The reaction was stirred at rt for 5 h, water was added 
and the resulting mixture was extracted three times with chloroform.  The combined organic 
layers were washed with brine, dried with sodium sulfate, filtered and concentrated to afford the 
crude (Z)-N-((2S, 3R, E)-1, 3-dihydroxyoctadec-4-en-2-yl)hexadec-9-enamide, which was used 
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directly for targeted tandem MS.  ESI-MS: mass calculated for C34H64NO3
-
 (loss of hydrogen): 
534.4892, mass detected: 534.4903, ppm difference 2.06. 
 
2.5.7. Absolute quantification, co-injection and tandem MS  
A 
2
H31-d18:1/16:0 ceramide standard (Avanti Polar Lipids) was used for absolute 
quantification of C16-C24 ceramides on the TOF instrument, using the same instrument, solvent 
and gradient conditions as general profiling.  The standard was added to chloroform prior to lipid 
extraction to account for metabolite loss during extraction.  Tandem MS was performed on an 
Agilent 6410 Triple Quad LC/MS instrument in Product Ion mode.  d18:1/16:0 ceramide 
standard was from Avanti Polar Lipids; d18:1/16:1 and d18:2/16:0 ceramide standards were 
synthesized.  The precursor ions were m/z 538.5 (d18:1/16:0 ceramide) and m/z 536.5 
(d18:2/16:0 and d18:1/16:1 ceramides) in positive mode, and m/z 536.5 (d18:1/16:0 ceramide) 
and m/z 534.5 (d18:2/16:0 and d18:1/16:1 ceramides) in negative mode. The time filter width 
was 0.07 min. The fragmentor voltage and collision energy were 132 V and 26 V unless 
otherwise indicated. The skimmer voltage and ΔEMV were 15 V and 400 V, respectively.  
Tandem MS range was initially set to 50-540 Da to capture the entire ceramide fragmentation 
range, and lowered to 230-290 Da to capture the region containing the greatest number of 
identifiable fragments.  The injection volume was 30 µL.  Tandem MS was recorded for 
mitochondrial and whole cell lipids from both WT and DKO MEFs to ensure presence of the 
same ceramide isomers in all sample fractions.  The same triple quadrupole instrument operated 
in MRM mode was used for co-injection; MEF whole cell lipid extract was used as sample, 25 
pmol of synthetic d18:2/16:0 ceramide was used as standard, and a combination of the sample 
and standard used for co-injection.  All samples were dissolved in chloroform such that the final 
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volume was 10 µL.  The fragmentor and collision energy were same as Product Ion.  The 
transition in negative mode was m/z 534.5  m/z 280.3; ΔEMV was 400 V; MS1 resolution was 
set to Wide and MS2 resolution to Unit.  The capillary voltage was 4.0 kV, the skimmer voltage 
was 15 V, the drying gas temperature was 350 °C, the drying gas flow rate was 8 L min
-1
 and the 
nebulizer pressure was 35 psi for all Triple Quad measurements.  Gradient and solvents were 
identical to general profiling.  
 
2.5.8. Cellular production of 
2
H12-d18:2/16:0 ceramide 
For each sample, 20 µL of 
2
H14-palmitoleic acid (Cayman Chemical) in DMSO (83 mM) 
was mixed with 10.5 mL media, and 10 mL of the media introduced to DKO MEFs in a 10 cm 
tissue culture dish.  20 µL of DMSO was used as control.  The treated cells were incubated at 
37 °C for 2 h or 21 h prior to harvest by scraping.  Lipids were extracted from cell pellets and the 
presence of 
2
H12-d18:2/16:0 ceramide product confirmed by dynamic MRM using the transition 
m/z 548.6  274.3 in positive mode.  The retention time was 42.55 min and the retention 
window was 10 min.  All other instrument, solvent and gradient conditions were identical to co-
injection and tandem MS.               
 
2.5.9. Quantification of ceramide isomers by MRM  
Individual ceramide isomers were quantified on the Triple Quad instrument using the 
same solvent, gradient and instrument parameters as tandem MS.  List of targeted transitions is 
provided in Table 2.2.  1/4-1/8 of mitochondrial sample (mitochondrial lipid extract from ~2.5 × 
10
8
 cells) or 1/3-1/6 of whole cell sample (lipid extract from ~1.5 × 10
7 
cells) was used for 
analysis.      
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2.5.10. Serum starvation 
 WT and DKO MEFs were plated and passaged three times.  The media was replaced with 
FBS-free media 48 h after the third passage.  No media was changed for control cells.  All cells 
were harvested by scraping 61 h after the third passage (13 h serum starvation).   
 
2.5.11. Cellular viability assay  
d18:2/16:0 and d18:1/16:0 ceramides (10 mM in DMSO, stored at -80 °C) were thawed 
at rt for 20 min (d18:2/16:0 ceramide is a clear solution at rt while d18:1/16:0 ceramide is a gel) 
before being warmed briefly in a water bath (70 °C, 2-5 min).  52.2 μL ceramide was transferred 
into a 15 mL Falcon tube at 70 °C, and 5 mL media (pre-warmed at 37 °C) added and 
immediately mixed with the ceramide to allow complete solubilization.  The resulting media was 
diluted serially as needed (for final ceramide concentrations of 25 μM, 50 μM and 100 μM, with 
final DMSO concentration maintained at 1 %) and the resulting dilutions added to 96-well plate 
(100 μL/well); media without DMSO and media containing 1 % DMSO without ceramide were 
used as controls.  MEFs (1000 cells in 5 μL media for each well) or iBMKs (2500 cells in 5 μL 
media for each) were added to the 96-well plate containing media with or without ceramides, and 
the plate incubated in a 37 °C incubator with 5 % CO2 for 24 h.  Viability was accessed via 
CellTiter-Glo® Lumiescent Cell Viability Assay (Promega) based on manufacturer’s instruction.  
Luminescence was measured on a Spectramax L plate reader (Molecular Devices). 
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Chapter 3 
 
A non-apoptotic role for BAX and BAK in 
COX-2 regulation  
 79 
 
3.1. Introduction  
The balance between apoptosis and survival is essential for maintenance of homeostasis 
and health in living systems [1, 2].  Apoptosis is an intricately regulated mechanism that 
proceeds through different cell type and signal-dependent pathways [2].  The mitochondrial 
apoptotic pathway is modulated by pro- and anti-apoptotic BCL-2 family members whose 
interactions in response to a diverse set of cellular signals regulate cell fate [1, 3, 4].  The anti-
apoptotic B-cell lymphoma-2 (BCL-2) is the founding member of the BCL-2 family, and its role 
in cancer was established when transgenic mice expressing a Bcl-2-lg minigene were found to 
accumulate B cells and develop lymphoma [1, 5-7].  Co-immunoprecipitation with BCL-2 led to 
identification of BAX, the first pro-apoptotic BCL-2 protein [8].  More than 20 BCL-2 members 
have been identified to date, and are classified based on structure and function into multidomain 
pro-apoptotic, multidomain anti-apoptotic and BH3 domain-only pro-apoptotic proteins [1, 9, 
10]. 
In addition to their roles in cell death, recent evidence points to novel, non-apoptotic 
functions for several BCL-2 members in metabolism [11-13], immunity [14] and mitochondrial 
morphogenesis [15].  Proteomics of mouse liver mitochondrial fractions identified a functional 
holoenzyme complex that included BAD and glucokinase [11].  BAD was required for complex 
assembly, and Bad
–/–
 mice displayed reduced glucose tolerance and abnormal glucose 
homeostasis [11].  More recently, genome-wide siRNA screen identified BID as a regulator of 
innate immunity; BID was found to interact with nucleotide-binding and oligomerization 
domains 1 and 2 (NOD1 and NOD2) in an inflammatory complex, and Bid
–/–
 mice displayed 
blunted response upon NOD agonist treatment [14].  These examples highlight the potential for 
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individual BCL-2 proteins to partake in unexpected biology, and suggest that other BCL-2 
members may also have non-apoptotic functions.  
BAX and BAK are key multidomain pro-apoptotic proteins required for the 
mitochondrial apoptotic pathway [1].  BAX and BAK oligomerization leads to mitochondrial 
outer membrane permeabilization (MOMP), a crucial step in apoptosis [1, 16].  Interestingly, 
BAX and BAK were also found to regulate mitochondrial morphogenesis; BAX and BAK 
double knockout (DKO) mouse embryonic fibroblasts (MEFs) displayed a short, fragmented 
mitochondrial morphology while BAX or BAK single knockout (SKO) MEFs did not exhibit 
this phenotype [15].  Given evidences supporting a role for lipids in activation of BCL-2 proteins 
during apoptosis [17, 18] and the close connection between membrane morphology and lipid 
composition [19, 20], we reasoned that BAX and BAK could participate in mitochondrial 
morphogenesis by interacting with mitochondrial lipids and/or regulating cellular lipid 
metabolism.  To test this hypothesis, we used an unbiased, global lipidomics approach to identify 
differences in lipid profiles among WT, DKO and SKO MEFs.   
 
3.2. Results 
3.2.1. Lipidomics uncovers a connection between BCL-2 proteins and eicosanoid 
metabolism   
Lipids from WT and DKO MEF mitochondria were subjected to liquid chromatography–
mass spectrometry (LC–MS) analysis (Figure 3.1A).  Data were analyzed by XCMS [21], which 
aligns, quantifies and statistically ranks fold changes of all detectable ions common to WT and 
DKO groups (Figure 3.1B).  Analysis of major lipid classes including free fatty acids, 
phospholipids, acylglycerols, acylcarnitines, glycerol ethers, cardiolipins, cholesterol and  
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Figure 3.1. Comparative lipidomic profiling of WT and DKO MEF mitochondria.  
A) Schematic of unbiased, comparative global lipidomic analysis of WT and 
DKO MEF mitochondrial lipid pools, allowing identification of metabolite 
changes between WT and DKO samples.   B) Volcano plot of all XCMS-
detectable ions from WT and DKO MEF mitochondria.  The m/z 369.23 ion, 
which is consistently down-regulated in DKO mitochondria relative to WT, is in 
green.  C) Extracted chromatographs of the m/z 369.23 metabolite in WT and 
DKO MEF mitochondria.  Two-tailed Student’s t-test, n=3. 
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cholesterol esters yielded no significant changes based on our criteria (≥ 3-fold change, p-value ≤ 
0.05) (Table 2.1).  While metabolites from major lipid classes were unaltered, an unidentified 
metabolite (m/z: 369.2255, calculated formula: C20H34O6) was consistently down-regulated in 
DKO MEF mitochondria relative to WT (Figure 3.1B, C).  Importantly, perturbation in the level 
of a single metabolite in a background of unchanging lipids supports specifity in the pathway 
that is altered.  
Database searches (Lipid Maps [22] and KEGG [23]) uncovered six known eicosanoids 
(6-keto-prostaglandin F1α, 16, 5-diketo-13, 14-dihydroxy-prostaglandin F1α, 20-hydroxy-
prostaglandin F2α, thromboxane B2, 19(R)-hydroxy-prostaglandin F2α and 19(R)-hydroxy-
prostaglandin E1) that matched the calculated molecular formula (Figure 3.2).  Structural  
 
 
Figure 3.2. Structures of eicosanoids with formula C20H34O6.  
 
similarities among these candidates presented a challenge toward characterizing the unidentified 
metabolite.  While our non-high resolution global lipidomics method allows injection of 
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relatively large sample volumes and simultaneous quantification of lipids from a wide range of 
lipid classes, this method is not suited to more sensitive resolution of the structurally similar 
eicosanoids, leaving open the possibility that the unidentified metabolite is a mixture of multiple 
species.  To address this question we performed tandem MS and chromatography optimization.       
 
3.2.2. Unidentified metabolite is 6-keto-PGF1α  
 Comparison between tandem MS spectra of candidate eicosanoid standards and 
endogenous m/z 369.23 metabolite strongly suggests that the latter is predominantly 6-keto-
prostaglandin F1α, (6-keto-PGF1α) (Figure 3.3A, B).  Based on our tandem MS findings we 
developed a robust chromatographic method enabling baseline separation of 6-keto-PGF1α away 
from additional eicosanoids (Figure 3.3B).  A column with increased length and decreased 
internal diameter and particle size than the global lipidomics column was chosen to achieve 
higher resolution of the structurally similar eicosanoids.  A water-acetonitrile solvent system was 
chosen over the previous water-methanol-isopropanol system to improve resolution and retention 
while countering increased column backpressure; addition of formic acid also significantly 
improved 6-keto-PGF1α peak shape (Figure 3.3C).  Co-injection of 6-keto-PGF1α standard with 
endogenous sample using the improved chromatographic method yielded a single peak 
corresponding to the m/z of 6-keto-PGF1α (Figure 3.3D).  The combination of tandem MS and 
co-injection provides strong evidence that the unidentified metabolite is 6-keto-PGF1α.   
 
 
3.2.3. Elevated arachidonic acid levels in DKO and SKO MEFs support BCL-2 regulation 
of prostaglandin biosynthesis 
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Prostaglandins are produced de novo in most cell types from arachidonic (C20:4) acid in 
response to mechanical trauma or inflammatory stimuli [24].  Upon release from membrane 
phospholipids by phospholipases, arachidonic acid is converted to the intermediate prostaglandin 
H2 and further processed into downstream eicosanoids by cell type-specific enzymes [24, 25] 
(Figure 3.4A).  Within this pathway, 6-keto-PGF1α is the hydrolysis breakdown product of the 
vasodilator and potent platelet activation inhibitor prostaglandin I2 (prostacyclin) (Figure 3.4A) 
[26, 27].  The relative stability of 6-keto-PGF1α has allowed its measurement as a marker for 
eicosanoid metabolism [28]. 
Reduced 6-keto-PGF1α levels in DKO MEFs could be the result of decreased 6-keto-
PGF1α production or increased catabolism.  In accordance with previous literature [29, 30], we 
did not observe significant amounts of additional prostaglandins, a possible consequence of the 
short half-lives of these metabolites [24, 31, 32].  Instead, we measured arachidonic acid levels 
in WT and DKO MEF mitochondria to determine if absence of BAX and BAK could have an 
impact over arachidonic acid metabolism.  Our analysis revealed a two-fold (p < 0.05) elevation 
in arachidonic acid in DKO MEF mitochondria relative to WT, with no changes in additional 
common free fatty acids (Figure 3.4B).  Decreased 6-keto-PGF1α and elevated arachidonic acid 
levels in DKO MEFs support a reduction in the rate of prostaglandin biosynthesis in the absence 
of BAX and BAK.   
To determine if BCL-2 regulation of eicosanoid metabolism requires both BAX and BAK, 
we extended our LC–MS analysis to include BAX and BAK single knockout (SKO) MEFs.  6-
keto-PGF1α was reduced in both DKO and Bax
–/–
 MEF mitochondria relative to WT (Figure 
3.4C); a similar but non-statistically significant trend was observed for the Bak
–/–
 model (Figure 
3.4C).  Arachidonic acid was significantly elevated in DKO, Bax
–/–
, and Bak
–/–
 MEF  
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Figure 3.3. Unidentified metabolite is 6-keto-PGF1α.  A) Preliminary tandem MS spectra 
of endogenous m/z 369.23 metabolite and candidate eicosanoid standards.  Spectra of 
endogenous metabolite and 6-keto-PGF1α standard are in red.  Fragmentor voltage and 
collision energy are 140 V and 27 V, respectively, for 19(R)-OH-PGE1, and 150 V and 
10 V for all additional samples.  B) Optimized tandem MS spectra for endogenous m/z 
369.23 metabolite and 6-keto-PGF1α standard.  Fragmentor voltage and collision energy 
are 140 V and 27 V.  C) Optimized chromatographic method for resolution of the six 
candidate eicosanoids, enabling baseline separation of 6-keto-PGF1α from additional 
species.  D) Co-injection of 6-keto-PGF1α with endogenous sample. 
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mitochondria relative to WT, with more significant metabolite change present in the absence of 
BAX than BAK (Figure 3.4C).  6-keto-PGF1α and arachidonic acid were further quantified in 
whole cell extracts to determine if the observed metabolite differences were organelle-specific.  
6-keto-PGF1α was reduced in DKO and Bax
–/–
 whole cell extracts (Figure 3.4D) while 
arachidonic acid was elevated in SKO MEFs (Figure 3.4D).  Taken together, our data 
demonstrate that BAX, and to a lesser extent BAK, regulate cellular eicosanoid metabolism, and 
imply that the levels or activities of eicosanoid biosynthetic enzymes are decreased in the 
absence of these proteins.  
 
 
Figure 3.4. Absence of BAX and/or BAK reduces eicosanoid metabolism.  A) Prostacyclin 
biosynthesis from arachidonic acid.  B) Levels of common free fatty acids (FFAs) in WT and 
DKO MEF mitochondria (n = 3).  C) 6-keto-PGF1α levels in WT, DKO and SKO MEF 
mitochondria (n = 3).  D) Arachidonic acid levels in WT, DKO and SKO MEF mitochondria (n 
= 3).  E) 6-keto-PGF1α levels in WT, DKO and SKO MEF whole cell lysates (n = 3-5).  F) 
Arachidonic acid levels in WT, DKO and SKO MEF whole cell lysates (n =3-5).  *, p ≤ 0.05, **, 
p ≤ 0.01, ***, p ≤ 0.001.  Two-tailed Student’s t test, SEM. 
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3.2.4. BAX and/or BAK regulate COX levels  
Conversion of arachidonic acid to prostaglandins is catalyzed by prostaglandin H 
synthase (PGHS, alternatively known as cyclooxygenase [COX]) at the ER and nuclear 
membranes [24].  Two COX isoforms are known; COX-1 is responsible for basal, constitutive 
prostaglandin production while COX-2 is an inducible enzyme that is activated by stress signals 
[24, 33].  Importantly, COX-2 is the primary target of non-steroidal anti-inflammatory drugs due 
to its physiological role in inflammation [33].  Elevated arachidonic acid and decreased 6-keto-
PGF1α levels in the absence of BAX and/or BAK could be a consequence of COX down-
regulation.  To test this hypothesis, COX expression in WT, DKO and SKO whole cell lysates 
was monitored by Western blot.  While COX-1 level was unaltered, COX-2 expression was 
significantly reduced in DKO and SKO lysates relative to WT (Figure 3.5A).  The extent of  
 
 
Figure 3.5. BAX and/or BAK regulate COX levels.  A) Western blots against 
COX-1 and 2 in WT, DKO and SKO MEFs.  B) RT-PCR of Cox-1 and 2 in WT 
and Bax
–/– 
MEFs 
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BCL-2 regulation of COX-2 correlated well with BCL-2-induced changes at the metabolic level, 
with absence of BAX causing stronger changes in both prostaglandin and COX-2 levels in 
comparison to BAK (Figure 3.4C, D; Figure 3.5A). 
Given the most significant difference in COX-2 expression was observed between WT 
and Bax
–/–
 MEFs (Figure 3.5A), we performed real time-PCR on Cox-1 and Cox-2 in these cells.  
Interestingly, Cox mRNA changes did not correlate with protein expression; Cox-1 mRNA was 
reduced in Bax
–/–
 MEFs while no change was observed in Cox-2 mRNA (Figure 3.5B).   
To compare WT and Bax
–/–
 MEF transcriptional profiles more globally and map the 
resulting differences into known biological processes, we also performed RNA sequencing 
followed by gene set enrichment analysis (GSEA).  GSEA of altered genes using the KEGG 
collection of canonical pathways (C2:CP:KEGG) revealed mapping into multiple gene sets 
including arachidonic acid metabolism and cytokine cytokine receptor interaction, both 
hallmarks of the cellular inflammatory response (Figure 3.6) and in agreement with our 
metabolomics and Western blot data.    
 
3.2.5. BAX impairs COX-2 induction by LPS   
COX-2 induction and subsequent increase in COX activity are key steps of the 
inflammatory cascade, as demonstrated by the success of COX-2 inhibitors in preventing 
inflammation [33].  A variety of agents stimulate COX-2 expression and inflammation, including 
E. coli lipopolysaccharide (LPS), a bacterial endotoxin and ligand for Toll-like receptor 4 (TLR4) 
[34].  While our data in MEFs clearly demonstrate BAX regulation of basal COX-2 expression, 
we also addressed the question of whether absence of BAX perturbs COX-2 induction by LPS, 
which would more accurately mimic an endogenous inflammatory response.  WT and Bax
–/–
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Figure 3.6. GSEA of RNA-Seq results from WT and Bax
–/–
 MEFs.  Enrichment 
results are shown for the arachidonic acid metabolism and cytokine cytokine 
receptor interaction gene sets. 
 
MEFs were harvested 0, 3 and 6 hours post-LPS treatment, and Cox mRNA and protein levels 
were measured (Figure 3.7A).  LPS increased Cox-2, but not Cox-1, transcript and protein levels 
in WT MEFs (3.7B, C).  Importantly, the Cox-2 response in Bax
–/–
 MEFs was significantly 
blunted, demonstrating a role for BAX in the cellular inflammatory response to LPS (Figure 
3.7B, C).  In addition, basal Cox-1 transcription, but not expression, was reduced in the absence 
of BAX, suggesting that BAX could also modulate Cox-1 transcription (Figure 3.5B; Figure 
3.7B, C).  Taken together, our data strongly support a diminished cellular inflammatory response 
through a marked reduction in COX-2 in the absence of BAX. 
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Figure 3.7. BAX impairs COX-2 induction by LPS.  A) Schematic of E. Coli LPS 
addition to MEFs.  B) RT-PCR of Cox-1 and 2 in LPS or PBS-treated WT and 
Bax
–/– MEFs.  Cells (n=3) were treated with LPS (1 μg/mL) or PBS for 6 h.  C) 
Western blots against COX-1 and 2 in LPS or PBS-treated WT and Bax
–/– 
MEFs.  
Cells were treated with LPS (1 μg/mL) or PBS for 0, 3 or 6 h.  *, p ≤ 0.05, **, p ≤ 
0.01, ***, p ≤ 0.001.  Two-tailed Student’s t test, SEM.  
 
3.2.6. BAX modulates kinetics of TLR4 signaling  
TLR4 belongs to the Toll-like receptor family, a well-characterized family of pattern 
recognition receptors (PRRs) involved in pathogen sensing [35].  TLR4 recognizes 
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lipopolysaccharide, a component of the outer membrane of Gram-negative bacteria [35].  LPS 
stimulation of TLR4 triggers recruitment of distinct adaptor proteins and assembly of 
downstream inflammatory complexes, resulting in activation of NFκB and MAP kinase (MAPK) 
cascades via TAK1, and subsequent transcription of inflammatory genes [35].  To determine if 
the blunted cellular response to LPS in the absence of BAX is attributable to a specific signaling 
pathway, WT and Bax
–/–
 MEFs were harvested at 15-minute intervals following LPS addition, 
and time-dependent phosphorylation along the NFκB and MAPK pathways monitored by 
phospho-Western blot.    
  Activation of the TAK1, TAB1 and TAB2/3 complex leads to phosphorylation of NEMO 
and activation of an IKK complex; phosphorylation of IκBα induces its degradation, freeing 
NFκB to be phosphorylated and act as a transcription factor in the nucleus (Figure 3.8A) [35].   
 
 
Figure 3.8. BAX modulates kinetics of TLR4 signaling.  A) Schematic of NFκB and MAPK 
signaling in response to LPS stimulation of TLR4.  B) Western blots demonstrating time-
dependent activation of NFκB and MAPK pathways in response to LPS treatment.  Cells were 
treated with LPS (2 μg/mL) at the indicated time points.  Cells at 0 min were treated with PBS.  
C) Western blots against non-phosphorylated proteins in the NFκB and MAPK pathways. 
 
TAK1 also activates the MAPK pathway (Figure 3.8A) by inducing phosphorylation of ERK, 
p38 and SAPK/JNK [35].  To assess response of these two pathways to LPS in the presence or 
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absence of BAX, we performed Western blot against IκBα, phosphorylated NFκB, and 
phosphorylated ERK, p38 and SAPK/JNK in LPS-treated WT and Bax
–/–
 MEFs.  LPS activated 
both NFκB and MAPK signaling in WT MEFs, as demonstrated by the time-dependent 
disappearance of IκBα and phosphorylation of NFκB and MAP kinases (Figure 3.8B).  
Interestingly, LPS-treated Bax
–/–
 MEFs displayed altered kinetics in NFκB and MAPK signaling; 
absence of BAX resulted in a stronger, but short-lived activation of both NFκB and MAPK 
pathways relative to WT (Figure 3.8B).  No significant differences in non-phosphorylated NFκB, 
ERK, p38 and JNK levels were observed between WT and Bax
–/–
 MEFs (Figure 3.8C), 
suggesting that altered phosphorylation kinetics in the absence of BAX was not a direct result of 
changes in the levels of these proteins.  Taken together, our findings suggest that BAX regulates 
COX-2 response to LPS by modulating the kinetics of NFκB and MAPK signaling. 
 
3.2.7. BAX co-immunoprecipitation supports BAX-protein interactions  
 Altered NFκB and MAPK signaling in the absence of BAX raises the question of whether 
this effect is due to direct interaction between BAX and downstream inflammatory complexes 
that assemble upon LPS binding to TLR4.  Similar changes in the kinetics of NFκB and MAPK 
signaling suggest that potential BAX-inflammasome interactions precede these two pathways 
and occur at or upstream of TAK1.  To test this hypothesis, we performed co-
immunoprecipitation against BAX in LPS-treated or untreated WT and Bax
–/–
 MEFs.  BAX was 
successfully precipitated in LPS-treated and untreated WT MEFs while no pulldown was 
observed in Bax
–/–
 MEFs (Figure 3.9).   
 Proteins were precipitated from co-IP fractions, digested with trypsin and analyzed by 
LC–MS to identify potential interactors of BAX.  Trypsin-digested samples were labeled with 6- 
 93 
 
 
Figure 3.9. Co-immunoprecipitation of BAX in LPS-treated or untreated WT and 
Bax
–/–
 MEFs. 
 
plex tandem affinity tags (TMTs) to enable peptide quantification.  A large WT/KO enrichment 
was observed for BAX (26-fold), in agreement with Western blot data (Figure 3.9, Table 3.1). 
Consistently enriched proteins and their detected fragments are listed in Table 3.1.  Interactions 
between BAX and 14-3-3 proteins have been previously demonstrated through co-IP [36, 37].  
Cytosolic localization of p53 induces apoptosis by directly activating BAX [38], and co-
localization of p53 and activated BAX in response to the apoptotic agent staurosporine has been 
observed via confocal microscopy [39], supporting a direct BAX-p53 interaction.  No BAX-
TRIM21 interaction is known; however, TRIM21 is of particular interest given its role in 
acquired and innate immunity through regulation of NFκB and IRF signaling [40, 41].  We hope 
to further confirm these findings via Western blot and MRM targeting known peptide fragments 
of enriched proteins; effects of knockdowns of enriched proteins on the cellular inflammatory 
response will also be examined.   
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Table 3.1. List of consistently enriched proteins from co-immunoprecipitation of BAX.  The 
most abundant detected peptide and its WT/KO enrichment for each protein are in bold.  Protein 
functions are based on UniProt (http://www.uniprot.org) search. 
 
3.3. Discussion  
The recent emergence of non-apoptotic functions for several BCL-2 proteins suggests 
that other members of this family might also be involved in biology outside of cell death [11, 14, 
15].  Here, we demonstrate that BAX and BAK regulate the magnitude of the cellular 
inflammatory response, as measured by NFκB and MAPK signaling, COX-2 expression and 
prostaglandin production.  Importantly, altered inflammatory response was present in both DKO 
and SKO MEFs, suggesting that BAX and BAK cannot compensate for each other in this 
function, which stands in contrast to their capacity to subserve each other’s pro-apoptotic and 
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mitochondrial morphogenesis roles [15, 42].  Thus, BAX and BAK are likely modulating the 
cellular inflammatory response through a separate pathway from their regulation of 
mitochondrial morphology and apoptosis, which are dependent on both proteins.  Differences in 
prostaglandin level and basal COX-2 expression were more pronounced in Bax
–/–
 than Bak
–/–
 
MEFs, leading us to focus on the role of BAX in COX-2 regulation.  
Endogenously, COX-2 expression is induced in response to inflammatory signals.  LPS 
treatment of macrophages leads to COX-2 upregulation and prostaglandin E2 production [43].  
Prostaglandin accumulation is also associated with increased COX-2 expression in inflamed 
tissues in rat models of adjuvant arthritis [44].  To mimic these conditions in MEFs we 
monitored changes in COX protein and RNA levels following LPS treatment.  Given the 
inducible nature of COX-2, significant differences in Cox-2 mRNA were only observed between 
WT and Bax
–/–
 MEFs in the presence of LPS (Figure 3.7B).  Absence of BAX inhibited the 
upregulation in Cox-2 mRNA and protein following LPS treatment (Figure 3.7B, C).  Taken 
together, our data clearly indicate that BAX regulates COX-2 at both transcriptional and 
translational levels in response to LPS.  
Paradoxically, Cox-1 mRNA was reduced in Bax
–/–
 MEFs while COX-1 expression was 
unaltered between WT and Bax
–/–
 cells in the presence or absence of LPS (Figure 3.5B; Figure 
3.7B, C).  While it is possible for BAX to regulate Cox-1 transcriptionally, the role of the latter 
in basal prostaglandin biosynthesis implies significant change in the level of the COX-1 enzyme 
could be detrimental to the cell.  Consequently, similarity in COX-1 expression between WT and 
Bax
–/–
 MEFs could be a translational or post-translational compensatory mechanism on the part 
of Bax
–/–
 cells to restore COX-1 production to wild type levels.  RNA sequencing of WT and 
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Bax
–/–
 MEFs followed by GSEA revealed mapping to pathways associated with inflammation as 
further support of our observations on the metabolite and enzyme levels (Figure 3.6).    
To our knowledge, this is the first report linking BAX and BAK to the regulation of 
prostaglandins, COX-2 and inflammation; however, the BCL-2 family member BID was recently 
shown to have a role in inflammation and innate immunity [14], suggesting that there may be a 
general connection between inflammation and the BCL-2 family.  BID is downstream of NOD1 
activation, which has been implicated in intestinal inflammation [14].  Together with Toll-like 
receptors and two other receptor families, the NOD proteins belong to a group of pattern 
recognition receptors (PRRs) that recognize a variety of ligands associated with microbial 
infection or tissue damage [35].  BID mediates formation of the NOD signalome upon NOD 
activation, leading to production of inflammatory cytokines and chemokines; NOD activation in 
the absence of BID results in significantly blunted inflammatory response, as demonstrated by 
reduced NFκB and MAPK signaling, and cytokine production [14].  
Based on our finding that BAX is upstream of LPS-induced COX-2 upregulation we 
hypothesize that BAX could also be participating in the assembly of downstream inflammatory 
complexes upon LPS binding to TLR4; absence of BAX could lead to complex destabilization 
and subsequently, reduced NFκB and MAPK signaling, and COX-2 translation [45].  
Surprisingly, LPS treatment of Bax
–/–
 MEFs induced significantly more rapid activation but also 
deactivation of both NFκB and MAPK pathways (Figure 3.8B), and no detectable increase in 
COX-2 (Figure 3.7C), relative to WT.  We hypothesize that absence of BAX could increase the 
kinetics of inflammatory complex assembly due to the presence of fewer components in the 
complex; however, assembled complexes lacking BAX could also be more destabilized and 
prone to degradation than WT, resulting in the altered signaling kinetics in Bax
–/–
 MEFs (Figure 
 97 
 
3.10).  It is worth noting that in the NOD pathway, removal of BAX had no impact on 
inflammatory response [14], indicating that different BCL-2 proteins may regulate distinct 
inflammatory pathways initiated by different PRRs.  The elucidation of these connections 
represents a new frontier in understanding the non-apoptotic roles of BCL-2 proteins and 
supports a more general function for the BCL-2 family in immunity. 
 
 
Figure 3.10. A model illustrating altered kinetics of LPS-induced TLR4 signaling in the absence 
of BAX.    
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Co-immunoprecipitation of BAX identified five consistently WT-enriched proteins 
(Table 3.1).  TRIM21 is of particular interest given its roles in innate and acquired immunity [46].  
TRIM21, also known as Ro52, is an autoantigen involved in autoimmune diseases such as 
systemic lupus erythematosus [46, 47].  TRIM21 has E3 ubiquitin ligase activity and regulates 
the levels of type I interferons and cytokines in response to viral or bacterial infection via 
ubiquitination of the interferon regulatory factors IRF3, 5 7 and 8 [47].  TRIM21 is tyrosine 
phosphorylated upon TLR3 or TLR4 stimulation, suggesting interaction between this protein and 
TLR signaling [48].  Interestingly, MEFs isolated from Trim21
–/–
 mice displayed higher levels of 
LPS-induced cytokine production relative to WT; luciferase reporter analysis revealed elevated 
NFκB activity in LPS-treated Trim21–/– MEFs relative to WT, supporting negative regulation of 
NFκB signaling by TRIM21 [41, 46].  It is worth noting that in a separate study demonstrating a 
PRR-independent role for TRIM21 in intracellular antibody recognition, no LPS induction of 
NFκB was observed in WT or Trim21–/– MEFs, although this could be attributable to differences 
in the concentration of LPS used [40].  The overlap of multiple inflammatory pathways both at 
the level of ligand binding and at NFκB suggests the possibility of TRIM21 involvement in 
different receptor signaling pathways depending on cell state; BAX interaction with TRIM21 
could affect the latter’s regulation of inflammatory responses through perturbations in NFκB 
and/or additional signaling pathways.   
  
3.4. Conclusion  
Global lipidomics of WT, BAX and BAK-double knockout, and BAX or BAK single 
knockout MEFs revealed down-regulation of 6-keto-PGF1α and accumulation of the eicosanoid 
precursor arachidonic acid in DKO and SKO MEFs relative to WT.  In agreement with 
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metabolite data, expression of the inducible prostaglandin biosynthetic enzyme COX-2 was 
significantly decreased in DKO and SKO MEFs relative to WT.  Absence of BAX resulted in 
blunted LPS-induced COX-2 upregulation by altering the kinetics of TLR4 signaling through 
both NFκB and MAPK pathways, supporting potential BAX-inflammasome interactions 
downstream of LPS binding to TLR4.  Co-immunoprecipitation followed by proteomics 
identified five potential interactors of BAX, including the protein-ubiquitin ligase TRIM21 with 
known roles in immunity [40, 41].  Knockdown of these proteins in mammalian cells and 
extension of our study into murine models could yield additional information on BAX-
inflammasome interactions and their effects on cytokine production and COX-2 regulation.    
 These studies uncover a novel role of BAX that will strongly impact the current 
understanding of COX-2 regulation.  COX-2 is the predominant enzyme responsible for the 
production of inflammatory prostaglandins.  Inhibition of this COX isoform formed the basis for 
the development of COX-2 inhibitors as drugs for treatment of inflammatory diseases such as 
rheumatoid arthritis [49].  Unfortunately, these drugs were ultimately recognized to increase 
cardiovascular risks most likely due to their effects on prostacyclin production [49].  The 
discovery of COX-2 regulation by BAX raises new questions and possibilities; the presence of 
this pathway in specific cell types or tissues could allow for controlled targeting of COX-2 
without diminishing its cardioprotective roles.  Future work will aim to elucidate the molecular 
mechanism linking BCL-2 proteins to COX-2, and explore potential applications of these 
insights toward the development of therapeutics.  
 
3.5. Methods  
3.5.1. Materials  
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Ammonium formate (516961), ammonium acetate (372331), ammonium hydroxide 
(338818) and lipopolysaccharides from E. coli 0111:B4 (L4391) were purchased from Sigma-
Aldrich.  Formic acid (06440) was from Fluka.  Water (365-4), methanol (230-4), isopropanol 
(323-4), acetonitrile (017-4) and chloroform (049-1L) for lipid extraction and LC–MS were from 
Honeywell Burdick & Jackson.  6-keto-prostaglandin F1α (10007219), 16, 5-diketo-13, 14-
dihydroxy-prostaglandin F1α (15270), 20-hydroxy-prostaglandin F2α (16950), thromboxane B2 
(19030), 19(R)-hydroxy-prostaglandin F2α (16910) and 19(R)-hydroxy-prostaglandin E1 (13910) 
were from Cayman Chemical.  Mouse anti-COX-1 (ab695), rabbit anti-COX-2 (ab15191), mouse 
anti-β-actin (ab8226) and rabbit anti-VDAC (ab15895) primary antibodies were from Abcam.  
Mouse anti-cytochrome c antibody (556433) was from BD Pharmingen.  NF-κB Pathway 
Sampler Kit (9936), MAPK Family Antibody Sampler Kit (9926) and phospho-MAPK Family 
Antibody Sampler Kit (9910) were from Cell Signaling Technology.  Protein A/G PLUS-
Agarose (sc-2003), rabbit anti-JNK1/3 (sc-474) and rabbit anti-BAX (sc-493) primary antibodies 
were from Santa Cruz Biotechnology.  IRDye 680LT donkey anti-rabbit (926-68023) and IRDye 
800CW goat anti-mouse (926-32210) secondary antibodies were from LI-COR.  RIPA buffer 
(89901) was from Thermo Scientific. 
 
3.5.2. Tissue culture and harvest 
Mouse embryonic fibroblasts were maintained in 5 % CO2 at 37 °C in Dulbecco’s 
Modified Eagle’s Medium (Life Technologies, 11965) supplemented with 10 % fetal bovine 
serum (Hyclone, SH300070.03), penicillin (70 µg/mL), streptomycin (110 µg/mL), non-essential 
amino acids (1X) and L-glutamine (final concentration 6 mM).  All cells were passaged (1:4-1:6) 
at least three times by trypsinization and harvested 36-40 h after the last passage by scraping.  
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Cell pellets were frozen at -80 °C except for mitochondria preparation, in which case 
mitochondria were isolated from cells immediately upon harvesting.  
 
3.5.3. Mitochondria isolation and lipid extraction 
Mitochondria were isolated from ~2.5 × 10
8
 cells based on known protocol [50] using a 
sucrose isolation buffer (250 mM sucrose, 10 mM Tris-HCl, 0.1 mM EGTA ∙ 4 Na, pH 7.4).  
Lipids were extracted from either mitochondria (from ~2.5 × 10
8
 cells) or whole cell (~10
7
 cells) 
pellets with modifications on known protocols [51, 52].  Pellets were either Dounce 
homogenized 30-40 times on ice or shaken for 30 s at rt (comparable extraction efficiencies were 
observed for the two methods by LC–MS [data not shown]) in 2:1:1 chloroform:methanol:citric 
acid buffer (100 mM trisodium citrate, 1 M NaCl, pH 3.6), vortexed (in glass vials) for 15-30 s 
and centrifuged at 2200 g, 4 °C for 6 min to allow separation between aqueous (top) and organic 
(bottom) layers.  The organic fraction was transferred to a new glass vial and concentrated under 
a gentle stream of nitrogen.  Dried lipids were stored at -80 °C and reconstituted in chloroform 
(unless otherwise indicated) for LC–MS. 
 
3.5.4. Global lipidomics of WT, DKO and SKO MEF mitochondria 
Global LC–MS profiling was performed on an Agilent 6220 LC-ESI-TOF instrument in 
positive and negative ionization modes with modifications on known protocol [53].  For negative 
mode a Gemini (Phenomenex) C18 column (5 µm, 4.6 mm × 50 mm) was used with a precolumn 
(C18, 3.5 µm, 2 mm × 20 mm).  Solvent A was 95: 5 water: methanol with 0.1 % ammonium 
hydroxide, and solvent B was 60:35:5 isopropanol:methanol:water with 0.1 % ammonium 
hydroxide.  For positive mode a Luna (Phenomenex) C5 column (5 µm, 4.6 mm × 50 mm) was 
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used with a precolumn (C4, 3.5 µm, 2 mm × 20 mm).  Solvent A was 95: 5 water: methanol with 
0.1 % formic acid and 5 mM ammonium formate, and solvent B was 60:35:5 
isopropanol:methanol:water with 0.1 % formic acid and 5 mM ammonium formate.  Identical 
gradient was used for both ionization modes.  The gradient was held at 0 % B between 0 and 5 
min, changed to 20 % B at 5.1 min, increased linearly from 20 % B to 100 % B between 5.1 min 
and 45 min, held at 100 % B between 45.1 min and 53 min, and returned to 0 % B at 53.1 min 
and held at 0 % B between 53.1 min and 60 min to allow column re-equilibration.  Flow rate was 
maintained at 0.1 mL/min between 0 min and 5 min to counter pressure increase due to the 
chloroform injection.  The flow rate was 0.4 mL/min between 5.1 min and 45 min, and 0.5 
mL/min between 45.1 min and 60 min.  Injection volume was 30 µL.  Capillary voltage was 3.5 
kV and fragmentor and skimmer voltages were 100 V and 60 V, respectively.  Drying gas 
temperature was 350 °C, drying gas flow rate was 10 L/min and nebulizer pressure was 45 psi.  
Data were collected in both profile and centroid modes using a mass range of 100-1500 Da. 
Data from general profiling were analyzed via targeted and untargeted approaches.  For 
the targeted approach, extracted ion chromatograms (EICs) corresponding to the m/z of known 
metabolites were manually integrated in MassHunter Quantitative Analysis (Agilent 
Technologies), and the resulting ion counts compared between WT and KO groups to give 
relative quantification for known lipids.  Statistical significance was determined by two-tailed 
Student’s t-test.  All errors were standard errors of the mean.  For the untargeted approach, LC–
MS raw data were converted from .d to .mzXML format with trapper-4.3.1 
(http://sourceforge.net/projects/sashimi/files).  WT and KO samples were sorted into two groups 
and analyzed via XCMS [21].  Following filtering of XCMS output files by statistical 
significance (p-value ≤ 0.05), fold change (≥ 3) and reproducibility across four independent data 
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sets, the remaining metabolite changes were further confirmed by manual integration in 
Qualitative Analysis and Student’s t-test.  Molecular formulae for unidentified metabolites were 
generated using formula calculator in Quantitative Analysis.   
 
3.5.5. Co-injection and tandem MS  
Co-injection for 6-keto-PGF1α was performed in negative mode on the Agilent 6220 LC-
ESI-TOF instrument.  A Luna (Phenomenex) C18(2) column (3 µm, 250 mm × 2.00 mm) was 
used.  Solvent A was 90: 10 water: acetonitrile with 5 mM ammonium acetate and 0.1 % formic 
acid, and solvent B was 50: 50 water: acetonitrile with 5 mM ammonium acetate and 0.1 % 
formic acid.  The gradient was held at 0 % B between 0 and 5 min, increased linearly from 0 % 
B to 100 % B between 5.1 min and 45 min, held at 100 % B between 45.1 min and 53 min, and 
returned to 0 % B at 53.1 min and held at 0 % B between 53.1 min and 70 min to allow column 
re-equilibration.  The flow rate was maintained at 0.1 mL/min between 0 min and 5 min, 
increased to 0.25 mL/min at 5.1 min and maintained at 0.25 mL/min for the rest of the run.  1.7 
pmol 6-keto-PGF1α was used as standard and a mixture of WT and Bak
–/–
 MEF mitochondrial 
lipid extracts was used as sample; for co-injection, the endogenous lipid extract and standard 
were combined and half of the mixture was injected.  The injection volume was 3 µL and all 
samples were reconstituted in 1:1 chloroform.  Tandem MS was performed on an Agilent 6410 
Triple Quad LC/MS instrument operated in Product Ion mode.  The precursor ion was m/z 369.2 
in negative mode.  MS2 range was set to 50-371 Da to capture the entire fragmentation range of 
the targeted metabolite.  Time filter width was 0.07 min.  Fragmentor voltage and collision 
energy were 140 V and 27 V, respectively.  ΔEMV was 400 V.  Capillary voltage was 4.0 kV, 
skimmer voltage was 15 V, drying gas temperature was 350 °C, drying gas flow rate was 8 
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L/min and nebulizer pressure was 35 psi.  All additional parameters were identical to co-
injection.   
 
3.5.6. Quantification of 6-keto-PGF1α and arachidonic acid in whole cell lysates  
6-keto-PGF1α and arachidonic acid were measured on the Agilent 6410 Triple Quad 
LC/MS instrument operated in multiple reaction monitoring (MRM) mode.  Fragmentor voltages 
for 6-keto-PGF1α and arachidonic acid were 140 V and 113 V, respectively.  Precursor-to-
product ion transitions for arachidonic acid were m/z 303.2  m/z 59.0 (CE = 19 V), m/z 303.2 
 m/z 259.2 (CE = 4 V) and m/z 303.2  m/z 205.2 (CE = 4 V), and the transitions for 6-keto-
PGF1α were m/z 369.2  m/z 163.0 (CE = 27 V) and m/z 369.2  m/z 245.2 (CE = 27 V).  All 
transitions yielded similar DKO/WT fold changes for each metabolite.  Ion counts from the m/z 
303.2  m/z 59.0 and m/z 369.2  m/z 163.0 transitions were used for quantification.  
Additional parameters were identical to tandem MS.  Arachidonic acid was monitored with the 
same column and gradient as global profiling.  6-Keto-PGF1α was monitored with both the global 
profiling gradient and the optimized acetonitrile-water gradient used for co-injection, yielding 
comparable results.      
 
3.5.7. Real time-PCR 
Total RNA was isolated from WT and Bax
–/–
 MEFs with the RNeasy Mini Kit (Qiagen) 
and reverse transcribed with the QuantiTect Reverse Transcription Kit (Qiagen) following 
manufacturer’s instructions.  Primers for Cox-1 (NM_008969), Cox-2 (NM_011198) and Bax 
(NM_007527) were from Qiagen.  Quantification for genes of interest was performed with the 
QuantiTect SYBR Green PCR Kit (Qiagen) on a MX3000p thermal cycler (Stratagene).  
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Relative mRNA levels were calculated using the comparative Ct method with Gapdh (forward: 
5’-GTG AGG CCG GTG CTG AGT AT-3’, reverse: 5’-TCA TGA GCC CTT CCA CAA TG-3’, 
Integrated DNA Technologies) as reference gene [54].  
 
3.5.8. RNA sequencing and gene set enrichment analysis (GSEA)  
 RNA sequencing for WT, DKO and SKO MEFs was performed by the sequencing 
facility at Center for Cancer Computational Biology (Dana Farber Cancer Institute, Boston, MA).  
Assembled .gtf files were imputed into Cuffdiff (http://cufflinks.cbcb.umd.edu) to generate a list 
of detectable genes and corresponding KO/WT fold changes, which was used for GSEA.  GSEA 
was performed by Dr. Arthur Liberzon (GSEA and MSigDB Team, Broad Institute, Cambridge, 
MA) using the C2:CP:KEGG, C2:CP, C2:CGP and C5:BP collections.          
 
3.5.9. LPS treatment 
WT and Bax
–/–
 MEFs were passaged (1:4-1:6) at least three times by trypsinization and 
treated with LPS (1 mg/mL solution in PBS) 24-40 h after the last passage.  Final LPS 
concentration was 1 µg/mL.  Equal volumes of PBS were used as negative control.  Cells were 
harvested on ice by scraping into cold PBS 0, 3 and 6 h post-LPS addition and stored at -80 °C 
prior to real time-PCR and Western blot against COX-1/2.  For phospho-Western blot against 
NFκB and MAPK pathways, WT and Bax–/– MEFs were treated with LPS (1 mg/mL solution in 
PBS, final concentration 2 µg/mL) and harvested on ice by scraping into cold PBS either 15, 30, 
45, 60 and 80 min or 15, 30, 60, 120 and 240 min post-LPS addition.  Each harvested pellet was 
frozen immediately at -80 °C before the next time point.  Cells for the 0 min time point were 
 106 
 
treated with PBS without LPS and harvested by scraping immediately prior to LPS addition to 
the other samples.     
 
3.5.10. Western blot 
Protein concentrations were recorded in Quick Start 1X Bradford dye reagent (Bio-Rad, 
500-0205).  Cell pellets (~200-400 μg protein) were diluted in PBS with protease inhibitors 
(1.5X inhibitor cocktail [87786, Thermo Scientific], 10 mM sodium fluoride, 10 mM sodium 
orthovanadate), mixed with 3X Laemmli buffer, sonicated at 4 °C and boiled at 100 °C for ~5 
min.  The resulting samples were aliquoted (30-60 μg/gel) and stored at -80 °C prior to being 
loaded onto gels.  Western blots were performed following standard protocol.  PVDF membranes 
were imaged on an Odyssey Infrared Imager (LI-COR).  
 
3.5.11. Co-immunoprecipitation and protein precipitation   
 WT and Bax
–/–
 MEFs (~10
8
 cells/sample) were treated with either PBS or LPS (1 mg/mL 
solution in PBS, final concentration 1 µg/mL) for 30 min and quickly harvested by scraping into 
PBS at RT.  All subsequent steps were performed in cold room.  Cell pellets were lysed in RIPA 
buffer (1 mL/sample) with protease inhibitors (1X EDTA-free inhibitor cocktail [11836170001, 
Roche], 5 mM sodium fluoride, 1 mM sodium orthovanadate) for 10 min with rotation and 
centrifuged at 14000 g for 10 min.  40 μL rabbit anti-BAX antibody and 100 μL A/G PLUS-
Agarose beads were added to the supernatant, and the mixture incubated with rotation in cold 
room overnight.  Beads were pelleted by centrifugation (1000 g, 3 min) and washed three times 
with RIPA buffer with protease inhibitors (1 mL each time).  Washed beads were boiled in 30 μL 
3X Laemmli buffer, centrifuged at 14000 g for 10 min, and the supernatant stored at -80 °C. 
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 Proteins from Laemmli buffer were precipitated with ethanol and chloroform for 
proteomic analysis.  To ensure presence of visible protein pellets, samples from three individual 
co-IP experiments were combined (total volume ~100 μL) on ice.  5X cold ethanol (pre-chilled 
overnight at -80 °C) was added, and the samples were mixed briefly by inversion and 
immediately incubated at -20 °C for 30 min.  1X room temperature chloroform was then added, 
at which point precipitates were observed immediately.  The resulting samples were mixed 
briefly by inversion and incubated at -20 °C for an additional 30 min.  Precipitated proteins were 
pelleted by centrifugation (20000 g, 10 min, 4 °C) and stored at -80 °C prior to proteomic 
analysis.    
 
3.5.12. Proteomics  
 Sample preparation and LC–MS were performed by Dr. Bogdan Budnick at the Mass 
Spectrometry and Proteomics Resource Laboratory (FAS Center for Systems Biology, Harvard 
University, Cambridge, MA).  Precipitated proteins were alkylated, digested with trypsin and 
labeled using commercially available 6-plex tandem affinity tags (TMTs) for quantification.  
Samples were injected onto a nanoACQUITY UPLC system (Waters) equipped with a 5 cm × 
100 μm capillary trapping column (New Objective) packed with 5 μm C18 AQUA beads 
(Waters) and a PicoFrit SELF/P analytical column (15-μm tip, 25-cm length, New Objective) 
packed with 3 μm C18 AQUA beads (Waters).  The UPLC system was online with a LTQ-
Orbitrap Elite (Thermo Fisher) instrument configured with nanospray ESI interface and HCD 
cell.  Data analysis was performed in Proteome Discoverer (Thermo Scientific) or IP2 
(Integrated Proteomics Applications) to yield comparable results. 
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Chapter 4 
 
Development of a LC–MS-based workflow for characterization 
of a novel lipid class involved in type 2 diabetes 
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4.1. Introduction 
 Type 2 diabetes mellitus (T2D) is a metabolic syndrome affecting more than 300 million 
people worldwide [1, 2].  T2D is characterized at its early stage by insulin resistance and fasting 
hyperinsulinemia, progressing toward the clinical presentation of fasting or postprandial 
hyperglycemia [3]; long term complications include blindness, kidney failure, amputation and 
cardiovascular disease [1].  Correlation between obesity and T2D [1, 4, 5], along with altered 
carbohydrate usage and fatty acid oxidation observed in insulin resistant populations [3, 6, 7], 
suggest that metabolic changes associated with T2D are complex and involve interactions among 
all major branches of central metabolism.  Paradoxically, mice overexpressing GLUT4, the 
major glucose transporter in insulin-sensitive tissues, display enhanced insulin sensitivity but 
also increased lipogenesis, suggesting that the protective effect of GLUT4 overexpression could 
be due to altered lipid profile [8, 9].  A comprehensive comparison of lipid profiles from WT and 
adipose-specific GLUT4 overexpressor (AG4OX) mice could yield valuable information on the 
connection between GLUT4 upregulation and lipid metabolism in the promotion of insulin 
sensitivity.   
 Liquid chromatography–mass spectrometry (LC–MS) has emerged as an important 
technique of metabolomics with applications in numerous biological settings [10-12].  Coupling 
of LC to MS-based detection methods allows time-dependent resolution of metabolite classes, 
enabling targeted or untargeted analysis of a large number of metabolites from one biological 
sample [10].  Untargeted global lipidomics of WT and fatty acid amide hydrolase (FAAH) 
knockout mice led to discovery of N-acyl taurines, a novel lipid class regulated by FAAH in 
murine nervous system and peripheral tissues [13].  Recent advancements in reproducibility and 
resolution of chromatography-based techniques, coupled with significant improvement in MS 
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sensitivity, have also enabled comprehensive targeted quantification of hydrophilic and 
hydrophobic metabolites at higher sensitivity than targeted approaches [10, 14, 15].   
 The comprehensiveness and high sensitivity of LC–MS-based metabolomics suggest this 
technique is a suitable choice for comparison of lipid profiles from WT and AG4OX mice.  
Lipidomics undertaken by Homan et al. revealed significant upregulation of a novel class of 
lipids comprised of fatty acids conjugated to hydroxy fatty acids (fatty acid hydroxy fatty acid, 
designated FAHFA) in AG4OX subcutaneous (SQ) white adipose tissue (WAT) relative to WT 
(Figure 4.1).  Of the multiple FAHFA family members detected, the authors chose to focus on 
 
 
Figure 4.1. Comparative lipidomics of SQ WAT from WT and AG4OX mice.  A) 
Schematic of unbiased, comparative global lipidomic analysis of WT and 
AG4OX murine lipids, allowing identification of metabolite changes.  B) Volcano 
plot of ions (>10
5
 ion count, 10-50 min) from WT and AG4OX SQ WAT lipids.  
Ions corresponding to fatty acid hydroxy fatty acids (FAHFAs), which are 
consistently elevated in AG4OX SQ WAT relative to WT, are circled in black.  
Two-tailed Student’s t-test. 
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palmitic acid hydroxy stearic acid (PAHSA) given its high AG4OX/WT fold change (data not 
shown) and lack of unsaturation site, which eliminates data set complexity associated with 
double bond isomers. 
 PAHSA is comprised of palmitic acid (PA) esterified to the internal hydroxyl group in 
hydroxystearic acid (HSA).  PAHSA positional isomers are designated 2-PAHSA through 18-
PAHSA, based on location of the hydroxylated stearic carbon from the carboxylic acid.  The 
structure of 9-PAHSA is shown in Figure 4.2, where palmitic acid is esterified to HSA at the 
ninth stearic carbon from the carboxylic acid.  Alternative locations of hydroxylation are 
numbered in Figure 4.2.       
 
Figure 4.2. Structure of 9-palmitic acid hydroxy stearic acid (9-PAHSA).  All 
possible locations of hydroxylation are numbered.  
  
 Potential existence of multiple PAHSA isomers raises the question of whether these 
species could be differentially regulated in the context of GLUT4 overexpression, which is the 
first step toward understanding the roles of these novel lipids in type 2 diabetes.  To answer this 
question, quantification of individual PAHSA isomers in serum and tissues is crucial; 
unfortunately, this was not achieved with our untargeted global lipidomics method due to limited 
sensitivity and lack of chromatographic resolution for individual isomers.  In this work, we 
present the development of a targeted LC–MS workflow for analysis of PAHSA isomers and 
additional FAHFA family members.  Implementation this method in human and murine sera and 
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multiple murine tissues yielded sensitive, reproducible quantification of PAHSA isomers and 
additional FAHFAs, demonstrating selective regulation of distinct FAHFA pools in a tissue and 
subject-dependent manner.   
 
4.2. Results  
4.2.1. Optimization of multiple reaction monitoring (MRM) parameters for PAHSA 
detection  
 Global lipidomics through liquid chromatography (LC)–time of flight (TOF) mass 
spectrometry (MS) enabled targeted and untargeted analyses of known and novel metabolites 
with high mass accuracy; however, relatively low biological abundance of PAHSAs presented a 
challenge for measurement of these lipids across multiple murine tissue types [11].  To reduce 
quantity of samples necessary for analysis and improve data consistency, we switched to a 
targeted approach using a triple quadrupole mass spectrometer operated in multiple reaction 
monitoring (MRM) mode.    
 MRM has emerged as a powerful analytical technique that enables targeted, simultaneous 
quantification of multiple metabolites with high sensitivity [11, 14-16].  By subjecting the 
metabolite of interest (precursor ion) to an optimized set of fragmentation conditions and 
monitoring a specific fragment (product ion) that consistently originates from the precursor, 
MRM takes advantage of the characteristic precursor-to-product ion transition specific to each 
metabolite, allowing unambiguous identification and detection of known metabolites with high 
signal-to-noise ratio [11, 16].  As most metabolites with distinct structures will generate unique 
transitions, it is possible for many species to be monitored at once.  Given many metabolites 
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fragment to yield multiple product ions at consistent ratios, multiple transitions could be 
optimized and monitored for each metabolite to increase the confidence of identification.    
 Tandem MS of 9-PAHSA (precursor ion m/z 537) yielded three characteristic fragments 
(product ions) at m/z 255, 299 and 281, corresponding to precursor-to-product ion transitions 
m/z 537  255, m/z 537  281 and m/z 537  299 (Figure 4.3).  Fragmentor voltage for the 
precursor ion and collision energies (CEs) for all fragments were optimized manually to 
maximize signal-to-noise ratio for each transition.  Of the fragments observed, m/z 255 
corresponds to palmitic acid, m/z 299 to hydroxystearic acid, and m/z 281 to the hydroxystearic 
acid dehydration product C18:1 fatty acid (Figure 4.3).  It is important to note that 9-PAHSA 
  
 
Figure 4.3. MRM of 9-PAHSA.  MRM parameters are optimized based on 
characteristic fragmentation of 9-PAHSA (m/z 537) into palmitic acid (m/z 255), 
hydroxystearic acid (m/z 299) and C18:1 fatty acid (m/z 281).   
 
consistently fragments with the relative fragment abundances m/z 255 > 281 > 299, which is 
reflected in the relative abundances of the corresponding precursor-to-product ion transitions 
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(m/z 537  255 > m/z 537  281 > m/z 537  299, Figure 4.3).  Consequently, appearances of 
peaks from all three transitions with identical retention times and at PAHSA-characteristic ratios 
are importance criteria for the PAHSA structural assignment.   
 
4.2.2. Chromatography optimization for resolution of PAHSA isomers  
 Presence of nearly identical major fragments in the tandem MS spectra of PAHSAs with 
different positions of fatty acid conjugation implies that MRM cannot distinguish PAHSA 
isomers (data not shown).  Consequently, quantification of individual PAHSA isomers requires 
baseline chromatographic resolution.  All optimizations were performed on a solution of 
synthesized 4, 5, 6, 
13
C-8 (all 
13
C standards are uniformly heavy-labeled on palmitic acid), 9, 
13
C-9, 10, 11 and 12-PAHSA standards using a C18 column (3 μm, 100 Å, 2.0 × 250 mm) online 
with a triple quadrupole mass spectrometer in MRM mode.  We hypothesized that the 
combination of column length and small particle size could sharpen standard peaks while 
allowing time for isomer resolution.  A methanol-water system was initially tested, and 0.01 % 
ammonium hydroxide was added to all solvents to improve ion generation.  Preliminary tests 
with water-to-methanol gradient elution did not yield good isomer resolution; comparable result 
was obtained with 90:10 methanol:water isocratic elution (Figure 4.4A).  Significantly improved 
resolution was observed with 89.5:10.5 methanol:water, where reduced flow rate and addition of 
ammonium acetate led to increased peak retention and separation (Figure 4.4A); unfortunately, 
peak broadening and tailing also occurred, while the significantly delayed retention times (110-
190 min) rendered analysis of large numbers of samples impractical, prompting us to further 
adjust the methanol:water ratio.  
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Figure 4.4. Chromatography optimization for resolution of PAHSA isomers.  A) 
Comparison between methanol:water gradient and isocratic elutions and among 
different isocratic methanol:water ratios.  B) Optimization of flow rate for the 
93:7 methanol:water isocratic system and replacement test with 97:3 
acetonitrile:water at 0.25 mL/min.  C) Finalized LC method enabling resolution of 
4, 5, 6, 
13
C-8, 9, 
13
C-9, 10, 11 and 12-PAHSA standards.    
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 Methanol:water ratios from 89:11 to 100:0 were examined while maintaining the 
concentration of ammonium hydroxide and acetate.  In comparison to the 89.5:10.5 
methanol:water isocratic system, 93:7 methanol:water at 0.36 mL/min yielded significantly 
sharpened peaks at the cost of slightly decreased resolution (Figure 4.4A).  While we had 
maintained a high flow rate (0.36 mL/min) in the 93:7 methanol:water system for the purpose of 
minimizing peak broadening and sample analysis time, we hypothesized that decreasing the flow 
rate could increase sample resolution.  A range of flow rates was tested while maintaining the 
93:7 methanol:water ratio and concentration of solvent modifiers (Figure 4.4B).  93:7 
acetonitrile:water was also tested to yield no observable peak separation (Figure 4.4B).  
Reduction in flow rate significantly improved peak resolution for the 93:7 methanol:water ratio, 
and baseline separation was achieved for almost all PAHSAs at 0.20 mL/min (Figure 4.4B).  
Figure 4.4C illustrates measurement of 4, 5, 6, 
13
C-8, 9, 
13
C-9, 10, 11 and 12-PAHSA standards 
using the optimized LC method coupled to MRM.  Similar to the 9-PAHSA standard used during 
MRM optimization (Figure 4.3), m/z 536  255 is the dominant transition for all PAHSA 
standards tested (Figure 4.4C).  
 In conjunction with chromatography optimization, effect of injection volume on 
resolution was also evaluated.  Injection of standards in more than 3 μL chloroform significantly 
compromised resolution (Figure 4.5A), a potential consequence of unfavorable solvent-solvent 
interactions and polarity difference between the carrier and elution solvents.  When the carrier 
solvent was switched to methanol, no significant resolution loss was observed between 2 μL and 
15 μL (Figure 4.5B); 6 μL 1:1 methanol:chloroform was also tolerated (Figure 4.5C).    
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Figure 4.5. Effect of injection volume on PAHSA isomer resolution.  A) Injection 
volume tests with chloroform.  B) Injection volume tests with methanol.  C) 
Injection volume tests with 1:1 methanol:chloroform.  
 
4.2.3. Preliminary PAHSA analysis in PG WAT 
 The optimized LC–MS workflow was applied toward PAHSA analysis in WT murine 
perigonadal (PG) white adipose tissue (WAT).  Lipid extraction was performed with slight 
modification on the Bligh-Dyer method [17], enabling extraction of major lipid classes including 
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fatty acids, phospholipids, sphingolipids, acyglycerols, cardiolipins, cholesterol and cholesterol 
esters.  Lipids were isolated from 130 mg tissue, reconstituted in 30 or 60 μL chloroform, and 2 
μL sample subjected to analysis.  While 13/12, 11, 10 and 9-PAHSAs were detected in both 
samples ion counts were low for all species (Figure 4.6).  This was due to high concentrations of 
nonpolar lipids such as triglycerides (TGs) in WAT [18]; TGs contributed significant volume 
toward the reconstituted sample, limiting the percentage of sample that could be injected while 
increasing ion suppression.  Insolubility of TGs in methanol also restricted the carrier solvent to 
chloroform, preventing injection of larger sample volumes.  To address this problem we 
performed solid phase extraction. 
          
 
Figure 4.6. Preliminary test of optimized LC–MS workflow on WT murine PG 
WAT lipids.   
 
4.2.4. Optimization of solid phase extraction for PAHSA enrichment  
 Solid phase extraction (SPE) is a widely used technique that separates analytes in 
solution based on their interactions with a solid support [19].  In the context of metabolomics, 
SPE enables enrichment of specific metabolite pools while removing other metabolites and 
 124 
 
contaminants that could cause signal suppression and/or impair chromatographic resolution [11, 
20].  SPE workflow for FAHFA enrichment is illustrated in Figure 4.7A.  This method was 
tested on a solution of 4, 5, 6, 
13
C-8, 9, 
13
C-9, 10, 11 and 12-PAHSA standards.  Ethyl acetate 
eluent (18 mL total) was collected in 1 mL fractions, and presence of PAHSAs in each fraction 
determined by MRM (Figure 4.7B).  PAHSAs eluted rapidly across the first two ethyl acetate 
fractions with no significant carryover into addition fractions; no PAHSAs were observed in the 
95:5 hexane: ethyl acetate fraction (Figure 4.7B).      
 
 
Figure 4.7. Solid phase extraction for FAHFA enrichment.  A) SPE workflow.  B) 
MRM of total (16 mL as one fraction) 95: 5 hexane: ethyl acetate (nonpolar lipids) 
fraction and 1 mL ethyl acetate (FAHFA) fractions.  All fractions were 
concentrated to dryness and 1/3 of each sample used for analysis.    
 125 
 
 Metabolite recovery was calculated for each PAHSA standard (Figure 4.8).  Fractionation 
did not lead to loss of 8, 9, 10, 11 and 12-PAHSAs; slight increase in ion count for these species 
in the fractionated sample relative to unfractionated could be due to decreased ion suppression 
through removal of impurities.  Fractionation led to some loss of 6, 5 and 4-PAHSAs (23-66 %).  
   
 
Figure 4.8. Metabolite recovery from fractionation for individual PAHSA isomers.  All fractions 
were concentrated to dryness and 1/3 of each sample used for analysis.     
  
 While fractionation led to loss of 4, 5 and 6-PAHSA standards, it is worth noting that 
influence of different PAHSA isomer positions on lipid-matrix interactions could be more 
pronounced in the absence of lipid background.  Consequently, metabolite recovery should be 
evaluated in the presence of background lipids as a more accurate representation of the 
endogenous system.  To address this question, we compared recovery of 4, 5, 6 and 
13
C-9-
PAHSA standards using WT murine liver lipids as background; liver was chosen for its 
relatively simple PAHSA profile (preliminary analysis in WT liver revealed only presence of 
13/12 and 9-PAHSAs, data not shown).  A solution of 4, 5, 6 and 
13
C-9-PAHSAs (input) was 
analyzed without fractionation (Figure 4.9A).  An aliquot of the same PAHSA solution was 
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added to liver tissue, and the resulting tissue extracted, fractionated and analyzed by LC–MS; 
lack of significant amount of endogenous 4, 5 and 6-PAHSAs in liver provided a clean 
background for detection of the added standards (Figure 4.9B).  
13
C-9/4, 
13
C-9/5 and 
13
C-9/6-
PAHSA ratios were calculated for the unfractionated input (Figure 4.9A) and the standards in 
fractionated liver (Figure 4.9B), and results compared between the two groups (Figure 4.9C).  
13
C-9/4, 
13
C-9/5 and 
13
C-9/6-PAHSA ratios changed only slightly between input and fractionated 
liver, suggesting that in a complex lipid environment, fractionation efficiency is only minimally 
dependent on PAHSA isomer positions (Figure 4.9C).   
 
 
Figure 4.9. Metabolite recovery from fractionation for PAHSA isomers in the 
presence of background lipid.  A) Unfractionated PAHSA standards as input.  B) 
Detection of exogenous 
13
C-9, 4, 5 and 6-PAHSA standards (same solution as 
input) in WT murine liver lipids following fractionation.  C) Comparison of 
13
C-
9/6, 
13
C-9/5 and 
13
C-9/4-PAHSA ratios between unfractionated input and 
fractionated input in liver lipids.     
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4.2.5. Evaluation of lipid recovery and solvent effect in murine adipose tissues   
 Prior to implementation of our SPE workflow on a wider scale, we evaluated PAHSA 
recovery following fractionation of WT murine brown adipose tissue (BAT).  Fractionated or 
unfractionated BAT lipids were analyzed by LC–MS and quantified with an internal 13C-9-
PAHSA standard.  Fractionation did not lead to significant PAHSA loss, and enabled detection 
of additional low-abundance PAHSA isomers (5, 7 and 8) in BAT (Figure 4.10A).   
 As mentioned in section 4.2.3, TGs in unfractionated WAT reduced solubility in 
methanol and limited injection volume to 2 μL chloroform (Figure 4.6).  TG removal allowed 
sample reconstitution in methanol and injection of higher volumes.  To ensure no solvent-
dependent PAHSA loss, fractionated WT PG WAT lipids were solubilized in either methanol (10 
μL injection) or chloroform (2 μL injection), and absolute PAHSA quantifications compared 
between the two groups to yield similar results (Figure 4.10B).  Importantly, injection of larger  
 
Figure 4.10. Tests of fractionation efficiency and carrier solvents in murine 
adipose tissues.  A) Comparison of PAHSA isomer levels between unfractionated 
and fractionated WT murine BAT (n=1).  B) Comparison of PAHSA isomer 
levels between chloroform and methanol-reconstituted fractionated WT murine 
PG WAT lipids (n=5).  
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sample volumes increased the quantity of sample that could be analyzed on-column, significantly 
improving signal-to-noise ratio and enabling measurement of low-abundance PAHSAs not 
detectable in unfractionated samples.  The finalized workflow is in Figure 4.11.        
 
 
Figure 4.11. Finalized workflow for PAHSA isomer analysis.   
 
4.2.6. PAHSA isomer distribution in murine serum, tissues and diets  
 Using our finalized LC–MS workflow, PAHSA isomers were quantified in WT murine 
serum, PG and SQ WATs, BAT, liver, pancreas, kidney, heart, gastrocnemius muscle (GNM) 
and brain.  A 
13
C-9-PAHSA internal standard was used for absolute quantification.  Extracted ion 
chromatographs of the m/z 536  255 transition are shown for all samples in Figure 4.12A.  9-
PAHSA is the major isomer in majority of samples (Figure 4.12A, B).  Highest total PAHSA  
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Figure 4.12. PAHSA isomer distribution in WT murine serum and tissues.  A) Extracted 
ion chromatographs (m/z 537  255) of WT murine serum and tissues.  B) PAHSA 
isomer levels in WT murine serum and tissues (n=4-5).   
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level is found in BAT, with adipose tissues displaying widest isomeric range; 13/12, 9 and 8-
PAHSAs were the only detectable isomers in liver (Figure 4.12 A, B).  Variability in PAHSA 
distribution across tissue types implies tissue-dependent metabolism and/or trafficking.   
 PAHSA analysis was also performed in food to assess the diet-dependence of in vivo 
PAHSA distribution.  LC–MS of fractionated lipids from apple, broccoli, beef, chicken, egg 
white and yolk revealed significant variation in both the major isomer and relative isomeric 
ratios across dietary sources (Figure 4.13A).  PAHSA level in egg yolk was significantly higher 
  
 
Figure 4.13. PAHSA isomer distribution in dietary sources.  A) PAHSA isomer 
levels in fruit, vegetable, meat and egg (n=3).  B) PAHSA isomer levels in chow 
and high fat murine diets (n=3).  *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001.  Two-
tailed Student’s t test, SEM.     
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(approximately one to two orders of magnitude) than all other dietary sources examined (Figure 
4.13A).   
 PAHSAs were also detected in murine chow and high fat diet (HFD) (Figure 4.13B).  
Significantly higher PAHSA levels were observed in chow relative to HFD, a possible 
consequence of low conjugated fatty acid level in the HFD fat source.  Importantly, major 
PAHSA isomer in chow and HFD is 10-PAHSA while the major isomer in WT murine serum 
and most tissues is 9-PAHSA (Figure 4.13B).  Taken together, our data demonstrate that murine 
serum and tissue PAHSA distribution is not a direct reflection of diet, supporting generation of 
additional PAHSA species through in vivo metabolism.  
 
4.2.7. Analysis of additional FAHFA family members 
  While we have focused on PAHSAs based on detectability during global lipidomics and 
ease of isomer analysis in the absence of unsaturation sites, complexity in the structures of free 
fatty acids in mammalian systems could translate into similar complexity in the range of possible 
FAHFA family members [21, 22], raising the question of whether different FAHFAs are 
selectively regulated in a tissue-specific manner or in the context of GLUT4 overexpression.  To 
answer these questions, we expanded our MRM method to include additional FAHFAs. 
 Given all FAHFAs are comprised of a fatty acid (FA) conjugated to hydroxy fatty acid 
(HFA), variability in FAHFA structure is a direct reflection of variability in the FA and HFA 
chains.  Candidate FAs and HFAs are shown in Figure 4.14A.  Palmitoleic acid (16:1), palmitic 
acid (16:0), oleic acid (18:1) and stearic acid (18:0) were selected due to their abundance in 
mammalian tissues [21, 22].  Arachidonic acid (20:4) and docosahexaenoic acid (22:6) were 
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included given their roles in inflammation and interaction with G-protein coupled receptors [23-
27].  Selection of six candidates for FA and six candidates for HFA implies a total of 36 
  
 
Figure 4.14. Additional FAHFA family members.  A) Candidate structures for 
fatty acid and hydroxy fatty acid.  B) Extracted ion chromatographs (m/z 537  
255) of selected FAHFAs in WT murine PG WAT.   
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structurally distinct FAHFAs.  MRM transitions were calculated for these candidates based on 
PAHSA parameters, and two transitions were monitored for each FAHFA.  Selected spectra are 
in Figure 4.14B.  Similar to PAHSA, multiple peaks were observed for each additional FAHFA, 
suggesting presence of multiple isomers (Figure 4.14B).      
 Using the expanded MRM method, 16 FAHFAs with different combinations of 16:1, 
16:0, 18:1 and 18:0 acyl chains, and nine PAHSAs with 20:4 or 22:6 as one of the two acyl 
chains, were detected in WT murine PG WAT (Figure 4.15A).  As a direct reflection of relative 
free fatty acid levels in murine tissues [21], 20:4 and 22:6 acyl chain-containing FAHFAs were 
approximately 50 to 100 fold lower in abundance than FAHFAs without these acyl chains 
(Figure 4.15A).  Similar analysis in human sera taken from three individuals revealed variation 
in FAHFA distribution and selective regulation of different FAHFA pools in a subject-dependent 
manner (Figure 4.15B).  Importantly, comparison of FAHFA levels between WT and AG4Ox 
murine sera revealed selective elevation of multiple FAHFA members in AG4Ox serum, with all 
elevated species containing either HPA or HSA (Figure 4.15C).  Taken together, our data 
demonstrate successful implementation of our LC–MS workflow in the analysis of serum and 
tissue PAHSAs and FAHFAs.  Further investigation into FAHFA metabolism and biology will 
yield valuable information on the roles of these novel lipids in type 2 diabetes and other disease 
states.   
 
4.3. Discussion 
 Global lipidomics of WT and AG4OX SQ WAT revealed upregulation of palmitic acid 
hydroxy stearic acids (PAHSAs) under adipose-specific GLUT4 overexpression (Figures 4.1, 
4.2).  To determine PAHSA isomer distribution in serum and tissues, we optimized a LC–MS- 
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Figure 4.15. FAHFA levels in sera and adipose tissue.  A) FAHFA levels in WT 
murine PG WAT (n=4).  B) FAHFA levels in sera taken from three individuals 
(n=3).  C) FAHFA levels in sera from WT and AG4OX mice (n=1).     
 
based workflow enabling sensitive targeted detection of PAHSAs by multiple reaction 
monitoring; baseline resolution of majority of PAHSA isomers between 4 and 13 allowed 
quantification of individual isomers indistinguishable by MRM due to their nearly identical 
fragmentation mechanisms.  
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 Tandem MS of 9-PAHSA yielded three major fragments at m/z 255, 299 and 281 (Figure 
4.3), corresponding to precursor-to-product ion transitions m/z 537  255, m/z 537  299 and 
m/z 537  281.  The m/z 537  255 transition yielded the highest ion count in all PAHSA (4, 5, 
6, 9, 10, 11 and12) standards tested (Figure 4.4C), a likely consequence of stability of the 
palmitic (m/z 255) ion relative to the more chemically labile hydroxystearic (m/z 299) ion, which 
undergoes further fragmentation to yield unsaturated C18 fatty acid (m/z 281).  It is worth noting 
that while m/z 537  255 is the major transition for all PAHSA standards, relative ratios of 
detected transitions (537  255/537  281, 537  255/537  299 and 537  281/537  299) 
are slightly dependent on isomer position.  A lower 537  255/537  281 ratio was found for 6-
PAHSA relative to 9-12-PAHSAs (Figure 4.4C) while m/z 537  255 was the only detectable 
transition for 4-PAHSA (Figure 4.4C).  These differences could be attributed to differences in 
stability among the 9, 6 and 4-hydroxystearic (m/z 299) product ions as well as the 9, 6 and 4-
unsaturated C18 fatty acids (m/z 281), where hydroxyl group or double bond distance from 
carboxylic acid could be a determinant of stability.  It is unknown if efficiency of generation for 
the palmitic (m/z 255) product ion is dependent on isomer position; however, lack of 
unsaturation in palmitic acid implies that all generated ions will exhibit identical stability profile 
regardless of precursor, and suggests that the m/z 537  255 transition is the most reliable 
choice for use in quantification.  Accuracy of absolute quantification could be improved through 
use of multiple PAHSA internal standards.   
 While MRM targets the precursor-to-product ion transition unique to each metabolite, 
lack of exact mass could lead to false positives in cases where two different metabolites share 
similar precursor and product ion masses.  Consequently, monitoring of multiple transitions per 
metabolite increases the confidence of identification.  For majority of PAHSA isomers, 
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appearances of peaks for all three transitions at identical retention times and with the major peak 
corresponding to m/z 537  255 are important criteria for the PAHSA structure assignment; 
simultaneous monitoring of all three transitions enables elimination of contaminant peaks.  As 
Figure 4.16 illustrates, initial survey of WT murine kidney via the m/z 537  255 transition 
(black line) indicates that the major isomer is 8-PAHSA; however, overlay of all three transitions 
revealed significantly higher m/z 537  281 (red line) ion count than m/z 537  255 for the two 
peaks eluting after 9-PAHSA (Figure 4.16).  While our MRM method has not been tested on a 8- 
 
 
Figure 4.16. PAHSA profile of WT murine kidney.  Relative abundances of 
transitions for majority of PAHSA isomers are m/z 537  255 > m/z 537  281 
≥ m/z 537  291. 
 
PAHSA standard, dominance of the m/z 537  255 transition in all PAHSA standards (4, 5, 6, 9, 
10, 11 and 12) examined (Figure 4.4C) implies a complete reversal of this trend for PAHSAs (7 
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and 8) in the middle of the isomer series is unlikely, and suggests that the two peaks eluting after 
9-PAHSA in kidney are potential contaminants that should be excluded from analysis. 
 LC–MS of murine serum and tissues also revealed a highly abundant peak at ~95 min 
with higher m/z 537  281 ion count than m/z 537  255 (GNM is shown as example in Figure 
4.17A).  Importantly, tandem MS of the 95 min peak yielded fragments closely matching those 
from d18:1/16:0 ceramide (Figure 4.17B).  It is worth noting that the loss-of-proton precursor ion 
for d18:1/16:0 ceramide is m/z 536, consequently, the 95 min peak (detected under PAHSA 
MRM parameters with m/z 537 as precursor) represents naturally occurring 
13
C or 
2
D-d18:1/16:0 
ceramides; presence of 
13
C or 
2
D at different locations on the ceramide backbone or acyl chain 
leads to characteristic one-Dalton mass shifts in the tandem MS fragments of the 95 min peak 
(Figure 4.17B).  Co-injection with GMN and d18:1/16:0 ceramide standard using ceramide-
specific or PAHSA-specific MRM parameters yielded one peak as strong support that the 95 min 
peak is isotopic
 
d18:1/16:0 ceramide rather than 2 or 3-PAHSA (Figure 4.17C).   
 Presence of ceramide in fractionated murine lipids was not surprising, given ethyl acetate 
elution during SPE was not FAHFA-specific, and could lead to co-elution of additional lipids 
with similar lipid-matrix interactions.  Fractionation successfully removed nonpolar lipids such 
as TGs, allowing higher injection volume in methanol and analysis of larger quantity of sample 
on-column.  Importantly, TG removal reduced column contamination, prolonging column 
lifetime and eliminating the need for exhaustive washing between sample runs.  A more 
thorough survey of fractionation conditions could improve the specifity of FAHFA isolation and 
minimize co-elution of additional lipids.    
 Variability in PAHSA isomer distribution across murine tissues in a diet-independent 
manner raises questions on FAHFA metabolism in vivo (Figures 4.12, 4.13).  Sampling of  
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Figure 4.17. Identification of contaminant peak in PAHSA analysis of murine 
lipids.  A) Extracted ion chromatographs of WT murine GNM.  B) Tandem MS of 
d18:1/16:0 ceramide standard and contaminant peak at ~95 min.  C) Co-injection 
of WT murine GNM lipids with d18:1/16:0 ceramide standard monitored by 
ceramide-characteristic and PAHSA-characteristic transitions.  
 
FAHFA family members in sera from three individuals revealed selective regulation of distinct 
FAHFA pools in a subject-specific manner, and selective upregulation of HSA and HPA-
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containing FAHFAs was observed in AG4OX serum relative to WT.  It would be of interest to 
investigate the biological functions of different FAHFAs in the context of GLUT4 knockdown or 
overexpression.  Comprehensive FAHFA measurements in insulin sensitive and resistant 
populations could also yield valuable information on the roles of these lipids in humans with 
potential therapeutic implications.      
 
4.4. Conclusion  
 A LC–MS workflow was optimized to enable sensitive quantification of palmitic acid 
hydroxy stearic acid (PAHSA) isomers and additional fatty acid hydroxy fatty acids (FAHFAs), 
members of a novel lipid class upregulated in adipose tissue of AG4OX mice.  MRM parameters 
were optimized with 9-PAHSA standard to yield three precursor-to-product ion transitions.  A 
methanol-water isocratic solvent system was optimized to achieve baseline resolution of almost 
all PAHSA isomers between 4 and 13.  Solid phase extraction of serum and tissue lipids 
removed nonpolar lipids such as TGs and significantly enriched FAHFAs, enabling measurement 
of low-abundance PAHSA isomers undetectable in unfractionated samples.  Our workflow was 
successfully implemented to yield reproducible, robust quantification of PAHSA isomers and 
FAHFA family members in serum and tissues.  Further investigation into the biological functions 
of this novel lipid class in murine GLUT4 knockout or overexpression models and in humans 
will bear significant implications over the roles of lipids in disease and development of 
therapeutics.   
 
4.5. Methods 
4.5.1. Materials 
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Ammonium formate (516961), ammonium acetate (372331) and ammonium hydroxide 
(338818) were from Sigma-Aldrich.  Formic acid (06440) was from Fluka.  Water (365-4), 
methanol (230-4), isopropanol (323-4), acetonitrile (017-4), hexane (212-4), ethyl acetate (100-4) 
and chloroform (049-1L) for lipid extraction, SPE and LC–MS were from Honeywell Burdick & 
Jackson.  Solid phase extraction cartridges (HyperSep Silica, 500 mg/6 mL) were from Thermo 
Scientific (60108-411).  Organic solvents for chemical syntheses were from EMD Millipore 
(Billerica, MA).  (R)-9-hydroxystearic acid was from Indofine Chemical Company, Inc. 
(Hillsborough, NJ) and 
13
C16-palmitic acid was from Cambridge Isotopes Laboratories, Inc. 
(Andover, MA).  All additional chemicals for syntheses were from Sigma-Aldrich unless 
otherwise stated.       
 
4.5.2. Animal studies  
 AG4OX mice (FVB background) were previously described [9, 28].  Female WT FVB 
mice were used in all LC–MS analyses, and age and gender-matched to AG4OX mice for all 
comparative lipidomic studies.  Animals were euthanized with CO2, the tissues dissected, flash 
frozen in liquid nitrogen and stored at -80 °C prior to lipid extraction.  All animal care and use 
procedures were in strict accordance with the standing committee on the use of animals in 
research and teaching at Harvard University and at the Beth Israel Deaconess Medical Center 
Animal Research Facility.  
. 
4.5.3. Lipid extraction 
 Lipid extraction was performed with modification on the Bligh-Dyer method [17].  All 
glasswares were chilled on ice for at least 5 min prior to extraction.  Murine tissues and frozen 
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meat for dietary analysis were kept on dry ice to avoid thawing, quickly sectioned with razor 
blade and weighed (60-150 mg) before being Dounce homogenized immediately on ice for 40 
strokes in 1.5 mL:1.5 mL:3 mL citric acid buffer (100 mM trisodium citrate, 1 M NaCl, pH 
3.6):methanol:chloroform.  Apple, broccoli and egg (140-210 mg) were sectioned with razor 
blade at room temperature before being processed in the same way as tissues.  
13
C-9-PAHSA 
standard (0.5-8 pmol per sample depending on sample type) was added to chloroform prior to 
extraction.  The resulting mixture was poured into a glass vial on ice, the Douncer was washed 
with 0.5 mL chloroform without standard, and the wash combined with the Dounced mixture 
(total volume ~6.5 mL).  The mixture was centrifuged at 2200 g, 6 min, 4 ºC to separate organic 
and aqueous phases, and the organic (bottom) phase containing lipids was transferred into a glass 
vial with a Pasteur pipet, dried under a gentle stream of N2 and stored at -80 ºC prior to solid 
phase extraction (SPE).  Frozen serum was thawed on ice and citric acid buffer was added to a 
final volume of 1-1.75 mL based on volume of serum used, followed by addition of 1-1.75 mL 
methanol and 2-3.5 mL chloroform; the resulting mixture was shaken vigorously for 30 s and 
vortexed for 15 s before being centrifuged and processed in the same way as tissues and food 
items.  165 μL murine serum was used for PAHSA isomer analysis, 265 μL murine serum and 
450-900 μL human serum were used for analysis of additional FAHFA family members.      
 
4.5.4. SPE 
 SPE was performed at room temperature via gravity flow.  The column was conditioned 
with 15 mL hexane.  Extracted lipids (in 200 μL chloroform) were loaded onto column.  
Nonpolar lipids were eluted with 16 mL 5 % ethyl acetate in hexane, followed by elution of free 
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fatty acids and FAHFAs with 16 mL ethyl acetate.  FAHFA fractions were dried under a gentle 
stream of N2 and stored at -80 ºC prior to LC–MS.    
 
4.5.5. Targeted LC–MS  
 FAHFAs were measured on an Agilent 6410 Triple Quad LC/MS instrument via multiple 
reaction monitoring (MRM) in negative ionization mode, using a Luna C18 (2) (Phenomenex, 
00G-4251-B0) column with an in-line filter (Phenomenex, AF0-8497).  The solvent was 93:7 
methanol:water with 5 mM ammonium acetate and 0.01 % ammonium hydroxide, and PAHSA 
isomers were resolved by isocratic elution at 0.2 mL/min for 120 min.  Each extracted and 
fractionated sample (from 165-900 μL serum, 60-150 mg tissue, or 140-210 mg food) was 
reconstituted in 25 μL methanol and 10 μL was injected for analysis when possible.  In cases 
where large quantities of fractionated lipids were observed, or lipids were not completely soluble 
in methanol, the sample was reconstituted in 20 μL chloroform and 2 μL was injected.  
Transitions for endogenous PAHSAs were m/z 537.5  m/z 255.2 (CE = 30 V), m/z 537.5  
m/z 281.2 (CE = 25 V) and m/z 537.5  m/z 299.3 (CE = 23 V), and transition for 13C-9-
PAHSA was m/z 553.5  m/z 271.3 (CE = 30 V).  Fragmentor voltage and dwell time were 205 
V and 300 ms, respectively, for each transition.  Skimmer voltage was 15 V and ΔEMV was 400 
V.  MS1 resolution was set to Wide and MS2 resolution to Unit.  Capillary voltage was 4.0 kV, 
drying gas temperature was 350 °C, drying gas flow rate was 8 L min
-1
 and nebulizer pressure 
was 35 psi.  Identical gradient and instrument parameters were used for detection of all 
additional FAHFAs with the exception of dwell time, which was reduced to 30 ms to 
accommodate additional transitions.  All FAHFA transitions are in Table 4.1. 
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Transition Precursor ion Product ion CE 
POHPO_transition1 505.4 253.2 30 
POHPO_transition2 505.4 251.2 25 
POHPA_transition1 507.4 253.2 30 
POHPA_transition2 507.4 271.2 23 
PAHPO_transition1 507.4 255.2 30 
PAHPO_transition2 507.4 251.2 25 
PAHPA_transition1 509.5 255.2 30 
PAHPA_transition2 509.5 253.2 25 
POHOA_transition1 533.5 253.2 30 
POHOA_transition2 533.5 279.2 25 
OAHPO_transition1 533.5 281.2 30 
OAHPO_transition2 533.5 251.2 25 
PAHOA_transition1 535.5 255.2 30 
PAHOA_transition2 535.5 279.2 25 
OAHPA_transition1 535.5 281.2 30 
OAHPA_transition2 535.5 253.2 25 
POHSA_transition1 535.5 253.2 30 
POHSA_transition2 535.5 281.2 25 
SAHPO_transition1 535.5 283.2 30 
SAHPO_transition2 535.5 251.2 25 
PAHSA_transition1 537.5 255.2 30 
PAHSA_transition2 537.5 281.2 25 
PAHSA_transition3 537.5 299.3 23 
13
C-PAHSA 553.5 271.3 30 
SAHPA_transition1 537.5 283.2 30 
SAHPA_transition2 537.5 253.2 25 
OAHOA_transition1 561.5 281.2 30 
OAHOA_transition2 561.5 279.2 25 
OAHSA_transition1 563.5 281.2 30 
OAHSA_transition2 563.5 299.3 23 
SAHOA_transition1 563.5 283.3 30 
SAHOA_transition2 563.5 279.2 25 
SAHSA_transition1 565.5 283.3 30 
SAHSA_transition2 565.5 281.2 25 
    
AAHPO_transition1 555.4 303.2 30 
AAHPO_transition2 555.4 251.2 25 
POHAA_transition1 555.4 253.2 30 
POHAA_transition2 555.4 301.2 25 
AAHPA_transition1 557.5 303.2 30 
AAHPA_transition2 557.5 253.2 25 
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PAHAA_transition1 557.5 255.2 30 
PAHAA_transition2 557.5 301.2 25 
AAHOA_transition1 583.5 303.2 30 
AAHOA_transition2 583.5 279.2 25 
OAHAA_transition1 583.5 281.2 30 
OAHAA_transition2 583.5 301.2 25 
AAHSA_transition1 585.5 303.2 30 
AAHSA_transition2 585.5 281.2 25 
SAHAA_transition1 585.5 283.2 30 
SAHAA_transition2 585.5 301.2 25 
AAHAA_transition1 605.5 303.2 30 
AAHAA_transition2 605.5 301.2 25 
    
DHAHPO_transition1 579.4 327.2 30 
DHAHPO_transition2 579.4 251.2 25 
POHDHA_transition1 579.4 253.2 30 
POHDHA_transition2 579.4 325.2 25 
DHAHPA_transition1 581.5 327.2 30 
DHAHPA_transition2 581.5 253.2 25 
PAHDHA_transition1 581.5 255.2 30 
PAHDHA_transition2 581.5 325.2 25 
DHAHOA_transition1 607.5 327.2 30 
DHAHOA_transition2 607.5 279.2 25 
OAHDHA_transition1 607.5 281.2 30 
OAHDHA_transition2 607.5 325.2 25 
DHAHSA_transition1 609.5 327.2 30 
DHAHSA_transition2 609.5 281.2 25 
SAHDHA_transition1 609.5 283.2 30 
SAHDHA_transition2 609.5 325.2 25 
AAHDHA_transition1 629.5 303.2 30 
AAHDHA_transition2 629.5 325.2 25 
DHAHAA_transition1 629.5 327.2 30 
DHAHAA_transition2 629.5 301.2 25 
DHAHDHA_transition1 653.5 327.2 30 
DHAHDHA_transition2 653.5 325.2 25 
 
Table 4.1. FAHFA transitions and collision energies.  PAHSA parameters are in red.     
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4.5.6. Global lipidomics of WT and AG4OX SQ WAT  
Global LC–MS profiling was performed on an Agilent 1200 series binary pump online 
with an Agilent 6220 ESI-TOF spectrometer in positive and negative ionization modes with 
modifications on known protocol [29].  For negative mode a Gemini (Phenomenex) C18 column 
(5 µm, 4.6 mm × 50 mm) was used with a C18 precolumn (3.5 µm, 2 mm × 20 mm, Western 
Analytical).  Solvent A was 95:5 water:methanol with 0.1 % ammonium hydroxide, and solvent 
B was 60:35:5 isopropanol:methanol:water with 0.1 % ammonium hydroxide.  For positive mode 
a Luna (Phenomenex) C5 column (5 µm, 4.6 mm × 50 mm) was used with a C4 precolumn (3.5 
µm, 2 mm × 20 mm, Western analytical).  Solvent A was 95: 5 water: methanol with 0.1 % 
formic acid and 5 mM ammonium formate, and solvent B was 60:35:5 
isopropanol:methanol:water with 0.1 % formic acid and 5 mM ammonium formate.  Identical 
gradient was used for both ionization modes.  The gradient was held at 0 % B between 0 and 5 
min, changed to 20 % B at 5.1 min, increased linearly from 20 % B to 100 % B between 5.1 min 
and 45 min, held at 100 % B between 45.1 min and 53 min, and returned to 0 % B at 53.1 min 
and held at 0 % B between 53.1 min and 60 min to allow column re-equilibration.  Flow rate was 
maintained at 0.1 mL/min between 0 min and 5 min to counter pressure increase due to the 
chloroform injection.  The flow rate was 0.4 mL/min between 5.1 min and 45 min, and 0.5 
mL/min between 45.1 min and 60 min.  Injection volume was 30 µL.  Capillary voltage was 3.5 
kV and fragmentor and skimmer voltages were 100 V and 60 V, respectively.  Drying gas 
temperature was 350 °C, drying gas flow rate was 10 L/min and nebulizer pressure was 45 psi.  
Data were collected in both profile and centroid modes using a mass range of 100-1500 Da. 
Data from general profiling were analyzed via targeted and untargeted approaches.  For 
the targeted approach, extracted ion chromatograms (EICs) corresponding to the m/z of known 
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metabolites were manually integrated in MassHunter Quantitative Analysis (Agilent 
Technologies), and the resulting ion counts compared between WT and AG4OX groups to give 
relative quantification for known lipids.  Statistical significance was determined by two-tailed 
Student’s t-test.  All errors were standard errors of the mean.  For the untargeted approach, LC–
MS raw data were converted from .d to .mzXML format with mzStar.  WT and AG4OX samples 
were sorted into two groups and analyzed via XCMS [30].  Following filtering of XCMS output 
files by ion count (> 5 × 10
4
) and statistical significance (p-value ≤ 0.05), the remaining 
metabolite changes were further confirmed by manual integration in Qualitative Analysis and 
Student’s t-test.  Molecular formulae for unidentified metabolites were generated using formula 
calculator in Quantitative Analysis.   
 
4.5.7. Preliminary PAHSA structural characterization by Q-TOF   
 Tandem MS of PAHSAs was performed on an Agilent 1200 series binary pump 
online with an Agilent 6510 quadrupole-time of flight mass spectrometer with an ESI 
source.  Total runtime of the global lipidomics LC method (section 4.5.6) was lowered to 45 
min, and the linear gradient lowered to 30 min to reduce sample acquisition time; all solvent 
and column conditions were identical.  Collision energy was 20 V for generation of the 
major fragments m/z 255, 281 and 299, and 50 V (for 12-PAHSA) for generation of 
additional diagnostic fragments from the hydroxystearic acyl chain at predictable locations 
around the hydroxylated carbon, based on previous tandem MS study of 12-HSA [31].  
Target m/z was 537.488, MS scan range was 100-1000 Da and MS2 scan range was 50-
1000 Da with an acquisition time of 1000 ms.  Capillary voltage was 3.5 kV, fragmentor 
 147 
 
voltage was 100 V and skimmer voltage was 60 V.  Drying gas temperature was 350 C, 
drying gas flow rate was 10 L/min and nebulizer pressure was 45 psi. 
 
4.5.8. Synthesis of PAHSA standards 
All glasswares were oven dried for at least 24 h prior to synthesis.  Reactions were 
performed under nitrogen atmosphere unless otherwise stated.  Analytical thin-layer 
chromatography (TLC) was performed on precoated silica gel F-254 plates and visualized by 
phosphomolybdic acid (PMA) stain.  Flash chromatography was performed using 230-400 mesh 
silica gel from EMD.  
1
H NMR spectra were acquired at 400 MHz.  
 
 
Figure 4.18. Synthesis of 9-PAHSA. 
 
4.5.8.1. Synthesis of nonadec-1-en-6-ol 
 Pent-4-en-1-ylmagnesium bromide (0.5 M solution in THF, 21.2 mL, 10.6 mmol, 
1.5 eq.) was added to a stirring solution of tetradecanal (1.5 g, 7.1 mmol, 1 eq.) in ice bath.  
The solution was stirred and allowed to warm to room temperature (rt) overnight (16 h).  
The reaction was quenched with saturated ammonium chloride (1 mL), concentrated onto 
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celite 545 (10 g) and purified by silica gel chromatography (85: 15 hexanes: ethyl acetate) 
to afford a white solid (570 mg, 28 %).  Rf = 0.17, 90: 10 hexanes: ethyl acetate.  
1
H NMR 
(400 MHz, CDCl3): δ 5.846-5.761 (m, 1H), 5.022-4.920 (m, 2H), 3.584 (s, 1H), 2.070-2.055 
(d, 2H), 1.42-1.24 (m, 29H), 0.863 (t, 3H).  ESI+: found [M+NH4
+
], C19H42NO
+
: m/z 
300.3259, calculated C19H42NO
+
: m/z 300.3261, ΔPPM = 0.67.  
 
4.5.8.2. Synthesis of nonadec-1-en-6-yl palmitate  
 To a stirred solution of nonadec-1-en-6-ol (570 mg, 2 mmol, 1 eq.) in DCM (20 mL) 
was added palmitic anhydride (1.2 g, 2.4 mmol, 1.2 eq.), 4-(dimethylamino)pyridine (122 
mg, 1 mmol, 0.5 eq.) and triethylamine (1.1 mL, 8 mmol, 4 eq.).  The solution was stirred 
overnight (16 h) at rt.  The reaction was concentrated onto celite 545 (10 g) and purified by 
silica gel chromatography (90: 10 hexanes: ethyl acetate) to afford a clear, colorless oil (750 
mg, 71%).  Rf = 0.33, 85: 15 hexanes: ethyl acetate.  
1
H NMR (400 MHz, CDCl3): δ 5.846-
5.761 (m, 1H), 5.022-4.920 (m, 2H), 3.584 (s, 1H), 2.070-2.055 (d, 2H), 1.42-1.24 (m, 29H), 
0.863 (t, 3H).  ESI+: found [M+H
+
], C35H69O2
+
: m/z 521.5302, calculated C35H69O2
+
: m/z 
521.5292, ΔPPM = 1.92. 
 
4.5.8.3. Synthesis of 5-PAHSA.  
Ozone was bubbled into a stirred solution of nonadec-1-en-6-yl palmitate (104 mg, 0.2 
mmol, 1 eq.) in DCM at -78 °C until the solution turned blue, oxygen was then bubbled until the 
reaction was colorless.  Triphenylphosphine (104 mg, 0.4 mmol, 2 eq.) was added and the 
reaction warmed to rt.  The reaction was concentrated after 2 h; sodium hypochlorite (112 mg of 
80 % grade stock, 1 mmol, 5 eq.), sodium phosphate monobasic (138 mg, 1 mmol, 5 eq.), 2 
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methylbut-2-ene (1.6 mL,16 mmol, 80 eq.), water (3.6 mL) and tert-butanol (14 mL) were added 
and the reaction stirred overnight.  The reaction was concentrated, taken up in DCM and washed 
with 10 % HCl in a separatory funnel.  The organic layer was dried with sodium sulfate, filtered 
and rotovaped to yield a waxy solid bordering on oil.  The crude product was dissolved in 
minimal volume of ethyl acetate and purified by silica gel chromatography (80: 20 hexanes: 
ethyl acetate) to afford a white solid (750 mg, 71%).  Rf = 0.33, 85: 15 hexanes: ethyl acetate.  
1
H NMR (400 MHz, CDCl3): δ 5.846-5.761 (m, 1H), 5.022-4.920 (m, 2H), 3.584 (s, 1H), 2.070-
2.055 (d, 2H), 1.42-1.24 (m, 29H), 0.863 (t, 3H).  ESI-: found [M - H]
-
, C34H65O4
-
: m/z 537.4905, 
calculated C34H65O4
-: m/z 537.4888, ΔPPM = 3.16. 
 Syntheses of additional PAHSAs were performed with the same procedure as 5-PAHSA; 
the starting materials in section 4.5.8.1 were adjusted based on location of the hydroxylated 
carbon in the stearic acyl chain. 
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Appendix Chapter 1 
Oxysterol metabolism in the absence of the Sonic hedgehog 
receptor Patched1 
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A1.1. Introduction 
The Sonic hedgehog (Shh) pathway plays critical roles in cellular proliferation, 
development and stem cell function [1].  Shh signaling occurs through a series of repressive 
interactions [1-3].  In the absence of the secreted protein Shh, the 12-pass transmembrane 
receptor Patched1 (Ptc1) inactivates the 7-pass transmembrane receptor Smoothened (Smo); Shh 
binding to Ptc1 inhibits the latter and leads to Smo activation [1-3].  Smo inhibits Suppressor of 
Fused (SuFu), leading to downstream transcription via the Gli family of transcription factors [1-
3].  Mutations in Shh signaling are associated with cancer and severe developmental defects in 
mice and humans [1, 4].       
 While key protein components of the Shh pathway have been identified, detailed 
mechanism of Ptc1 inhibition of Smo remains unclear [1, 5].  Shh treatment of murine fibroblasts 
induced Smo translocation into and Ptc1 disappearance from primary cilia, signal-sensing cell 
surface projections found on most vertebrate cells [6]; Smo translocation places Smo at the 
correct location for downstream signaling given presence of SuFu and Gli at the cilia [1, 6].  
Importantly, oxygenated derivatives of cholesterol (oxysterols) with diverse functions in 
apoptosis, receptor signaling and platelet aggregation [7] have been shown to activate Shh 
signaling [1, 6, 8].  20S-hydroxycholesterol (20S-OHC) induced Smo translocation into primary 
cilia [6] and significantly increased Shh signaling in a Shh luciferase reporter assay [9]; 25-OHC 
increased Ptc1-LacZ reporter activity in meduloblastomas isolated from mice with one copy of 
Ptc1 replaced by LacZ [8].  More recently, use of affinity probes revealed binding of 20S-OHC 
and the 20S-OHC inhibitor 22-azacholesterol to the extracellular, cysteine-rich domain of Smo 
[5], a separate site from Smo’s heptahelical bundle binding site that is the target of many small 
molecule Smo activators and inhibitors including SAG and cyclopamine [5, 10-12].    
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 Two models for oxysterol-Shh pathway interactions have been proposed (Figure A1.1).  
Structural similarity of Smo to G-protein coupled receptors (GPCRs) and study of GPCR 
kinetics support existence of Smo in an active or inactive conformational state with different 
cellular localization [1, 13, 14] (Figure A1.1); Ptc1 inhibition leads to Smo activation and 
movement into the primary cilia, while inactive Smo is carried in intracellular vesicles [1, 15] 
(Figure A1.1).  Ptc1 could inhibit Smo downstream signaling by down-regulating oxysterols that 
activate Smo (Figure A1.1, Model A); alternatively, oxysterols could activate the Shh pathway 
via direct Ptc1 inhibition (Figure A1.1, Model B).  Oxysterol activation of Shh signaling in Ptc1-
deficient cells and oxysterol-Smo binding support Model A [5, 8, 9]; however, Ptc1 also 
possesses a sterol-sensing domain necessary for regulation of Smo activity [16].   
 
 
Figure A1.1. Two models for oxysterol-Shh pathway interactions.  Models were adapted from 
Rothatgi et al. [1]. 
 
While dependence of Shh signaling on oxysterols has been demonstrated in multiple 
settings, the majority of methods involved treatment with exogenous oxysterols [5, 8, 9].  
Consequently, effects of Shh activation or absence of key components of the Shh pathway on 
endogenous sterol levels remain unknown; evaluation of sterol profile in the absence of Ptc1 
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could yield valuable information on potential Ptc1 regulation of sterol metabolism, and help 
distinguish between the two models proposed in Figure A1.1.  To address this important question, 
we performed targeted liquid chromatography (LC)–mass spectrometry (MS) analysis in WT and 
Ptc1
–/–
 mouse embryonic fibroblasts (MEFs) using the method developed by McDonald et al. 
[17], which enables sensitive quantification of a wide range of sterols from one biological 
sample [17].  Our analysis revealed changes in levels of multiple oxysterols in the absence of 
Ptc1, suggesting that Ptc1 regulates Shh signaling through modulation of oxysterol metabolism.       
 
A1.2. Results and discussions  
 WT and Ptc1
–/–
 mouse embryonic fibroblasts (MEFs) and media from these cells were 
extracted with slight modifications on the Bligh-Dyer method [18].  We chose to profile both 
cells and media to determine if oxysterols could be released from cells.  Solid phase extraction 
removed nonpolar metabolites such as cholesterol esters and triglycerides, enriching sterols for 
LC–MS [17].  A workflow is illustrated in Figure A1.2.   
 
Figure A1.2. Workflow for sterol analysis.  
 
Targeted LC–MS was performed based on the method of McDonald et al. on a triple 
quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode [17].  As 
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stated in previous chapters, MRM quantifies characteristic product ions consistently generated 
from targeted precursor ions based on fragmentation parameters optimized for each precursor.  
Common sterol structures and precursor-to-product ion transitions with instrument parameters 
are in Figure A1.3A, B [17].  Targeted sterols include hydroxycholesterols, epoxycholesterols, 
ketocholesterol, cholesterol and cholesterol biosynthetic intermediates (Figure A1.3A, B).  Either 
the [M + H]
+
 or [M + NH4]
+
 species was monitored as the precursor ion [17].  Common 
fragmentation pathways include loss of ammonia and/or water [17].   
Predicted fragment structures for 25-OHC are in Figure A1.3C.  Ammonium adduct of 
25-OHC ([M + NH4]
+
, precursor ion m/z 420.4) undergoes loss of ammonia and/or water to yield 
[M + H]
+
 (m/z 402.4), [M - H2O + H]
+
 (m/z 385.3) and [M - 2H2O + H]
+
 (m/z 367.3) fragments 
[17, 19, 20].  Multiple fragmentation pathways translate to multiple precursor-to-product ion 
transitions (m/z 420  367, m/z 420  385 and m/z 385  367 were included in the method of 
McDonald et al.; m/z 385  367 could also be used to monitor some cholesterol biosynthetic 
intermediates) for each OHC; appearance of peaks corresponding to different transitions at the 
same retention time adds confidence to the OHC structure assignment.  In agreement with 
instrument parameters used by McDonald et al., intensity of the ammonium adduct is highly 
dependent on dry gas temperature [17].  In our optimization, stepwise reduction of drying gas 
temperature from 350 °C to 100 °C led to a corresponding increase in the strength of the 
ammonium adduct for 
2
H7-cholesterol and all OHC standards examined.  Figure A1.4A 
illustrates the scan spectra for 
2
H7-cholesterol at 350 °C and 100 °C.  Ammonium adduct (m/z 
411.4) was clearly detected at 100 °C; the sodium adduct (m/z 416.4) present at higher 
temperatures could not be used as MRM precursor ion due to generation of a neutral product 
following loss of sodium ion during fragmentation.  No drying gas temperatures below 100 °C 
 158 
 
 
Figure A1.3. MRM analysis of sterols.  A) Structures of common sterols.  Structure of 
cholesterol with positional numbering is in red [17].  B) MRM transitions and instrument 
parameters for common sterols; parameters are taken from the method of McDonald et al. 
[17].  C) Predicted fragment structures for 25-hydroxycholesterol.  
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were tested due to inclusion of water in our solvent system, which could not be removed 
efficiently at lower temperatures.    
 
 
Figure A1.4. Effect of drying gas temperatures on 
2
H7-cholesterol adducts 
formation.    
 
Sterol profiles from WT and Ptc1
–/–
 MEFs and media were evaluated by LC–MS using 
the transitions in Figure A1.3B.  WT and Ptc1
–/–
 extracted ion chromatographs (EICs) for each 
transition were overlaid, and changing peaks identified and integrated manually.  For majority of 
transitions multiple peaks were observed (data not shown), a likely consequence of the diversity 
of sterols with slight differences in structure and identical fragmentation mechanisms.  While 
losses of ammonia and water are common fragmentation pathways that could be shared by 
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multiple sterols, fragmentation within sterol rings, which could yield more information on subtle 
structural differences, is difficult due to the former’s relative stability, which requires high 
collision energies and often generates inconsistent product ions [19, 21].   
Of all transitions monitored, the largest number of statistically significant Ptc1
–/–
-WT 
changes was present in the m/z 420  367 transition, corresponding to loss of ammonia and two 
water molecules from the ammonium adduct of OHC.  This is in keeping with evidences 
supporting a role for OHCs in Shh signaling [1].  Overlaid m/z 420  367 spectra for WT and 
Ptc1
–/–
 media (WT in black, Ptc1
–/–
 in red) are in Figure A1.5; four consistent metabolite 
changes are present at 20.3 min (WT-elevated), 22.2 min (Ptc1
–/–
 -elevated), 22.6 min (WT-
elevated) and 28.8 min (Ptc1
–/–
 -elevated).  Similar changes were observed for cells (data not 
shown).  Retention time comparison with OHC standards suggests that the 22.2 min and 22.6 
min metabolites are 24S and 25-OHC, respectively; no matches were found for the 20.3 min and 
28.8 min metabolites (Figure A1.5).          
 While retention time comparison between sample and external standards could facilitate 
structure assignment, retention time drifts across multiple sample runs hamper retention time 
alignment.  Consequently, confirmation of structure requires co-elution of comparable quantities 
of sample and standard to yield one peak.  To perform co-elution with 24S and 25-OHC 
standards, the chromatographic method from McDonald et al. was lengthened to increase 
separation among OHCs [17].  EICs for 20S, 22R/S, 24R/S, 25 and 27-OHC standards with the 
lengthened LC method are in Figure A1.6; close to baseline resolution allows co-elution for 24S 
and 25-OHCs to be carried out with minimal interference from adjacent peaks.   
 161 
 
It is worth noting that for majority of standards, appearance of peaks corresponding to all 
three OHC transitions (m/z 420  367, m/z 420  385 and m/z 385  367) increases the 
confidence of identification (Figure A1.6) [17].  Relative intensities of OHC transitions depend  
 
Figure A1.5. Altered hydroxysterol profile in the absence of Ptc1.  m/z 420.4  m/z 
367.3 extracted ion chromatographs of WT and Ptc1
–/–
 media are overlaid and changing 
peaks identified and integrated manually.  Retention time comparison with external 
standards suggests that the 22.2 min and 22.6 min peaks are 24S and 25-
hydroxycholesterol, respectively. 
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on position of hydroxylation; while the major transition for 22R/S, 24R/S and 25-OHCs is m/z 
420  367, m/z 385  367 and m/z 420  385 are the major transitions for 20S and 27-OHC, 
respectively (Figure A1.6).  Discrepancy in the major transition observed is a consequence of 
differences in relative stabilities of the m/z 420, m/z 385 and m/z 367 ions in different OHCs.  
Prevalence of the m/z 420 385 transition (loss of one ammonia and one water) in 27-OHC 
could be due to unfavorable loss of the second hydroxyl group at carbon 27, which generates a 
primary cation (Figure A1.3A).  Prevalence of the m/z 385  367 transition in 20S-OHC implies 
the major precursor ion is m/z 385 rather than the unfragmented ammonium adduct m/z 420, 
suggesting in-source fragmentation of the m/z 420 ion to m/z 385, which then undergoes 
collision-induced dissociation (CID) to yield the m/z 367 product ion; ready formation of the m/z 
385 ion in the absence of CID suggests that the hydroxyl group at carbon 20 could be 
significantly more labile than other locations, which could be explained by stability of the 
resulting tertiary cation following fragmentation (Figure A1.3A).   
 
 
Figure A1.6. Chromatographic resolution of OHC standards.  Gradient was 
optimized based on the LC method of McDonald et al. [17].   
 163 
 
Co-injection was performed with the lengthened LC method by combining endogenous 
sample with either the 24S or 25-OHC standard, yielding one peak in both cases (Figure A1.7A).   
 
 
Figure A1.7. Structure confirmation and relative quantification of OHCs in WT 
and Ptc1
–/–
 MEFs and media.  A) Co-injection of sample with 24S or 25-
hydroxycholesterol.  B) Relative quantification of 24S-hydroxcholesterol, 25-
hydroxycholesterol and unidentified hydroxycholesterols or related species in WT 
and Ptc1
–/–
 MEFs and media.    
 
Taken together, our data demonstrate down-regulation of 25-OHC and upregulation of 24S-OHC, 
as well as changes in two additional unidentified OHCs or related species, in Ptc1
–/–
 media and 
cells relative to WT (Figure A1.7B).  Observations of similar changes in cells and media suggest 
that OHCs could be released or trafficked across the plasma membrane as signaling lipids.  
Importantly, our findings demonstrate altered oxysterol metabolism in the absence of Ptc1, 
supporting model A (Figure A1.1) of oxysterols-Shh pathway interactions where Ptc1 inhibits 
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Smo through modulation of oxysterol levels and/or metabolism.  25-OHC has been shown to 
stimulate Shh signaling in multiple contexts [8, 9]; down-regulation of this species in Ptc1
–/–
 
MEFs could be a compensatory mechanism to reduce Shh signaling and excessive cellular 
proliferation.  Alterations in different OHCs and OHC-related metabolites in the absence of Ptc1 
also implies Ptc1 could regulate Shh signaling by tuning the ratios of distinct OHC pools 
depending on the homeostatic need of the cell; it might also be possible for some OHC 
populations to interact with Ptc1 as part of a Ptc1-sterol feedback loop.  Identification of 
unknown OHCs and comprehensive analysis of sterol metabolism in the context of Shh pathway 
activation could yield addition information on the roles of different sterols in Shh signaling.   
 
A1.3. Conclusion 
 Comparative lipidomics uncovered altered sterol profile in MEFs and MEF media in the 
absence of the Sonic hedgehog (Shh) receptor Ptc1, in agreement with previous findings 
supporting requirement of Shh signaling for sterol biosynthesis and roles of several oxysterols in 
Shh pathway activation [1, 5, 8].  Targeted LC–MS with slight modifications on the method of 
McDonald et al. enabled detection of a wide range of sterols including cholesterol, cholesterol 
biosynthetic intermediates, hydroxy, epoxy and ketocholesterols [17].  Our analysis uncovered 
down-regulation of 25-OHC and upregulation of 24S-OHC in Ptc1
–/–
 MEFs and media relative 
to WT.  Our findings suggest that Ptc1 could inhibit Smo downstream signaling by modulating 
cellular oxysterol distribution.  Identification of additional altered sterols and evaluation of sterol 
metabolism and sterol-protein interactions in the context of Shh pathway activation could yield 
valuable information on the detailed connection between small molecules and proteins in the 
Sonic hedgehog pathway.   
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A1.4. Methods 
A1.4.1. Materials  
Ammonium acetate (372331) was from Sigma-Aldrich.  Water (365-4), methanol (230-4), 
toluene (347-1L), isopropanol (323-4), hexane (212-4), chloroform (049-1L) and solid phase 
extraction cartridges (9050, 100 mg silica, 1 mL) were from Honeywell Burdick & Jackson.  
22R-OHC (700058), 22S-OHC (700057), 24R-OHC (700071), 24S-OHC (700061), 25-OHC 
(700019), 27(25R)-OHC (700021), 7-ketocholesterol (700015), 5α, 6α-epoxycholesterol 
(700032) and 5β, 6β-epoxycholesterol (700033) were from Avanti Polar Lipids.  20α-OHC (sc-
209393) was from Santa Cruz Biotechnologies.     
 
A1.4.2. Tissue culture and harvest 
Mouse embryonic fibroblasts (MEFs) and media for metabolite profiling were prepared 
by Dr. Yu Wang and Dr. Sherry Zhang at the laboratory of Prof. Andrew McMahon.  MEFs 
were maintained in 5 % CO2 at 37 °C in Phenyl Red-containing Dulbecco’s Modified Eagle’s 
Medium supplemented with 10 % fetal bovine serum, penicillin and streptomycin.  Phenol Red-
free media were used for media profiling to prevent dye contamination of LC–MS.  Cells were 
harvested by scraping, and pellets frozen at -80 °C prior to lipid extraction.  Media were removed 
from culture dishes, centrifuged to pellet residual cell debris and the supernatants frozen in 15 
mL Falcon tubes at -80 °C prior to extraction.       
 
A1.4.3. Lipid extraction 
Lipids were extracted from MEFs (~10
7
 cells from 10 cm dish) with slight modification 
on the Bligh-Dyer method [18].  Pellets were either Dounce homogenized 30-40 times on ice or 
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shaken for 30 s at room temperature (comparable extraction efficiencies were observed for the 
two methods by LC–MS [data not shown]) in 1 mL:1 mL:2 mL phosphate buffered 
saline:methanol:chloroform, vortexed (in glass vials) for 15-30 s and centrifuged at 2200 g, 4 °C 
for 6 min to allow separation between aqueous (top) and organic (bottom) layers.  The organic 
fraction was transferred to a new glass vial and dried under a gentle stream of nitrogen.  Dried 
lipids were either immediately taken through solid phase extraction or stored at -80 °C for no 
more than one week prior to solid phase extraction.  Media were thawed at room temperature and 
extracted immediately upon thawing.  7-8 mL media were transferred into a glass vial on ice, 
followed by addition of 7-8 mL methanol and 14-16 mL chloroform.  The resulting mixture was 
shaken for 30 s at room temperature, vortexed for 15-30 s and processed following identical 
procedure as cells.  Internal standards were added to chloroform prior to extraction.  
 
A1.4.4. Solid phase extraction  
 Solid phase extraction was performed based on known protocol [17].  Lipids from MEFs 
(~10
7
 cells) or media (7-8 mL) were reconstituted in 1 mL toluene.  Solid phase extraction 
cartridge (100 mg silica, 1 mL) was conditioned with 2 mL hexane.  Lipids in 1 mL toluene were 
loaded onto column with a gentle vacuum.  Nonpolar lipids such as triglycerides and cholesterol 
esters were eluted dropwise (~2-3 drops per s) with 1 mL hexane.  Sterols were eluted dropwise 
(~2-3 drops per s) with 8 mL 30 % isopropanol in hexane.  The sterol fraction was dried under a 
gentle stream of nitrogen and reconstituted in methanol for LC–MS.     
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A1.4.5. LC–MS  
 Targeted analysis of sterols was performed with an Agilent 1200 series LC online with an 
Agilent 6410 Triple Quad LC/MS with an ESI source in positive ionization mode, with slight 
modifications on the protocol of McDonald et al. [17, 19].  A Luna C18 (2) (Phenomenex, 00G-
4251-B0) column with an in-line filter (Phenomenex, AF0-8497) was used.  Solvent A was 15: 
85 water: methanol with 5 mM ammonium acetate and solvent B was methanol with 5 mM 
ammonium acetate.  The gradient was held at 0 % B between 0 and 2 min, increased linearly 
from 0 % B to 100 % B between 2 min and 35 min, held at 100 % B between 35 min and 55 min, 
returned to 0 % B at 55.1 min and held at 0 % B between 55.1 min and 68 min to allow column 
re-equilibration.  Flow rate was 0.25 mL/min.  Each sample (from 7-8 mL media or ~10
7
 MEFs) 
was reconstituted in 30-40 μL methanol, and 10 μL injected for analysis.  All transitions, dwell 
times, DP and CE are listed in Figure A1.3.  Skimmer voltage was 15 V and ΔEMV was 400 V.  
MS1 resolution was set to Wide and MS2 resolution to Unit.  Capillary voltage was 4.0 kV, 
drying gas temperature was 100 °C, drying gas flow rate was 8 L min
-1
 and nebulizer pressure 
was 35 psi.   
 For data analysis, extracted ion chromatographs of WT and Ptc1
–/–
 replicates for each 
transition were overlaid, and peaks changing between WT and Ptc1
–/–
 groups manually identified 
and integrated.  Statistical significance was determined via two-tailed Student’s t test.  All errors 
were standard errors of the mean.   
 
A1.4.6. Co-injection  
 For co-injection, the LC runtime from section A1.4.5 was lengthened to improve 
resolution of oxysterols.  Solvent A was 15: 85 water: methanol with 5 mM ammonium acetate 
 168 
 
and solvent B was methanol with 5 mM ammonium acetate.  The gradient was held at 10 % B 
between 0 and 2 min, increased linearly from 10 % B to 65 % B between 2 min and 70 min, held 
at 65 % B between 70 min and 90 min, returned to 10 % B at 90.1 min and held at 10 % B 
between 90.1 min and 105 min to allow column re-equilibration.  Flow rate was 0.25 mL/min.  A 
mixture of sample and standard in 8 μL methanol was injected.  All instrument parameters were 
identical to section A1.4.5, with the exceptions that only the four transitions for 
Hydroxy/epoxycholesterols and Hydroxy/epoxycholesterols, cholesterol derivatives (Figure A1.3) 
were included, and dwell time was raised to 200 ms for each transition.    
 
A1.5. References      
[1] R. Rohatgi, M.P. Scott, Patching the gaps in Hedgehog signalling, Nat Cell Biol, 9 (2007) 
1005-1009. 
 
[2] Y. Wang, A.P. McMahon, B.L. Allen, Shifting paradigms in Hedgehog signaling, Current 
Opinion in Cell Biology, 19 (2007) 159-165. 
 
[3] J.E. Hooper, M.P. Scott, Communicating with Hedgehogs, Nat Rev Mol Cell Biol, 6 (2005) 
306-317. 
 
[4] A.E. Bale, Hedgehog Signaling and Human Disease, Annual Review of Genomics and 
Human Genetics, 3 (2002) 47-65. 
 
[5] D. Nedelcu, J. Liu, Y. Xu, C. Jao, A. Salic, Oxysterol binding to the extracellular domain of 
Smoothened in Hedgehog signaling, Nat Chem Biol, 9 (2013) 557-564. 
 
[6] R. Rohatgi, L. Milenkovic, M.P. Scott, Patched1 Regulates Hedgehog Signaling at the 
Primary Cilium, Science, 317 (2007) 372-376. 
 
[7] G.J. Schroepfer, Oxysterols: Modulators of Cholesterol Metabolism and Other Processes, 
Physiological Reviews, 80 (2000) 361-554. 
 
[8] R.B. Corcoran, M.P. Scott, Oxysterols stimulate Sonic hedgehog signal transduction and 
proliferation of medulloblastoma cells, Proceedings of the National Academy of Sciences, 103 
(2006) 8408-8413. 
 169 
 
[9] S. Nachtergaele, L.K. Mydock, K. Krishnan, J. Rammohan, P.H. Schlesinger, D.F. Covey, R. 
Rohatgi, Oxysterols are allosteric activators of the oncoprotein Smoothened, Nat Chem Biol, 8 
(2012) 211-220. 
 
[10] J.K. Chen, J. Taipale, K.E. Young, T. Maiti, P.A. Beachy, Small molecule modulation of 
Smoothened activity, Proceedings of the National Academy of Sciences, 99 (2002) 14071-14076. 
 
[11] M. Frank-Kamenetsky, X. Zhang, S. Bottega, O. Guicherit, H. Wichterle, H. Dudek, D. 
Bumcrot, F. Wang, S. Jones, J. Shulok, L. Rubin, J. Porter, Small-molecule modulators of 
Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists, 
Journal of Biology, 1 (2002) 10. 
 
[12] J.K. Chen, J. Taipale, M.K. Cooper, P.A. Beachy, Inhibition of Hedgehog signaling by 
direct binding of cyclopamine to Smoothened, Genes & Development, 16 (2002) 2743-2748. 
 
[13] J. Taipale, J.K. Chen, M.K. Cooper, B. Wang, R.K. Mann, L. Milenkovic, M.P. Scott, P.A. 
Beachy, Effects of oncogenic mutations in Smoothened and Patched can be reversed by 
cyclopamine, Nature, 406 (2000) 1005-1009. 
 
[14] A. De Lean, J.M. Stadel, R.J. Lefkowitz, A ternary complex model explains the agonist-
specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor, Journal of 
Biological Chemistry, 255 (1980) 7108-7117. 
 
[15] Y. Nakano, S. Nystedt, A.A. Shivdasani, H. Strutt, C. Thomas, P.W. Ingham, Functional 
domains and sub-cellular distribution of the Hedgehog transducing protein Smoothened in 
Drosophila, Mechanisms of Development, 121 (2004) 507-518. 
 
[16] V. Martı n, G. Carrillo, C. Torroja, I. Guerrero, The sterol-sensing domain of Patched protein 
seems to control Smoothened activity through Patched vesicular trafficking, Current Biology, 11  
601-607. 
 
[17] J.G. McDonald, B.M. Thompson, E.C. McCrum, D.W. Russell, Extraction and Analysis of 
Sterols in Biological Matrices by High Performance Liquid Chromatography Electrospray 
Ionization Mass Spectrometry, in: H.A. Brown (Ed.) Methods in Enzymology, vol. Volume 432, 
Academic Press, 2007, pp. 145-170. 
 
[18] E.G. Bligh, W.J. Dyer, A Rapid Method of Total Lipid Extraction and Purification, 
Canadian Journal of Biochemistry and Physiology, 37 (1959) 911-917. 
 
[19] J.G. McDonald, D.D. Smith, A.R. Stiles, D.W. Russell, A comprehensive method for 
extraction and quantitative analysis of sterols and secosteroids from human plasma, Journal of 
Lipid Research, 53 (2012) 1399-1409. 
 
 170 
 
[20] M.K. Pulfer, C. Taube, E. Gelfand, R.C. Murphy, Ozone Exposure in Vivo and Formation 
of Biologically Active Oxysterols in the Lung, Journal of Pharmacology and Experimental 
Therapeutics, 312 (2005) 256-264. 
 
[21] V. Wewer, I. Dombrink, K. vom Dorp, P. Doermann, Quantification of sterol lipids in 
plants by quadrupole time of flight mass spectrometry, Journal of Lipid Research, (2011). 
 
 
 
